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Molecular and cellular 
insights into iron regulation 
Abstract 
The iron hormone hepcidin is regarded as the main iron homeostatic regulator in 
the human body. It is predominantly produced by hepatocytes in response to 
systemic iron excess. However, since the cellular and molecular mechanisms 
involved in hepcidin expression are not fully understood, this project involved 
studying hepcidin expression and the role of the pro-region of the hepcidin pro-
hormone in regulation of iron homeostasis.  
 
Iron overdose in Chinese hamster ovary-transferrin receptor variant (CHO TRVb1) 
cells resulted in increased hepcidin peptide secretion after 30 min and 2 hours 
(p<0.03) as well as 24 and 48 hours (p<0.01). Also, partial characterisation of the 
previously unknown CHO-gene sequences of Hfe, Slc40-a1 and Irp2, was 
achieved. To determine the effect of intracellular iron overload on hepcidin 
expression, recombinant transferrin receptor 1 (rec-TfR1) HepG2 cells were 
created which express modified TfR1 to maximise iron uptake. Upon 
holotransferrin (5 g/L) treatment these cells showed significantly increased iron 
uptake which was in contrast to the response by Wt HepG2 cells. Also, it was 
shown for the first time that hepcidin peptide secretion increased upon iron 
overdose to HepG2 cells after 30 min, 2,4,24 and 48 hours (p<0.05). Also, 
holotransferrin treatment (5 g/L) increased hepcidin mRNA levels; in Wt HepG2 
cells by 0.6 fold (on average) after 30 min, 2,4,6 and 24 hours and in rec-TfR1 
HepG2 cells by 0.5 fold after 2 h (p<0.02). Gene expression studies of TfR1, 
SLC40-A1, and HFE upon iron overdose showed opposing functionalities of TfR1 
and SLC40-A1 in maintaining intracellular iron homeostasis and emphasised the 
significance of HFE in hepcidin induction. Additionally, localisation studies with the 
pre-pro derivative of preprohepcidin identified its presence in the nucleus, 
suggesting its involvement in the gene regulation process and thus possible 
participation in maintaining iron homeostasis.  
 
In conclusion, rec-TfR1 HepG2 cells partially resemble haemochromatotic cells 
and the findings indicate that hepcidin regulation involves the interaction between 
several iron-related genes and the extracellular and intracellular iron levels. 
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Chapter 1   
Introduction 
Iron is an essential element required by human beings for their survival and 
development. Although 13-18 mg of iron is obtained through diet per day, only 1-2 
mg is absorbed into the circulation. This dietary iron may be in two forms; the haem 
iron as present in meat and the non-haem iron which is mostly ferric (Fe3+) iron, as 
found in nuts, fruits and vegetables. Irrespective of the form of iron consumed the 
process of iron absorption occurs predominantly in the duodenum, from where it 
enters the circulation and is distributed to different parts of the body to be used for 
various metabolic purposes, as seen in Fig.1.1 (reviewed in Andrews, 2000 and 
Miret et al., 2003). 
 
The amount of iron absorbed by the duodenum is governed by various factors. For 
example, during iron deficiency iron absorption increases to 2-4 mg per day and 
during iron overload the absorption can reduce to 0.5 mg per day. Secondly, the 
process of iron absorption may be enhanced or inhibited by the presence of certain 
substances. For example, vitamin C creates an acidic environment in the lumen 
and enhances non-haem iron absorption by reducing ferric iron (Fe3+) to ferrous 
iron (Fe2+) making it more soluble and thus bioavailable. On the other hand, 
tannins present in tea and fruit juices, phytates present in cereals and polyphenolic 
compounds found in all plant products inhibit the absorption of dietary non-haem 
iron, as reviewed in Dzikaite et al., 2006 and Sharp and Srai, 2007.  
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Iron is absorbed into the circulation and utilised for various cellular processes, 
primarily for the production of red blood cells (Fig. 1.1). The high requirement of 
iron for erythropoesis is reflected in the fact that the total amount of iron in the body 
is 3-4 g, out of which about 2.5 g is bound to haemoglobin. Approximately two 
million red blood cells are synthesised every second in the bone marrow which 
requires 25-30 mg of iron per day for haem synthesis. Apart from erythropoesis, 
iron is also used in the synthesis of myoglobin which is an oxygen binding protein 
found in muscle tissues of vertebrates, aconitase, which converts citrate to 
Figure not included due to copyrights. 
Fig. 1.1 Pathways of iron absorption and utilisation  
Adapted from Andrews (2000).  
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isocitrate in the citric acid cycle and the membrane bound cytochromes, that are 
involved in electron transport chain in mitochondria. Also, iron acts as a cofactor for 
ribonucleotide reductase which converts ribonucleotides to deoxyribonucleotides, 
eventually used in DNA synthesis (reviewed in Andrews and Schmidt, 2007 and 
Muckenthaler et al., 2008). 
 
1.1 Iron absorption and distribution 
The three main cell types involved in iron metabolism are the iron-absorbing 
duodenal enterocytes, the iron-recycling reticuloendothelial macrophages and the 
iron-storing liver hepatocytes. Fig. 1.2 shows the cellular events in the absorption 
of iron. It begins when a ferric reductase duodenal cytochrome b (Dcytb) located 
on the apical surface of enterocytes reduces the poorly bioavailable Fe3+ iron to 
Fe2+ iron. The low pH of proximal duodenum along with an acidic climate of the 
brush border membrane maintains iron in the Fe2+ state. This Fe2+ iron can then be 
transported across the brush border membrane into the enterocyte via the protein, 
divalent metal transporter-1(DMT1). The process of haem iron uptake also occurs 
at the surface of enterocytes but through a different mechanism, briefly explained 
in section 1.2.1. Once inside the cell, iron enters the proposed labile iron pool (LIP) 
which may act as an iron reservoir for various cellular activities. Within the cell, 
excess iron is stored in the protein ferritin, where each ferritin molecule can hold up 
to 4500 iron atoms (reviewed in Andrews and Schmidt, 2007 and Miret et al., 2003). 
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           Key to Fig. 1.2 
 
 
Fig. 1.2  Cell types involved in iron absorption and circulation  
 
The mechanism of iron absorption and circulation, along with the roles of participating proteins are 
briefly shown in the figure. 
 
(I) Proposed programming of crypt cells to absorb iron.  
(II) Mature villus duodenal enterocytes absorb non-haem iron.  
(III) Hepatocytes store iron as well as produce hepcidin. Here, both TBI and NTBI uptake of iron 
occurs. 
(IV) Macrophages engulf senescent erythrocytes, particularly in the spleen, and recycle iron back 
into circulation through ferroportin. 
 
Processes in (III) and (IV) are common to both haem and non-haem iron transport and utilisation.  
Adapted from Muckenthaler et al., (2008).  
? 
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Iron can be translocated outside the enterocytes into the circulation through the 
sole known mammalian transmembrane iron-exporter, ferroportin. Ferroportin is a 
unidirectional ferrous exporter and is expressed on the basolateral surface of the 
enterocyte which is in access with the circulation. It is present on all cell types 
involved in iron transport (Nemeth et al., 2004). During the exit of iron from the 
enterocyte, ferroportin is assisted by the ferroxidase hephaestin which converts 
Fe2+ to Fe3+ whereas the ferroxidase ceruloplasmin assists in the loading of Fe3+ 
onto transferrin. Transferrin is the iron carrier protein in circulation which can hold 
up to two atoms of iron in the form of Fe3+ per protein molecule and this transferrin 
is referred to as diferric transferrin or holotransferrin. It transports iron throughout 
the body via the circulation and binds to the transferrin receptor-1 (TfR1) present 
on cell surfaces to form a complex of diferric transferrin-TfR1. This complex is then 
internalised into a vesicle. The low pH of vesicle and intracellular DMT1 assist in 
the release of iron from this complex into the cell cytoplasm (Miret et al., 2003, 
Muckenthaler et al., 2008).  
 
Once the iron is released into the cytoplasm, the complex without iron is then 
recycled back to the cell surface for further iron uptake. Each TfR1 can undertake 
approximately 100 such recycling processes in its lifetime. Thus TfR1 functions to 
bring iron into the cells and the cells maintain intracellular iron levels by changing 
the expression levels of TfR1 on the cell surface (Aisen, 2004, Huebers and Finch, 
1987). Hence, while maintaining normal intracellular iron levels, the more iron the 
cells require, the higher is the expression level of TfR1.  
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Although TfR1 is present on the surface of all cells involved in iron transport, 
another type of transferrin receptor, TfR-2, is expressed mainly on hepatocytes. It 
has been proposed that TfR-2 binds to HFE, the haemochromatosis protein, and  
induces hepcidin synthesis and may act as a sensor of diferric transferrin in the 
circulation (Gao et al., 2009). HFE has also been shown to interact with TfR1 to 
regulate transferrin-bound iron uptake, as shown in Fig. 1.2 (Kroot et al., 2011). 
 
Along with the transferrin-bound iron, non-transferrin bound iron (NTBI) is also 
found in the systemic circulation. Although its chemical nature has not been 
confirmed yet, it is predicted to be in the form of iron bound to citrate or acetate. 
Iron in circulation could also be associated with albumin and other low molecular 
weight species. The uptake of such NTBI by cells is predominantly mediated by 
calcium channels and metal iron transporters (Andrews and Schmidt, 2007, 
Crichton et al., 2002). 
 
1.1.1 Haem iron absorption 
Haem iron absorption is yet to be fully understood. It has been proposed that in the 
lumen, the haem moiety in food is processed to separate the globin fraction. The 
protoporphyrin ring enters the enterocyte in an intact form with the help of the 
haem carrier protein-1(HCP1) (Shayeghi et al., 2005), which is highly expressed in 
the duodenal cells. Once inside the enterocyte, haem oxygenase excises the iron 
present in the protoporphyrin ring and this iron (Fe2+) joins the labile iron pool    
(Fig. 1.3). From here, iron could either be stored in ferritin molecules for future use 
or could be exported outside the cell into the circulation via a pathway common to 
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non-haem iron export, seen in Fig. 1.2 parts (III) and (IV). The degradation of haem 
iron via haem oxygenase leads to the formation of biliverdin, which is further 
reduced to bilirubin by biliverdin reductase. Bilirubin is then transported to the liver 
and excreted into bile (Andrews and Schmidt, 2007, Miret et al., 2003, Raffin et al., 
1974, Sharp and Srai, 2007).  
 
 
 
 
                                
 
 
Iron absorbed through haem or non-haem pathways is partly retained in the 
intracellular ferritin of enterocytes. After 2-3 days, when enterocytes slough from 
the gut into the lumen, iron present in these cells is also lost via faeces (Andrews 
and Schmidt, 2007).  
 
1.2 Overview of proteins involved in iron absorption and iron circulation 
An overview of the functions of some of the significant proteins involved in iron 
absorption and circulation are shown in table 1.1. 
Proteolysis: 
globin is 
split from 
haem ring  
 
HCP1 
 
   Haem  
oxygenase 
     Dietary 
    sources        
    of Haem 
 
+ Bilirubin Fe2+
Labile iron pool  
Haem iron  
Fig. 1.3  Proposed model of haem iron uptake by an enterocyte 
 
Haem iron  
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Protein and 
chromosome 
location in 
humans 
Cell/tissue in 
which normally 
expressed 
Known or postulated function Result of mutation 
 
Named disorder Clinical 
manifestations 
HFE 
348-mer 
HFE 6p21.3 
 
All tissues except 
brain. 
Predominantly in 
hepatocytes. 
 
 
Regulates cellular iron absorption by 
binding to TfR1 on cell surface and 
reducing its affinity for 
holotransferrin.  
 
Regulates hepcidin production. 
Increased iron influx in 
cells leads to tissue iron 
overload and organ 
damage.  
 
Progressive increase in 
plasma iron. 
Haemochromatosis 
type 1 (HFE 1), 
most common form 
of iron overload,  
 
 
 
 
 
 
Intestinal iron 
hyperabsorption. 
 
Reduced hepcidin 
levels despite of iron 
overload, which 
normally induces 
hepcidin expression 
 
Cardiac disease, 
hypogonadism 
bronze skin 
pigmentation, hepatic 
cirrhosis, arthropathy 
and diabetes. 
 
 
 
 
 
Hemojuvelin  
426-mer 
HJV 1p21 
 
Adult and foetal 
liver, heart, and 
skeletal muscle. 
Membrane protein which exists in 
membrane bound and soluble forms. 
 
It functions as co-receptor for bone 
morphogenetic proteins (BMP) 
signalling.  
 
Regulates hepcidin production. 
Increased iron influx in 
cells.  
 
 
No hepcidin produced. 
Juvenile 
haemochromatosis 
or 
Haemochromatosis 
type 2A (HFE2A) 
Hepcidin  
25-mer 
HAMP 
19q13.1 
 
Predominantly in 
liver.  
Maintains systemic iron levels by 
regulating both intestinal iron 
absorption and iron release from 
macrophages. 
 
Lack of hepcidin leads to 
uncontrolled release of 
iron from macrophages. 
Iron overload in cells and 
tissues.  
Haemochromatosis 
type 2B 
(HFE2B) 
 
Transferrin 
receptor 2 
801-mer 
TfR2 7q22 
Homologue of 
TfR1. Mainly in 
liver  
Competes with TfR1 for binding with 
HFE. Acts as a sensor of 
holotransferrin in circulation.  
 
 
Regulates hepcidin production. 
Increased iron influx. High 
liver iron content.   
 
Haemochromatosis 
type 3 (HFE3)  
 
Table 1.1 continued overleaf.  
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Protein and 
chromosome 
location in 
humans 
Cell/tissue in which 
normally expressed 
Known or postulated function Result of mutation 
 
Clinical manifestations 
Ferroportin 
571-mer 
SLC40A1 2q32 
Macrophages, 
basolateral side of 
intestinal enterocytes, 
placenta, muscle and 
spleen. 
Exports iron from enterocytes, 
macrophages and placenta. 
Loss of function leads to 
decreased iron efflux by 
intestinal enterocytes and 
macrophages resulting in   
tissue iron overload of, 
particularly the   
reticuloendothelial cells. 
 
Increased levels of hepcidin and 
anaemia.  
Hepcidin resistance  
 
Transferrin 
698-mer 
Tf 3q21 
Synthesised in liver and 
circulates in blood. 
Iron carrier protein that transports 
iron from sites of absorption and 
haem degradation to those of 
storage and utilisation. 
 
Increased iron influx in 
cells. 
Increased retention of iron in the 
reticuloendothelial system and 
anaemia. 
Ceruloplasmin 
1065-mer 
CP 3q23-q25 
Expressed by liver and 
secreted in circulation. 
Multicopper oxidase. Assists in 
transporting iron outside the cells. 
Posesses ferroxidase activity 
oxidizing Fe2+ to Fe3+ without 
releasing radical oxygen species. 
Decreased iron efflux from 
cells. 
Iron accumulation in the brain as 
well as visceral organs, retinal 
degeneration and diabetes 
mellitus.  
 
Neurological manifestations seen 
unlike all other genetic 
haemochromatosis. 
 
Divalent metal 
transporter 1 
568-mer 
NRAMP2 
 
Ubiquitously expressed 
in transmembrane 
regions and also 
present intracellularly. 
Involved in apical iron uptake into 
duodenal enterocytes. Involved in 
iron transport from acidified 
endosomes into the cytoplasm. 
Unregulated iron uptake. Abnormal haemoglobin content in 
the erythrocytes which are 
reduced in size. Progressive liver 
iron overload. 
 
 
Table 1.1  Overview of important proteins involved in iron metabolism 
Information on proteins and clinical manifestations adapted from Andrews and Schmidt, (2007), Dzikaite et al., (2006), Gehrke et al., (2003) Jacolot 
et al., (2008) and Pieterangelo, (2006). 
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1.3 The iron hormone hepcidin  
The iron hormone hepcidin, also referred to as LEAP-1 (liver associated 
antimicrobial peptide), plays a significant role in maintaining iron homeostasis 
(Pigeon et al., 2001). In humans, hepcidin is encoded by the HAMP gene which 
contains 3 exons, located on chromosome 19q13.1. As explained in Fig. 1.4A, 
hepcidin is initially synthesised as an 84-mer preprohormone called preprohepcidin. 
 
 
 
 
 
                   
 
This preprohepcidin is cleaved by a signal peptidase to remove the N-terminal 24-
mer signal peptide. The remaining 60-mer peptide, referred to as prohepcidin is  
post-translationally cleaved by a furin like convertase to secrete the 25-mer mature 
bioactive hepcidin (2.7 kDa) which circulates in blood (Krause et al., 2000) at a 
concentration of 1.1-55 ng/mL (Ashby et al., 2009).  
Fig. 1.4A  Significant sites of cleavage in preprohepcidin (84-mer) 
Sites of action of signal peptidase and furin convertase are shown in the figure. Cleavages 
eventually lead to the bioactive hepcidin-25. 
  
MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASW MPMFQRRRRR DTHFPICIFCCGCCHRSKCGMCCKT 
<--Signal peptide-24 mer-> <------------------Pro-region –35 mer-------------> -----Hepcidin-25 mer----- 
<---------------------------------------Prohepcidin-60 mer------------------------------------->  
Signal peptidase 
cleavage site                     
Furin convertase 
cleavage site                     
Fig. 1.4B  Structure of bioactive hepcidin-25 
Hepcidin forms a hairpin-like structure (Hunter et al., 2002); figure adapted from 
protein databank (PDB), PDB ID 1M4F, available at http://www.rcsb.org/pdb/ 
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The small size of hepcidin-25 helps its excretion through urine where it offers 
antibacterial protection to the host (Ashby et al., 2009, Park et al., 2001). Although 
the most predominant form in circulation is hepcidin-25, other truncated forms like 
hepcidin-22 and hepcidin-20 have also been identified in human urine. These are 
either absent or present in low concentrations in the circulation (Park et al., 2001) 
which suggests that they are biologically less significant than hepcidin-25 in 
regulating iron levels. This has been supported by studies which showed that the 
N-terminal region is important for hepcidin-25 to exhibit its bioactivity and thus the 
other isoforms display much reduced iron regulatory activity as compared to 
hepcidin-25 (Nemeth and Ganz, 2006). It is not yet known if there are any other 
biological functions of these isoforms of hepcidin.  
 
Although hepcidin is predominantly produced by the liver hepatocytes, it is has 
been detected in low levels in the heart, brain, lung, tonsils, trachea, prostate gland, 
adipose tissue, adrenal gland, thyroid gland and bone marrow (Bekri et al., 2006, 
Krause et al., 2000, Park et al., 2001, Pigeon et al., 2001). Hepcidin exhibits 
antifungal and antibacterial properties and structurally resembles other known 
peptide antibiotics such as the defensins (Krause et al., 2000, Pigeon et al., 2001).  
 
So far, apart from humans, hepcidin has been found in mice, rats, dogs and fish 
(Nemeth et al., 2003). The furin cleavage site as well as the function and structure 
of hepcidin-25 are well conserved between fish and mammals. In particular, the 8 
cysteine residues in hepcidin-25, as seen in Fig .4B, are highly conserved amongst 
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species and the cysteines involved in the vicinal bond are believed to have 
structural and functional significance (Jordan et al., 2009).  
 
Along with similarities, there are some genomic differences between species with 
regards to hepcidin. Unlike the human genome which contains only one copy of the 
HAMP gene, mice possess two copies, Hamp-1 and Hamp-2, possibly due to a 
gene duplication event (Pigeon et al., 2001). Various studies were conducted to 
understand the functional significance of these two genes encoding hepcidin. It 
was earlier shown by Ilyin et.al (2003) that iron excess in the liver of mice 
upregulated both genes at the transcriptional level. Later, Lou (2009) showed that 
although Hamp-1 transgenic mice developed severe anaemia, Hamp-2 transgenic 
mice developed like the non-transgenic mice. This erased the possibility of 
functionality of Hamp-2 gene in mice. Hence, although the two genes encoding 
hepcidin are independently transcribed and bear high sequence similarity, Hamp-1 
is believed to be the bioactive molecule which regulates iron levels. Apart from 
mice, the fish Paralichthys olivaceus has also been shown to possess two genes 
encoding hepcidin (Kim et al., 2005). 
 
1.3.1 Function of hepcidin in systemic iron homeostasis 
Under normal physiological conditions regulation of iron takes place at both the 
systemic and cellular level. The systemic regulation of iron is mediated by hepcidin 
and the mechanism of its action is explained as follows. 
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The receptor of hepcidin is the transmembrane iron exporter ferroportin, located at 
the basolateral surface of duodenal enterocytes and on macrophages. As 
explained in Fig. 1.5, an increase in systemic iron levels lead to an increase in 
hepcidin expression (Nemeth and Ganz, 2006, Andrews and Schmidt, 2007). 
 
 
 
 
 
 
 
 
 
 
                    A 
Systemic iron deficiency 
                     B 
       Systemic iron excess 
Liver Liver 
Apical 
surface 
Apical 
surface 
Ferroportin at 
basolateral 
surface 
Ferroportin at 
basolateral 
surface 
Villus enterocyte Villus enterocyte Macrophage Macrophage 
Fe Fe Fe Fe 
Low levels  
of hepcidin 
High levels 
of hepcidin 
   Systemic iron levels maintained 
Fig. 1.5  Systemic regulation of iron by hepcidin 
 
A: Under systemic iron deficiency, less hepcidin is produced. Low levels of hepcidin are unable to 
degrade all ferroportin. Undegraded ferroportin export iron outside the cells into circulation to raise 
systemic iron levels.  
 
 
B: Under systemic iron excess, hepcidin levels rise. High levels of hepcidin degrade ferroportin 
which is now unable to export iron outside the cells. This results in iron retention within the cells 
and iron is not exported into the circulation. Systemic iron levels are thus not further elevated.  
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Once the hepatocytes secrete hepcidin into the circulation, hepcidin interacts with 
ferroportin present on cell surfaces. The complex is then internalised via 
endocytosis and ferroportin is degraded in the lysosomes through proteolysis 
(Nemeth et al., 2004). Since ferroportin functions as an iron exporter, this 
degradation of ferroportin inhibits iron release from enterocytes, macrophages and 
placental cells into the circulation, thus preventing further systemic iron elevation. 
In contrast, systemic iron deficiency leads to a decrease in hepcidin production 
(Pigeon et al., 2001) and a resultant increase in iron efflux from cells, thus raising 
systemic iron levels.  
 
The significance of hepcidin in regulating iron levels has been understood through 
knockout and over-expression studies. Mice that over-express Hamp-1 die of 
severe anaemia due to over-degradation of ferroportin, intracellular iron retention 
and unavailability of iron in the circulation for erythropoesis (Nicolas et al., 2002). 
Conversely, constitutive hepcidin expression in a mouse model of iron overload 
haemochromatosis prevented iron overload (Nicolas et al., 2003). This evidence 
indicates that hepcidin plays a crucial role in regulating systemic iron levels in the 
body by inhibiting duodenal iron absorption and controls the release and recycling 
of iron by macrophages and iron mobilisation from the hepatocytes.  
 
1.3.2 Overview of hepcidin regulation  
Apart from iron overload, conditions like inflammation and infection also lead to an 
increase in hepcidin production. In contrast, iron deficiency, increased 
erythropoesis and hypoxia lead to a decrease in hepcidin production. Also, as 
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explained in table 1.1, the presence of functional genes HFE, TfR2, HAMP and 
HJV are required to execute a normal hepcidin response and mutations in these 
genes lead to reduction or abolishment of hepcidin production. Regulators of 
hepcidin expression have been summarised in Fig. 1.6.   
 
 
 
                                                 
 
 
 
 
 
The purpose of modulation of hepcidin production during infections and 
inflammation is to support host defence mechanisms. For example, localised high 
doses of hepcidin have been found in phagosomes in macrophages infected with 
tuberculosis bacteria (Sow et al., 2007). This can be explained by the fact that 
these organisms require iron for survival. An increase in hepcidin production leads 
to more sequestration of iron within the cells thus reducing the bioavailability of iron 
for the invading pathogens. Also, the increase in hepcidin causes a lowered iron 
absorption in the duodenum (Nicolas et al., 2002). However, in the host this 
response also limits the bioavailability of iron for erythroid precursors and often 
contributes to the anaemia associated with infections and inflammation. 
Consequently, hepcidin acts as a marker of anaemia of inflammation (AI) (Ganz, 
• Functional genes HFE,TfR2, 
HAMP, HJV 
• Infection: lipopolysaccharide 
• Inflammation: Interleukin 6 
• Systemic iron overload  
• Mutations in genes HFE, 
TfR2, HAMP and HJV 
• Hypoxia 
• Increased erythropoesis 
• Systemic iron deficiency   
 
  Hepcidin 
suppression 
 
   Hepcidin 
  induction 
 
Genes and factors that lead to 
hepcidin induction  
 
Genes and factors that lead to 
hepcidin suppression  
 
Fig. 1.6  Factors affecting hepcidin production 
Important genes and factors that lead to an increase and decrease in hepcidin expression. 
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2011). Although several mechanisms for regulation of hepcidin have been 
proposed, there has been no evidence to date of any other type of control, except 
at transcriptional levels (Truksa et al., 2007). An overview of signal transduction 
pathways, in particular the bone morphogenetic proteins (BMP)-SMAD, janus 
kinase/signal transducer and activator of transcription-3 (JAK-STAT) and HIF 
pathways which appear to regulate hepcidin transcription, are shown in Fig. 1.7.  
 
Briefly, intracellular iron stores influence the binding of BMPs to their receptors on 
the cell surface (Fig. 1.7A and 1.7B). As shown in Fig. 1.7A, membrane-bound HJV 
(mHJV) acts as a BMP co-receptor and assists in this process. This leads to 
phosphorylation and activation of the intracellular SMAD proteins which transmit a 
signal to the nucleus to increase HAMP transcription in the cells (Babitt et al., 
2006). During inflammation, IL6 induces HAMP transcription via the JAK/STAT 
pathway (Babitt et al., 2006, Wang et al., 2005). As shown in Fig. 1.7B, when iron 
stores are low, mHJV is cleaved by furin and/or matripase 2 (a transmembrane 
protease encoded by the gene TMPRSS6, expressed predominantly in liver) to 
form soluble HJV (sHJV). The sHJV disrupts the BMP-mediated activation  
and instead leads to down-regulation of HAMP transcription (Finberg et al., 2010).  
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Fig. 1.7A Pathways leading to transcriptional up-regulation of hepcidin 
The complex of SMAD proteins enter the nucleus, bind to the promoter region of hepcidin 
gene and stimulate HAMP transcription. Also, the STAT3 dimer formed as a results of IL6 
binding to its receptor leads to upregulation of hepcidin. High liver iron stores promote 
hepcidin synthesis via the BMP pathway.  
Fig. 1.7B Pathways leading to transcriptional down-regulation of hepcidin 
Both furin and matripase 2 are able to cleave mHJV to soluble HJV. The soluble HJV does 
not allow a stable complex to be formed between BMP ligands and receptors, thus inhibiting 
HAMP transcription via the BMP pathway. Hypoxia inducible factor increases the 
transcription of genes that would cleave the mHJV to soluble HJV. 
Adapted from Andrews (2007). 
Key to figure : 
 
• BMP : bone 
morphogenetic 
proteins  
• mHJV : membrane 
bound HJV 
• IL 6 : interleukin 6 
 
•                Nucleus 
 
Key to figure : 
 
• HIF : hypoxia inducible 
factor 
• TMPRSS6 : gene 
encoding matripase 2 
 
• 
 
 Nucleus 
Increased  
HJV  
shedding 
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1.4 Regulation of cellular iron levels 
Cellular iron homeostasis is mediated by binding of the two iron regulatory  
proteins (IRP), IRP1 and IRP2, to iron responsive elements (IREs) on the mRNA of   
some iron-regulated genes. Binding of IRP1 to IRE in 5’ untranslated regions 
(UTRs) of transcripts prevent protein synthesis whereas binding of IRP1 to IREs in 
the 3’ region provides stability to mRNA and allows translation into proteins.  
The binding of the IRPs to the IREs is in turn regulated by the presence of iron (Fig. 
1.8).  
   
 
  
 
 
IRP2  
  Intracellular iron levels maintained 
IRP1  IRP1  
     4Fe-4S cluster   
      assembles in 
      IRP1. IRP1 is   
      unable to bind      
      mRNA  
mRNA 
stabilized   
 iron 
uptake 
proteins 
produced 
Unprotected 
mRNA degraded 
by endo-
nucleases 
 
Proteins 
not produced 
Inhibition of 
translation   
 
  No iron export 
and  storage 
proteins 
                                        
IREs remain free 
of IRP1 
  iron export 
and  storage 
proteins 
produced 
 
mRNAs of TfR1, DMT1, 
Ferroportin/Ferritin 
IRP1 binds to 
5’ or 3’ IREs 
on mRNA 
IRP2  
Fig. 1.8  Cellular regulation of iron by iron regulatory proteins (IRPs) 
Binding of IRPs to IREs in 5’ UTR and 3’ UTR lead to different effects. IRP binding to 5’ IREs result in 
inhibition of protein production whereas binding to 3’ IREs favour protein production.  
Cellular iron deficiency  Cellular iron excess  
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As shown in Fig. 1.8, when cellular iron levels are sufficient or in excess, an  
iron-sulphur cubane (4Fe-4S) is formed which prevents the binding of IRP1 to the  
IRE in 5’ UTR of mRNA of genes encoding ferroportin and ferritin. This permits 
translation of the mRNA into proteins to favour more iron storage within cells and 
more iron efflux. Thus cellular iron overload is prevented. In contrast, under cellular 
iron depletion, IRP1 is iron-free and can therefore bind to the IREs in 3’ UTR on 
transcripts of genes encoding TfR1 and intestinal DMT1. In doing so it stabilises 
the mRNAs and therefore increases the expression of both proteins, hence 
facilitating increased iron uptake by cells to eliminate cellular iron deprivation. Thus 
the IRP-IRE network maintains cellular iron levels (Muckenthaler et al., 2008). 
 
1.5 Iron homeostasis and disorders 
Iron is essential for survival and growth but free iron can be toxic. Since iron has 
the ability to accept and donate electrons, it can catalyse the Fenton reaction that 
leads to the generation of hydroxyl radicals. These radicals can cause severe 
damage to cells and tissues and thus high levels of iron can be deleterious. 
Additionally, there is no physiological pathway for iron excretion except by blood 
loss and the natural means of iron loss from the body occurring as a result of 
sloughing of mucosal cells and/or menstruation is minimal (Miret et al., 2003, 
Nemeth and Ganz, 2006). Hence maintaining iron homeostasis is crucial.  
 
The significance of body iron homeostasis can be realised by reflecting on the 
diseases and conditions in which iron homeostasis is disturbed. Considering iron  
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deficiencies, broadly, there are two types: absolute iron deficiency and functional 
iron deficiency. Absolute iron deficiency is characterised by depleted iron stores. 
This can be due to excessive blood loss or pregnancy when there is increased 
demand for iron or malnutrition when there is decreased supply of iron. This is also 
referred to as iron deficiency anaemia and could have one of the many observable 
effects such as developmental retardation in children. Surprisingly, a large 
proportion of the world population, approximately one third, is believed to be 
suffering from iron deficiency anaemia. On the other hand, functional iron 
deficiency, as seen in cancer and inflammation is referred to as anaemia of 
inflammation or anaemia of chronic disease. These are characterised by low serum 
iron levels despite replete iron stores due to iron-restricted erythropoesis (Munoz et 
al., 2011, Muckenthaler et al., 2008). 
 
Current treatments to alleviate iron deficiency anaemia involve increasing iron 
levels in the body by using ferrous salts. Although approximately 200 mg of 
inorganic iron per day is given to the patients, low doses have been found to be 
effective. Also, when the dose of iron is more than required, the unabsorbed iron 
salts cause nausea, abdominal pain and constipation. Thus low doses of iron salts 
between 50-100 mg of iron should be recommended (Munoz et al., 2011).  
On the other extreme of iron deficiency is iron overload, which could be acquired or 
functional. Examples of acquired iron overload are the iron overdose in children 
which is the commonest poisoning in children, iron overload as a result of repeated 
blood transfusions and/or alcohol consumption and Bantu siderosis (Munoz et al.,  
2011).  
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Functional iron overload, referred to as hereditary haemochromatosis, is the most 
frequent genetic disorder in Caucasians and results from defects in some of the 
genes involved in iron metabolism described in table 1.1. Under 
haemochromatosis, intestinal iron absorption can exceed iron loss by ~ 3 mg/day 
(Pietrangelo, 2006), the effect of which can be tissue specific. For instance the liver 
possesses high levels of antioxidants and cytoprotective enzymes. This suggests 
that a substantially high level of liver iron overload would be required to observe 
the toxic effects of iron. On the other hand, in the reticuloendothelial cells e.g. 
macrophages, only about a 2-3 fold increase in cellular iron would lead to changes 
in normal cell functions (Crichton et al., 2002, Munoz et al., 2011).  
 
Presently, phlebotomy is offered as the commonest therapy to remove excess iron 
from the body of haemochromatosis patients. The rationale behind this is to reduce 
the potential of iron-mediated tissue injury. However, since this strategy has its 
own complications, other therapeutic measures like using iron chelating drugs are 
also being used. This involves the use of iron chelators like deferoxamine, 
deferriprone and deferasirox which have their respective advantages. For example, 
deferriprone has a better half life than deferoxamine and is excreted in urine. 
Hence it is preferred over the use of deferoxamine. However, the use of these 
chelators has some limitations such as inadequate and/or variable chelation. Also, 
the lowest safety limit of iron overload with chelating therapies is yet to be 
determined (Munoz et al., 2011, Smith et al., 2011). 
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1.6 Hepcidin as a biomarker in diseases 
Since hepcidin is regarded as the main iron homeostasis regulator, involvement of 
hepcidin in any iron-associated disease is expected. For instance the levels of 
hepcidin-25 are high in the serum of patients suffering from anaemia of chronic 
disease. Also, increased hepcidin concentrations mark infections and inflammatory 
diseases like malaria and chronic kidney disease (Kroot et al., 2011). Not 
surprisingly, hepcidin has been identified as a type 2 acute phase protein (Nemeth 
et al., 2003). Levels of hepcidin are high in cases of obesity, acute myocardial 
infarction and acquired forms of non-haemochromatotic iron-overload resulting 
from excessive alcohol consumption, whereas iron deficiency anaemia shows 
inhibition of hepcidin synthesis and thus very low serum hepcidin concentrations 
(Kroot et al., 2011).  
 
Since hepcidin has been associated with such a wide range of conditions, its 
significance lies not only in maintaining iron homeostasis but also as a marker for 
diagnosing various disorders. One of the most recent applications of hepcidin as a 
biomarker is a study which proposed that measuring hepcidin concentrations can 
be a way to assess the requirement for iron supplementation in young athletes 
(Borrione et al., 2011). Additionally, a close relationship between iron and glucose 
metabolism has been previously shown. Increased iron stores were found to 
predict the development of type 2 diabetes while iron depletion was found to be 
protective (Fernandez-Real et al., 2002). Also, accumulation of iron in specific 
regions of the brain is associated with neurodegenerative diseases such  
Alzheimer’s disease and Parkinson’s disease (Crichton et al., 2002).  
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Hence studies related to iron regulation and hepcidin would lead to a better 
understanding of several aspects of human metabolomics and also find various 
diagnostic and therapeutic applications.  
  
1.7 Background and overall aims of the project 
In humans and in animal models, increased systemic iron levels lead to increased 
hepcidin levels and increased urinary hepcidin excretion (Lin et al., 2007, Nemeth 
et al., 2003, Pigeon et al., 2001). In humans, a 4-5 fold increase in hepcidin levels 
within 24 hours of iron dosage has been reported (Lin et al., 2007). Likewise, a 
high iron-supplemented diet given to mice resulted in a 10-fold higher iron 
concentration in the liver and a 4-fold increase in Hamp mRNA in the livers of 
these mice (Muckenthaler et al., 2003, Pigeon et al., 2001).  
 
However, these findings could not be replicated in vitro. High iron dosage to cells 
either increased or decreased or had no effect on hepcidin mRNA expression. For 
instance, holotransferrin treatment of HepG2 cells led to either a  decrease (Jacolot 
et al., 2008) or have no effect (Gehrke et al., 2003) on hepcidin mRNA. In primary 
hepatocytes it led to an increase (Lin et al., 2007, Rapisarda et al., 2010) or 
decrease (Nemeth et al., 2003) in hepcidin mRNA. Treatment of HepG2 cells using 
inorganic iron sources showed a dose-dependent hepcidin mRNA response (Fein 
et al., 2007) or a decrease in hepcidin mRNA (Jacolot et al., 2008). On the other 
hand in hepatocytes, such sources either showed no change (Lin et al., 2007, 
Pigeon et al., 2001), or a decrease in hepcidin mRNA expression (Dzikaite et al., 
2006, Nemeth et al., 2003). Other studies showed that hepcidin expression was 
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influenced by the plating and culturing time of hepatocytes (Lin et al., 2007) and by 
the presence and absence of serum  in the medium (Pigeon et al., 2001, Nemeth 
et al., 2003). The presence of macrophages along with the HepG2 cells was also 
crucial to observe a rise in hepcidin mRNA expression in HepG2 cells (Jacolot et 
al., 2008) whereas another group showed that the presence of other cell types was 
not necessary (Montosi et al., 2005).  
 
These varied and inconclusive findings require clarification and further investigation 
as it would aid in a better understanding of how iron regulates hepcidin, which is 
not yet known, or whether they both regulate each other via a feedback 
mechanism. 
 
One reason for the decrease in hepcidin transcription, as observed by some 
groups, could be due to the cells’ inability to uptake the supplemented iron. Most of 
these iron overdose experiments have been performed using inorganic sources of 
iron like ferrous sulphate, ferric ammonium citrate, ferric citrate or ferric 
nitrilotriacetic acid. Since the predominant physiologically relevant form of iron is 
the iron bound to transferrin, these inorganic iron sources may not be preferred by 
the cells as much as transferrin-bound iron. Secondly, iron uptake mechanisms of 
the inorganic iron sources are not fully defined yet. It is likely that such iron forms 
may enter the cells and be quickly sequestered, consequently leading to a 
decrease in hepcidin mRNA expression as the cells may not have recognised the 
high intracellular iron content.  
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Also, TfR1 on the cell surface controls the amount of iron intake by cells 
(Muckenthaler et al., 2008). If the cell is iron deficient it will express more TfR1 on 
its cell surface to encourage iron uptake until cellular iron sufficiency is reached. 
After this stage the cells would stop further TfR1 synthesis or decrease TfR1 
expression to prevent further iron uptake and thus intracellular iron overload. In this 
situation hepcidin mRNA expression may not increase because of the lack of 
intracellular iron overload. This may keep hepcidin levels stable rather than lead to 
an increase (Gehrke et al., 2003). In addition, commercially available 
holotransferrin is only between 5 % and 20 % diferric (Farnaud, personal 
communication). Transferrin containing such a low proportion of holotransferrin 
would not create an iron-rich environment for the cells to uptake high levels of iron. 
This would result in stable intracellular iron content and not an intracellular iron 
overload. These issues were addressed in this study in reference to hepcidin 
expression, where TfR1 on the cell surface of different cell lines and their 
responses under different conditions was also analysed. Whilst defining the nature 
of the supplemented iron source, cellular iron overload on iron supplementation 
was investigated.  
 
Overall aims  
1. To study the effect of iron supplementation on the regulation of hepcidin and 
other iron homeostasis regulators in the Chinese hamster ovarian cell lines and 
human liver carcinoma cell lines. 
2. To investigate the role of the pro-peptide region of the prohormone of hepcidin.  
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Chapter 2  
Materials and Methods 
2.1 Materials  
Primers for polymerase chain reaction (PCR), Hams’ F12 medium, Dulbecco’s 
Phosphate Buffered Saline (PBS) 1X and hygromycin B were purchased from 
Invitrogen (Loughborough, UK). Foetal calf serum (FCS) was purchased from 
Biosera (Ringmer, UK). PCR reagents, proteinase K, cDNA preparation, gel 
extraction and PCR product purification kits were purchased from Qiagen 
(Crawley, UK). The pGEM–T easy vector system was bought from Promega 
(Southampton, UK). All other reagents and labware were purchased from Sigma-
Aldrich (Poole, UK) and VWR (East Grinstead, UK) respectively, unless otherwise 
stated.  
 
2.2 Methods  
2.2.1 Cell culture 
All cell lines were grown and maintained in their respective maintenance medium in 
tissue culture flasks at 37 °C in a humidified atmo sphere of 95 % air and 5 % CO2. 
The maintenance medium was changed every 2-3 days and cells were passaged 
by trypsinisation (0.025 % trypisn EDTA for 5 minutes) on reaching 70-80 % 
confluence. To neutralise the trypsin, maintenance medium was added and 
centrifugation was performed at 1000 rotations per minute (rpm) (89 x g) for 5 min. 
The supernatant was removed, fresh maintenance medium was added to the cell 
pellet and the cells were plated at the required density for iron-related studies. 
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2.2.2 Chinese hamster ovary (CHO) cell lines 
Wild type CHO AA8 (Wt CHO) was a kind gift from Professor Keith Caldecott 
(University of Sussex, Falmer, East Sussex, UK). The CHO transferrin receptor 
variant cell line (CHO TRVb1 clone B6), constitutively expressing the human 
transferrin receptor-1 was kindly donated by Dr. Heinz Zoller (University of 
Innsbruck, Austria). These two CHO cell lines were maintained in Ham’s F12 
nutrient mixture (1X) containing 2 mM glutamax supplemented with 10 % FCS and 
1 % antibiotic/antimycotic solution (100X) (Fisher Scientific International Inc., UK).   
 
2.2.3 HepG2 cell lines 
2.2.3.1 Wild type HepG2 cells  
Wild type HepG2 (Wt HepG2), a hepatocarcinoma cell line, was bought from the 
Health Protection Agency (Colindale, London UK). These cells were maintained in 
Eagle’s Minimum Essential Medium (EMEM), 1 % non-essential amino acids,        
2 mM glutamax, 1 % antibiotic/antimycotic solution and 10 % FCS.  
 
2.2.3.2 Creation of recombinant HepG2 cells  
Recombinant HepG2 (rec-TfR1 HepG2), a HepG2 cell line that constitutively 
expresses human TfR1 receptor, was created in collaboration with Dr. Paul Brown 
(King’s College, London, UK). Details on the creation of this cell line are in 
appendix I.  
Principle: The coding region of human TfR1 gene, devoid of its IRE was cloned 
into the plasmid vector pCEP4 (Invitrogen-Life technologies, UK). This recombinant 
plasmid was transfected into Wt HepG2 cells, resultantly giving rise to the 
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recombinant HepG2 cells. Since the IRE of TfR1 has been removed, on iron 
supplementation the cells should take up iron continuously regardless of their 
intracellular iron content, permitting intracellular iron overload. The human TfR1 
mRNA and the protein sequence alignment below shows the region of interest 
cloned into the vector pCEP4. It also shows the primers designed for cloning and 
real time PCR. 
 
ggcggctcgggacggaggacgcgctagtgtgagtgcgggcttctagaactacaccgaccctc 62 
   R  L  G  T  E  D  A  L  V  -  V  R  A  S  R  T  T  P  T  L  
Gtgtcctcccttcatcctgcggggctggctggagcggccgctccggtgctgtccagcagc 122 
 V  S  S  L  H  P  A  G  L  A  G  A  A  A  P  V  L  S  S  S  
Catagggagccgcacggggagcgggaaagcggtcgcggccccaggcggggcggccgggat 182           
 H  R  E  P  H  G  E  R  E  S  G  R  G  P  R  R  G  G  R  D  
Ggagcggggccgcgagcctgtggggaaggggctgtggcggcgcctcgagcggctgcaggt 242 
 G  A  G  P  R  A  C  G  E  G  A  V  A  A  P  R  A  A  A  G  
 
     forward primer for cloning 
     Tgatatatgcggccgcaccatggatcaagctagatcagcattctc >>  
Tcttctgtgtggcagttcagaatgatggatcaagctagatcagcattctctaacttgttt 302 
 S  S  V  W  Q  F  R  M  M  D  Q  A  R  S  A  F  S  N  L  F  
Ggtggagaaccattgtcatatacccggttcagcctggctcggcaagtagatggcgataac 362 
 G  G  E  P  L  S  Y  T  R  F  S  L  A  R  Q  V  D  G  D  N  
Agtcatgtggagatgaaacttgctgtagatgaagaagaaaatgctgacaataacacaaag 422 
 S  H  V  E  M  K  L  A  V  D  E  E  E  N  A  D  N  N  T  K  
Gccaatgtcacaaaaccaaaaaggtgtagtggaagtatctgctatgggactattgctgtg 482 
 A  N  V  T  K  P  K  R  C  S  G  S  I  C  Y  G  T  I  A  V  
Atcgtctttttcttgattggatttatgattggctacttgggctattgtaaaggggtagaa 542 
 I  V  F  F  L  I  G  F  M  I  G  Y  L  G  Y  C  K  G  V  E  
Ccaaaaactgagtgtgagagactggcaggaaccgagtctccagtgagggaggagccagga 602 
 P  K  T  E  C  E  R  L  A  G  T  E  S  P  V  R  E  E  P  G  
Gaggacttccctgcagcacgtcgcttatattgggatgacctgaagagaaagttgtcggag 662 
 E  D  F  P  A  A  R  R  L  Y  W  D  D  L  K  R  K  L  S  E  
Aaactggacagcacagacttcaccagcaccatcaagctgctgaatgaaaattcatatgtc 722 
 K  L  D  S  T  D  F  T  S  T  I  K  L  L  N  E  N  S  Y  V  
Cctcgtgaggctggatctcaaaaagatgaaaatcttgcgttgtatgttgaaaatcaattt 782 
 P  R  E  A  G  S  Q  K  D  E  N  L  A  L  Y  V  E  N  Q  F  
Cgtgaatttaaactcagcaaagtctggcgtgatcaacattttgttaagattcaggtcaaa 842 
 R  E  F  K  L  S  K  V  W  R  D  Q  H  F  V  K  I  Q  V  K  
Gacagcgctcaaaactcggtgatcatagttgataagaacggtagacttgtttacctggtg 902 
 D  S  A  Q  N  S  V  I  I  V  D  K  N  G  R  L  V  Y  L  V  
Gagaatcctgggggttatgtggcgtatagtaaggctgcaacagttactggtaaactggtc 962 
 E  N  P  G  G  Y  V  A  Y  S  K  A  A  T  V  T  G  K  L  V  
Catgctaattttggtactaaaaaagattttgaggatttatacactcctgtgaatggatct 1022 
 H  A  N  F  G  T  K  K  D  F  E  D  L  Y  T  P  V  N  G  S  
Atagtgattgtcagagcagggaaaatcacctttgcagaaaaggttgcaaatgctgaaagc 1082 
 I  V  I  V  R  A  G  K  I  T  F  A  E  K  V  A  N  A  E  S  
Ttaaatgcaattggtgtgttgatatacatggaccagactaaatttcccattgttaacgca 1142 
 L  N  A  I  G  V  L  I  Y  M  D  Q  T  K  F  P  I  V  N  A  
Gaactttcattctttggacatgctcatctggggacaggtgacccttacacacctggattc 1202 
 E  L  S  F  F  G  H  A  H  L  G  T  G  D  P  Y  T  P  G  F  
Ccttccttcaatcacactcagtttccaccatctcggtcatcaggattgcctaatatacct 1262 
 P  S  F  N  H  T  Q  F  P  P  S  R  S  S  G  L  P  N  I  P  
Gtccagacaatctccagagctgctgcagaaaagctgtttgggaatatggaaggagactgt 1322 
 V  Q  T  I  S  R  A  A  A  E  K  L  F  G  N  M  E  G  D  C  
Ccctctgactggaaaacagactctacatgtaggatggtaacctcagaaagcaagaatgtg 1382 
 P  S  D  W  K  T  D  S  T  C  R  M  V  T  S  E  S  K  N  V  
Aagctcactgtgagcaatgtgctgaaagagataaaaattcttaacatctttggagttatt 1442 
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 K  L  T  V  S  N  V  L  K  E  I  K  I  L  N  I  F  G  V  I  
Aaaggctttgtagaaccagatcactatgttgtagttggggcccagagagatgcatggggc 1502 
 K  G  F  V  E  P  D  H  Y  V  V  V  G  A  Q  R  D  A  W  G  
           Forward primer for TfR1 >>> 
Cctggagctgcaaaatccggtgtaggcacagctctcctattgaaacttgcccagatgttc 1562 
 P  G  A  A  K  S  G  V  G  T  A  L  L  L  K  L  A  Q  M  F  
Tcagatatggtcttaaaagatgggtttcagcccagcagaagcattatctttgccagttgg 1622 
 S  D  M  V  L  K  D  G  F  Q  P  S  R  S  I  I  F  A  S  W  
 
                                                         <<< 
Agtgctggagactttggatcggttggtgccactgaatggctagagggatacctttcgtcc 1682 
 S  A  G  D  F  G  S  V  G  A  T  E  W  L  E  G  Y  L  S  S  
<<< Reverse primer for TfR1 
Ctgcatttaaaggctttcacttatattaatctggataaagcggttcttggtaccagcaac 1742 
 L  H  L  K  A  F  T  Y  I  N  L  D  K  A  V  L  G  T  S  N  
Ttcaaggtttctgccagcccactgttgtatacgcttattgagaaaacaatgcaaaatgtg 1802 
 F  K  V  S  A  S  P  L  L  Y  T  L  I  E  K  T  M  Q  N  V  
Aagcatccggttactgggcaatttctatatcaggacagcaactgggccagcaaagttgag 1862 
 K  H  P  V  T  G  Q  F  L  Y  Q  D  S  N  W  A  S  K  V  E  
Aaactcactttagacaatgctgctttccctttccttgcatattctggaatcccagcagtt 1922 
 K  L  T  L  D  N  A  A  F  P  F  L  A  Y  S  G  I  P  A  V  
Tctttctgtttttgcgaggacacagattatccttatttgggtaccaccatggacacctat 1982 
 S  F  C  F  C  E  D  T  D  Y  P  Y  L  G  T  T  M  D  T  Y  
Aaggaactgattgagaggattcctgagttgaacaaagtggcacgagcagctgcagaggtc 2042 
 K  E  L  I  E  R  I  P  E  L  N  K  V  A  R  A  A  A  E  V  
Gctggtcagttcgtgattaaactaacccatgatgttgaattgaacctggactatgagagg 2102 
 A  G  Q  F  V  I  K  L  T  H  D  V  E  L  N  L  D  Y  E  R  
Tacaacagccaactgctttcatttgtgagggatctgaaccaatacagagcagacataaag 2162 
 Y  N  S  Q  L  L  S  F  V  R  D  L  N  Q  Y  R  A  D  I  K  
Gaaatgggcctgagtttacagtggctgtattctgctcgtggagacttcttccgtgctact 2222 
 E  M  G  L  S  L  Q  W  L  Y  S  A  R  G  D  F  F  R  A  T  
Tccagactaacaacagatttcgggaatgctgagaaaacagacagatttgtcatgaagaaa 2282 
 S  R  L  T  T  D  F  G  N  A  E  K  T  D  R  F  V  M  K  K  
Ctcaatgatcgtgtcatgagagtggagtatcacttcctctctccctacgtatctccaaaa 2342 
 L  N  D  R  V  M  R  V  E  Y  H  F  L  S  P  Y  V  S  P  K  
Gagtctcctttccgacatgtcttctggggctccggctctcacacgctgccagctttactg 2402 
 E  S  P  F  R  H  V  F  W  G  S  G  S  H  T  L  P  A  L  L  
Gagaacttgaaactgcgtaaacaaaataacggtgcttttaatgaaacgctgttcagaaac 2462 
 E  N  L  K  L  R  K  Q  N  N  G  A  F  N  E  T  L  F  R  N  
 
                                                 <<<  ctgcaa 
Cagttggctctagctacttggactattcagggagctgcaaatgccctctctggtgacgtt 2522 
 Q  L  A  L  A  T  W  T  I  Q  G  A  A  N  A  L  S  G  D  V  
 
         <<< Reverse primer for cloning 
Accctgtaactgttactcaaaattattcctaggcgcgcg  
Tgggacattgacaatgagttttaaatgtgatacccatagcttccatgagaacagcagggt 2582 
 W  D  I  D  N  E  F  -  M  -  Y  P  -  L  P  -  E  Q  Q  G  
                         
Agtctggtttctagacttgtgctgatcgtgctaaattttcagtagggctacaaaacctga 2642 
 S  L  V  S  R  L  V  L  I  V  L  N  F  Q  -  G  Y  K  T  -  
Tgttaaaattccatcccatcatcttggtactactagatgtctttaggcagcagcttttaa 2702 
 C  -  N  S  I  P  S  S  W  Y  Y  -  M  S  L  G  S  S  F  -  
Tacagggtagataacctgtacttcaagttaaagtgaataaccacttaaaaaatgtccatg 2762 
 Y  R  V  D  N  L  Y  F  K  L  K  -  I  T  T  -  K  M  S  M  
Atggaatattcccctatctctagaattttaagtgctttgtaatgggaactgcctctttcc 2822 
 M  E  Y  S  P  I  S  R  I  L  S  A  L  -  W  E  L  P  L  S  
Tgttgttgttaatgaaaatgtcagaaaccagttatgtgaatgatctctctgaatcctaag 2882 
 C  C  C  -  -  K  C  Q  K  P  V  M  -  M  I  S  L  N  P  K  
Ggctggtctctgctgaaggttgtaagtggttcgcttactttgagtgatcctccaacttca 2942 
 G  W  S  L  L  K  V  V  S  G  S  L  T  L  S  D  P  P  T  S  
Tttgatgctaaataggagataccaggttgaaagacctctccaaatgagatctaagccttt 3002 
 F  D  A  K  -  E  I  P  G  -  K  T  S  P  N  E  I  -  A  F  
Ccataaggaatgtagcaggtttcctcattcctgaaagaaacagttaactttcagaagaga 3062 
 P  -  G  M  -  Q  V  S  S  F  L  K  E  T  V  N  F  Q  K  R  
Tgggcttgttttcttgccaatgaggtctgaaatggaggtccttctgctggataaaatgag 3122 
 W  A  C  F  L  A  N  E  V  -  N  G  G  P  S  A  G  -  N  E  
Gttcaactgttgattgcaggaataaggccttaatatgttaacctcagtgtcatttatgaa 3182 
 V  Q  L  L  I  A  G  I  R  P  -  Y  V  N  L  S  V  I  Y  E  
Aagaggggaccagaagccaaagacttagtatattttcttttcctctgtcccttcccccat 3242 
 K  R  G  P  E  A  K  D  L  V  Y  F  L  F  L  C  P  F  P  H  
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Aagcctccatttagttctttgttatttttgtttcttccaaagcacattgaaagagaacca 3302 
 K  P  P  F  S  S  L  L  F  L  F  L  P  K  H  I  E  R  E  P  
Gtttcaggtgtttagttgcagactcagtttgtcagactttaaagaataatatgctgccaa 3362 
 V  S  G  V  -  L  Q  T  Q  F  V  R  L  -  R  I  I  C  C  Q  
Attttggccaaagtgttaatcttaggggagagctttctgtccttttggcactgagatatt 3422 
 I  L  A  K  V  L  I  L  G  E  S  F  L  S  F  W  H  -  D  I  
Tattgtttatttatcagtgacagagttcactataaatggtgtttttttaatagaatataa 3482 
 Y  C  L  F  I  S  D  R  V  H  Y  K  W  C  F  F  N  R  I  -  
Ttatcggaagcagtgccttccataattatgacagttatactgtcggttttttttaaataa 3542 
 L  S  E  A  V  P  S  I  I  M  T  V  I  L  S  V  F  F  K  -  
Aagcagcatctgctaataaaacccaacagatactggaagttttgcatttatggtcaacac 3602 
 K  Q  H  L  L  I  K  P  N  R  Y  W  K  F  C  I  Y  G  Q  H  
Ttaagggttttagaaaacagccgtcagccaaatgtaattgaataaagttgaagctaagat 3662 
 L  R  V  L  E  N  S  R  Q  P  N  V  I  E  -  S  -  S  -  D  
 
                          TfR1-IRE forward primer >>> 
Ttagagatgaattaaatttaattaggggttgctaagaagcgagcactgaccagataagaa 3722 
 L  E  M  N  -  I  -  L  G  V  A  K  K  R  A  L  T  R  -  E  
Tgctggttttcctaaatgcagtgaattgtgaccaagttataaatcaatgtcacttaaagg 3782 
 C  W  F  S  -  M  Q  -  I  V  T  K  L  -  I  N  V  T  -  R  
Ctgtggtagtactcctgcaaaattttatagctcagtttatccaaggtgtaactctaattc 3842 
 L  W  -  Y  S  C  K  I  L  -  L  S  L  S  K  V  -  L  -  F  
 
                                <<< TfR1 reverse primer  
Ccatttgcaaaatttccagtacctttgtcacaatcctaacacattatcgggagcagtgtc 3902 
 P  F  A  K  F  P  V  P  L  S  Q  S  -  H  I  I  G  S  S  V  
Ttccataatgtataaagaacaaggtagtttttacctaccacagtgtctgtatcggagaca 3962 
 F  H  N  V  -  R  T  R  -  F  L  P  T  T  V  S  V  S  E  T  
Gtgatctccatatgttacactaagggtgtaagtaattatcgggaacagtgtttcccataa 4022 
 V  I  S  I  C  Y  T  K  G  V  S  N  Y  R  E  Q  C  F  P  -  
Ttttcttcatgcaatgacatcttcaaagcttgaagatcgttagtatctaacatgtatccc 4082 
 F  S  S  C  N  D  I  F  K  A  -  R  S  L  V  S  N  M  Y  P  
Aactcctataattccctatcttttagttttagttgcagaaacattttgtggtcattaagc 4142 
 N  S  Y  N  S  L  S  F  S  F  S  C  R  N  I  L  W  S  L  S  
Attgggtgggtaaattcaaccactgtaaaatgaaattactacaaaatttgaaatttagct 4202 
 I  G  W  V  N  S  T  T  V  K  -  N  Y  Y  K  I  -  N  L  A  
Tgggtttttgttacctttatggtttctccaggtcctctacttaatgagatagcagcatac 4262 
 W  V  F  V  T  F  M  V  S  P  G  P  L  L  N  E  I  A  A  Y  
Atttataatgtttgctattgacaagtcattttaatttatcacattatttgcatgttacct 4322 
 I  Y  N  V  C  Y  -  Q  V  I  L  I  Y  H  I  I  C  M  L  P  
Cctataaacttagtgcggacaagttttaatccagaattgaccttttgacttaaagcagag 4382 
 P  I  N  L  V  R  T  S  F  N  P  E  L  T  F  -  L  K  A  E  
Ggactttgtatagaaggtttgggggctgtggggaaggagagtcccctgaaggtctgacac 4442 
 G  L  C  I  E  G  L  G  A  V  G  K  E  S  P  L  K  V  -  H  
Gtctgcctacccattcgtggtgatcaattaaatgtaggtatgaataagttcgaagctccg 4502 
 V  C  L  P  I  R  G  D  Q  L  N  V  G  M  N  K  F  E  A  P  
Tgagtgaaccatcatataaacgtgtagtacagctgtttgtcatagggcagttggaaacgg 4562 
 -  V  N  H  H  I  N  V  -  Y  S  C  L  S  -  G  S  W  K  R  
Cctcctagggaaaagttcatagggtctcttcaggttcttagtgtcacttacctagattta 4622 
 P  P  R  E  K  F  I  G  S  L  Q  V  L  S  V  T  Y  L  D  L  
Cagcctcacttgaatgtgtcactactcacagtctctttaatcttcagttttatctttaat 4682 
 Q  P  H  L  N  V  S  L  L  T  V  S  L  I  F  S  F  I  F  N  
Ctcctcttttatcttggactgacatttagcgtagctaagtgaaaaggtcatagctgagat 4742 
 L  L  F  Y  L  G  L  T  F  S  V  A  K  -  K  G  H  S  -  D  
Tcctggttcgggtgttacgcacacgtacttaaatgaaagcatgtggcatgttcatcgtat 4802 
 S  W  F  G  C  Y  A  H  V  L  K  -  K  H  V  A  C  S  S  Y  
Aacacaatatgaatacagggcatgcattttgcagcagtgagtctcttcagaaaacccttt 4862 
 N  T  I  -  I  Q  G  M  H  F  A  A  V  S  L  F  R  K  P  F  
Tctacagttagggttgagttacttcctatcaagccagtacgtgctaacaggctcaatatt 4922 
 S  T  V  R  V  E  L  L  P  I  K  P  V  R  A  N  R  L  N  I  
Cctgaatgaaatatcagactagtgacaagctcctggtcttgagatgtcttctcgttaagg 4982 
 P  E  -  N  I  R  L  V  T  S  S  W  S  -  D  V  F  S  L  R  
Agtagggccttttggaggtaaaggtata                                 5010 
 S  R  A  F  W  R  -  R  Y     
 
 
 
Fig. 2.1  Alignment of human TfR1 mRNA and protein 
The alignment shows the coding region of TfR1 cDNA that was cloned into vector pCEP4. 
It also shows the IRE located in the 3’ region (Casey et al., 1988) as well as the actual 
endonuclease site within the IRE region (Binder et al., 1994). Information on TfR1 
obtained from Proteinknowledgebase UniProtKB at www.uniprot.org/uniprot/P02786. 
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Fig. 2.2 is a representation of the plasmid pCEP4 into which the TfR1 segment  
of interest was cloned. Since the plasmid pCEP4 contains a hygromycin B 
resistance gene, the rec-TfR1 HepG2 cells were maintained in the same medium 
as the Wt HepG2 cells, with the addition of 200 µg/mL hygromycin B as a selection 
for exclusive growth of recombinant HepG2 cells. 
 
 
 
 
2.2.3.3 Creation of HepG2 cells containing empty plasmid: HepG2 (p) cells 
HepG2 (p) cells were created to be used as a control in iron supplementation 
experiments. The cells were created by transfection of the Wt HepG2 cells with the 
empty pCEP4 plasmid. The method of creation was as per X-tremeGENE-9 DNA 
transfection reagent protocol (Roche, West Sussex, UK) and is briefly described as 
follows.  
Pre- transfection cell culture conditions: Wt HepG2 cells were seeded at a 
density of 8 x104 cells per well in 6 wells of a 24 well plate. Cells were allowed to 
Fig. 2.2  Schematic of the cloning vector  
pCEP4 plasmid 
Image adapted from life technologies at 
http://products.invitrogen.com/ivgn/product/V04450 
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grow for 48 hours until they reached approximately 60 % to 70 % confluence, 
ready to be transfected.  
 
Preparation of transfection medium: On the day of transfection, the transfection 
medium was prepared. This was composed of X-9 (transfection reagent) and 
serum-free EMEM. These two were mixed in 3 different ratios, each ratio in 
duplicate. The ratios were 3:100, 4:100 and 6:100, i.e. 3 µL of X-9 and 100 µL of 
serum free medium, 4 µL of X-9 and 100 µL of serum-free EMEM, and 6 µL of X-9 
and 100 µL of serum-free EMEM. These 6 tubes containing the transfection 
medium were divided into 2 sets; one set was for the test (plasmid) and the other 
for the control (no plasmid). The test set of tubes were supplemented with 1 µg of 
the plasmid pCEP4. To the control set, instead of the plasmid, serum-free and 
antibiotic-free medium was added. All preparations were mixed gently and 
incubated at room temperature (RT) for 20 min.  
 
Transfection: For transfection, Wt HepG2 cells growing in the maintenance 
medium, as described above, were washed once with PBS to remove any cell-
bound antibiotics. To each of the 6 wells, 1 mL of EMEM (with 10 % FCS and 
without antibiotics) was added. 50 µL from each of the transfection preparations 
was added to each of the respective wells, the plate was mixed gently and the cells 
were incubated at 37 ºC in an incubator for 48 hours. Following this, the 
transfection medium was removed and replaced with maintenance medium 
containing 500 µg/mL of hygromycin B. The medium was replaced after 3 days, 
and the cells were maintained in a medium containing 500 µg/mL hygromycin B. 
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After 3 weeks, the cells were maintained in a maintenance medium containing 200 
µg/mL of hygromycin B and passaged in the same way as the other HepG2 cell 
lines. 
 
2.2.4 Liquid nitrogen storage and cell revival 
All cell lines were stored in NUNC vials in 90 % FCS and 10 % dimethyl sulphoxide 
(DMSO) in the Cryo 1°C freezing container, (Nalgene ), at -80 ºC for 24 hours and 
then transferred to liquid nitrogen for long term storage. When reviving the cells 
from liquid nitrogen, frozen vials were quickly defrosted in an incubator at 37 ºC. To 
wash away the DMSO, contents were transferred to a 15 mL centrifuge tube, 
followed by addition of warm maintenance medium and centrifugation at 1000 rpm 
(89 x g) for 4 min. The supernatant was discarded and the cell pellet was 
resuspended in maintenance medium and seeded in a 25 cm2 flask containing 
warm maintenance medium to initiate cell growth.   
 
2.2.5 DNA extraction from cell lines and rodent liver tissues 
DNA was extracted from cells in order to perform PCRs to confirm the presence of 
a gene of interest and/or to confirm its sequence identity by subsequent 
sequencing. DNA was also extracted from rodent tissues which served as a 
positive control in PCRs since the expected product size with respective primers 
was known. 
Principle: Addition of lysis buffer makes cells permeable and lyses the cells. 
Sodium dodecyl sulphate (SDS) present in the lysis buffer removes membrane 
lipids and thus assists the lysis buffer. Proteinase K added later inactivates 
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nucleases that degrade DNA; its action is enhanced by SDS. It also removes the 
cellular and histone proteins bound to DNA, making the DNA more “accessible”. 
Finally, isopropanol precipitates the DNA.  
 
Methodology: DNA extraction from tissues and cell lines was performed using the 
isopropanol-ethanol precipitation method (Maniatis et al., 1982). To extract DNA 
from cell lines, cells were grown in a 75 cm2 tissue culture flask. On reaching  
80-90 % confluence, cells were trypsinised and transferred to a 15 mL centrifuge 
tube. After centrifugation at 800 x g for 5 minutes, the supernatant was removed. 
To the cell pellet or rodent liver tissues, 3 mL of lysis buffer [100 mM Tris (pH 8), 
50 mM NaCl, 10 mM EDTA, 0.2 % SDS] and 10 µL of proteinase K (20 mg/mL) 
was added, mixed and incubated overnight in a water bath maintained at 65 ºC. 
After overnight incubation, contents were transferred to a 1.5 mL eppendorf tube 
and centrifuged at 13,000 rpm (16,060 x g) for 20 min. The supernatant was 
transferred to a fresh eppendorf tube and 600 µL of cold isopropanol was added, 
the tubes were vortexed and again centrifuged at 13,000 rpm (16,060 x g) for 15 
min. The supernatant was discarded and 2 µL of 5 M sodium chloride, 100 µL of 
distilled water and 200 µl of cold absolute ethanol (BDH, East Grinstead, UK) were 
added, mixed and incubated at -20 ºC for 1 hour. The tubes were then centrifuged 
at 13,000 rpm (16,060 x g) for 10 min, the supernatant was discarded and the 
pellet was dried in a speed vacuum. The DNA pellet was suspended in 50 µL of 
nuclease-free, diethylpyrocarbonate (DEPC)-treated water (Ambion, Warrington, 
UK) and stored at -20 ºC. 
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2.2.6 DNA purification and concentration 
The extracted DNA was purified and concentrated to improve its quality for PCRs 
and subsequent sequencing.  
Methodology: To the DNA to be purified, 10 M ammonium acetate was added (at 
1/10th of DNA solution to be purified). Following this, an equal volume of 100 % 
isopropanol was added and the mixture was then incubated at RT for 20 min.  
Centrifugation was performed at 13,000 rpm (16,060 x g) for 10 min at RT. The 
supernatant was removed, 100 µL of 70 % ethanol was added, the tubes were 
vortexed and centrifuged at 13,000 rpm (16,060 x g) for 10 min at RT. The 
supernatant was removed and the precipitated DNA was suspended in 50 µL of 
nuclease-free water. The DNA was stored at -20 ºC and only the DNA preparations 
with a 260/280 ratio >1.8 were used in PCRs. 
 
2.2.7 Primer design and gene annotation   
The following databases, software programmes, algorithms and tools were used to 
design primers.  
a. National Center for Biotechnology Information (NCBI) for accession of gene 
sequences and software blastn to match the characterised sequence of a 
gene with existing gene sequences in the database.  
b. Genome Net for Clustal-W alignment, a multiple sequence alignment tool to 
align gene sequences from different species, aiming to identify most 
conserved regions to design primers.  
c. Software Primer 3 (available at http://frodo.wi.mit.edu/) to design gene- 
specific primers.  
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All primers were designed to have similar properties such as GC content close to 
60 %, melting temperature (Tm) close as 60 ºC and product size less than 200 
base pairs (bp) to facilitate their use in real time PCR. Once the primers were 
designed, each primer was checked for its gene specificity at the NCBI database 
with blastn.  
 
Tables 2.1, 2.2 and 2.3 shows all the primers used for PCRs and real time PCRs. 
• Table 2.1 lists the primers designed based on conserved nucleotides between 
human, mouse and rat. These were the primers used for the 1st and 2nd rounds 
of CHO gene sequencing.  
• Table 2.1 also shows the CHO-specific primers, referred as “CHO for x forward” 
and “CHO for x reverse”, where is x the gene of interest. These were designed 
exclusively on the characterised CHO gene sequence and were used in real 
time PCR optimisations with the CHO cells.  
• Table 2.2 shows the hepcidin primers used for rat, mouse and human 
genomes, published by other research groups.  
• Table 2.3 shows the primers used for PCR optimisations and real time PCR 
with HepG2 cells.  
The genes have been annotated in the text as follows: 
Protein  Gene encoding the protein in 
humans  
Gene annotation in text  
Hepcidin  HAMP (Hamp in rodents) Hepcidin gene 
Ferroportin SLC40A1 Ferroportin gene 
TfR1 TfRC TfR1 gene 
HFE HFE HFE gene 
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Genes Forward (F) primers 5’ to 3’ Reverse (R) primers 5’ to 3’ 
                                                     Primers designed based on multiple sequence alignments of different species 
Hfe  (F)   CTCTTCATGGGTGCCTCA  (R)   CACCCTTTCAGNCTCTGACT   
(F1)   CAATNGCTNNAGGGTGACTTC  (R1)   AAGAGTTGGTCATCCACGTAG  
(F2)   ATAATCATGAGAATCGCCGTG (R2)   TTCACCAAAGNAGGCACTTG  
Ferroportin  (F)   ATCGGATGTGGCACTTTGC  (R)   GCCACTTTAAGTCTNGCATTCT  
(F1a)   CTTTCCAACTTCAGCTACAGTGTT  (R1)   CGTAGACAGCTGTCAAGAGGA   
(F1b)   TCCAACTTCAGCTACAGTGTT   
(F2)   TAGCAGGCTCTGTTCTGG  (R2a)   CCATTATTCCAGTTATNGCTGATGC   
(R2b)   ATTATTCCAGTTATNGCTGATGC  
Irp2 (F)   AATGCACCAAATCCTGGAG  (R)   AGGCACTGGTTGCAAATG   
(F1)   TAATATGGTCTCCGGCGATG  (R1)   TCCTCGGCAGGTAGTCTGG  
(F2)   CCAGACTACCTGCCGAGGA (R2)   CATTTAAGCAAGCCTGGAAATC  
Hepcidin  (F)   GCTGCCTGTCTCCTGCTTC (R)    ATGGGGAAGTTGRTGTCTC  
(F1)   CTGCCTGTCTCCTGCTTC (R1a)   ATGGGGAAGTTGNTGTCTC 
(R1b)   AGGNCAGGAATNAATANTGGGG 
(F2)   NCTCCTGCTNCTCCTCCT   (R2a)   AGAANNNGCANATGGGGAAG  
(R2b)   ATGGGGAAGTNGNTGTCTC    
Genes and 
source of 
primers                                                
Primers designed for Real time PCR on the basis of characterised CHO sequence 
Hfe Hfe for CHO (F)   AACCACAGTAAGGGCAGTAAGC  Hfe for CHO (Rx)   GAGGCACTTGCTGCTTCAG  
Hfe for CHO (Ry)   GCTCTCCATTCCAGTGTCGT  
Ferroportin FPN for CHO (F)   ATGGGTGCTCACTGTCTGCTA  FPN for CHO (R)   GCATTCATATCTGCTAATCTGCTTC  
Irp2 Irp2 for CHO (F)   ATTCTTGGGTGGGGAGTTG  Irp2 for CHO (R)   CCTACTTGCCTGAGGTGCTT   
Beta actin 
(Bahr et al., 
2009) 
(F)   GCTCTTTTCCAGCCTTCCTT (R)   GAGCCAGAGCAGTGATCTCC  
 
Pabpn1 
(Bahr et al., 
2009) 
(F)   GTGGCCATCCTAAAGGGTTT 
 
(R)   CGGGAGCTGTTGTAATTGGT 
 
CHO 
endogenous 
TfR1 
(F)   CCCAGCAGAAGCATTATCTTT (R)   TTCCCATCAATTGGATGTCTT 
 Table 2.1 Primers for CHO gene sequencing and real time PCR 
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Forward (F) primers 5’ to 3’ Reverse (R) primers 5’ to 3’ 
Source of Primers                                                                      Hepcidin primers published by other research groups 
(Fein et al., 2007) (FF)   CTGCAACCCCAGGACAGAG  (RR)   GGAATAAATAAGGAAGGGAGGGG   
(Lin et al., 2007) Mouse hepcidin -1 (F)   
TTGCGATACCAATGCAGAAGA   
Mouse hepcidin -1 (R)    
GATGTGGCTCTAGGCTATGTT  
(Dzikaite et al., 2006) Rat hepcidin (F)-x   
TGACAGTGCGCTGCTGATG   
Rat hepcidin (R)-x   
GGAATTCTTACAGCATTTACAGCAGA   
(Zhang et al., 2004) Rat hepcidin F-y   
CGAGACACCAACTTCCCCATAT  
Rat hepcidin R-y   
GCTCTTGGCTCTCTATGTTATGCA   
pGEM-T easy vector primers  
(Greenwell., P.) 
(F) GCGGCCGCGGGAATTCG   
 
(R)  GGCGGCCGCGAATTCA   
 
 
 
Genes and source of primers Forward (F) primer 5’ to 3’ Reverse (R) primer 5’ to 3’ 
Primers designed for HepG2 cells 
Hepcidin  (F I)  ACAGCCAGACAGACGGCACGA  (R I)  TTCGCCTCTGGAACATGGGCATC  
(F II)  CCTGACCAGTGGCTCTGTTT  (R II)  CACATCCCACACTTTGATCG  
TfR1  (F)  AAAATCCGGTGTAGGCACAG  (R)  TTAAATGCAGGGACGAAAGG   
TfR1-IRE  (F Ia)  AAGCGAGCACTGACCAGATAA  (R I)  TGCTCCCGATAATGTGTTAGG  
(F Ib)  GGTTGCTAAGAAGCGAGCAC   
F2  CCTAACACATTATCGGGAGCA   (R2)  TTCAAGCTTTGAAGATGTCATTG   
GAPDH  (F)  GCCAAAAGGGTCATCATCTC (R)  GGTGCTAAGCAGTTGGTGGT 
Primers for HepG2 cells, as published by other research groups 
Hepcidin (Jacolot et al., 2008) (F III)  CCTGACCAGTGGCTCTGTTT  (R III)  CTCTGGAACATGGGCATCCA  
Hepcidin (Wrighting and Andrews, 2006) (F IV) CTGCAACCCCAGGACAGAG  (R IV)  GGAATAAATAAGGAAGGGAGGGG  
HFE (Jacolot et al., 2008) (F I)  TGATCTGGGAGCCCTCACC  (R I)  GACGACAAAAACAGCAATTCC  
HFE (Rapisarda et al., 2010) (F II)   AGAACAGGGCCTACCTGGAG  (R II)  TGTGTCACCTTCACCAAAGG  
Ferroportin (Jacolot et al., 2008) (F I)  TGTTTCTGGTAGAGCTCTAT  (R I)  GATATAGCAGGAAGTGAGAA  
Ferroportin (Recalcati et al., 2010) (F II)  GGGGTCGCGTAGTGTCAT  (R II)  CAGGTAGTCGGCCAAGGAT  
18s (Provenzano et al., 2007) (F)   AACTTTCGATGGTAGTCGCCG  (R)   CCTTGGATGTGGTAGCCGTT  
Actin (Rapisada., personal communication) (F)  CCAACCGCGAGAAGATGA  (R)   CCAGAGGCGTACAGGGATAG  
 Table 2.3  Primers for PCR optimisations and real time PCR with HepG2 cells 
Table 2.2 Primers used for hepcidin gene sequencing in CHO cells 
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2.2.8 Polymerase chain reactions (PCRs) 
PCRs were performed to confirm the presence of a gene of interest, followed by 
sequencing to confirm product identity.  
Principle: Primers bind to DNA at complementary regions and Taq Polymerase, 
extends the primers by adding complementary bases to the free 3’ OH end of the 
primers, until it reaches the end of a defined region. After the first cycle of PCR, 
two strands of DNA are produced, identical to the original strands. In the second 
cycle these form the template for synthesis of the correctly sized amplicons. 
Subsequent cycles lead to a logarithmic increase in the number of copies of the 
region of DNA, defined by the primers. 
 
Methodology:  The PCR protocol adapted from Qiagen’s Taq PCR master mix 
protocol (Qiagen) is shown in Table 2.4. The annealing and extensions times were 
chosen depending on the size of the product expected. For example, the annealing 
time of 1 min and final extension of 10 min were chosen for products more than 
500 bp in length. Different annealing temperatures shown in table 2.4 represent the 
temperature gradient PCRs, as explained in the following section. All PCRs were 
performed on the Eppendorf® Mastercycler gradient.  
Contents Volume  PCR cycle steps 
DEPC water 5.5 µL 1. Initial denaturation temperature: 94 ºC for 3 min 
2. Denaturation: 94 ºC for 30 sec 
3. Annealing: 55 ºC , 58 ºC or 60 ºC for 45 sec or 1 min  
4. Extension: 72 ºC for 1 min  
5. Repeat step 2 to 4, 29 times 
6. Final extension: 72 ºC for 5 or 10 min 
7. Final hold: 4 ºC 
Qiagen Taq PCR 
master mix (2X) 
12.5 µL 
5µM Forward primer 2.5 µL 
5µM Reverse primer 2.5 µL 
DNA template (200ng) 2 µL 
Total volume 25 µL 
 
 
Table 2.4  PCR protocol and cycles  
The volume of contents is adapted from Qiagen’s Taq PCR master mix kit protocol. 
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2.2.9 Temperature and magnesium chloride gradient PCR 
In order to identify the most appropriate annealing temperature for primer binding 
to the DNA template, multiple PCR tubes were set up for a sample and subjected 
to a gradient of annealing temperatures ranging from 51 ºC to 61 ºC. To avoid 
variability between PCR mixtures in different tubes, a single PCR master mix with 
the DNA was aliquoted in 25 µL volumes in each 0.2 mL PCR tube and then 
placed at desired temperatures on the PCR machine. The temperature which 
resulted in the highest product formation and a unique product was chosen as the 
most appropriate annealing temperature. A magnesium chloride (MgCl2) gradient 
PCR was set up in a range from 1.5 mM to 4 mM to facilitate more specific binding 
of primers. The annealing temperature chosen was as identified by the 
temperature gradient PCR.  
 
2.2.10 Agarose gel electrophoresis 
The presence and size of a PCR product was determined by agarose gel 
electrophoresis. 
Principle:  During electrophoresis, porous agarose helps in migration of DNA from 
the negative electrode to the positive electrode. Ethidium bromide intercalates 
between the double strands of DNA and fluoresces when exposed to UV light. This 
detects the presence of product. 
Methodology: After the PCR, 5 µL of 5X DNA loading buffer (Bioline, London, UK) 
was added per 25 µL of a PCR reaction. 18 µL of amplicon was run on 0.8 %, 1 %, 
2 % or 3 % agarose gel (Web scientific, Cheshire, UK ) using 1X Tris-Borate-EDTA 
buffer (Fisher Scientific International Inc., Loughborough, UK). Alongside the 
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products to be analysed, 10 µL sample of a DNA ladder (Web scientific Cheshire, 
UK), as seen in Fig. 2.3, was loaded in one well. The gel was electrophoresed at 
100 volts until the loading dye had run 2/3rd of the gel. The gel was then observed 
under a UV transilluminator to check the DNA products.  
                                                          
 
 
 
2.2.11 Cloning and transformation  
Two PCR products of similar sizes on agarose gel are difficult to gel extract and 
sequence. Cloning of a dual product segment into a vector, followed by 
transformation and selection of clones aid in extraction and subsequent 
sequencing of each product.  
Principle: The dual product segment was cut from the gel and ligated to a plasmid 
vector; the principle being that one plasmid would ligate to only one product. This 
created two kinds of recombinant plasmids, each one with one of the two products. 
These recombinant plasmids were then transformed into competent cells to obtain 
multiple copies of plasmids. These plasmids were then extracted from the 
competent cells and PCRs were performed to check sequence identity. 
 
3000 bp 
2000 bp 
1500 bp 
 
1000 bp 
800 bp 
700 bp 
600 bp 
500 bp 
400 bp 
300 bp 
 
200 bp 
 
100 bp 
Fig. 2.3 A typical DNA ladder 
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Methodology: The dual product segment was gel extracted and purified using 
Qiagen’s gel extraction kit, according to manufacturer’s instruction. The purified 
section was then ligated to the pGEM-T Easy Vector system I and the recombinant 
plasmids were transformed into competent Escherichia coli XL-1 Blue cells, 
according to the manufacturer’s protocol. For transformation, Luria-Bertani (LB) 
agar and LB broth were prepared and autoclaved at 121 ºC for 15 min. The LB 
agar was heated in a microwave oven and cooled to 40-50 ºC. Since the plasmid 
pGEM-T contains ampicillin resistance gene, ampicillin solution (100 µg/mL) was 
filtered using 0.22 µm filter unit and added to the LB agar. Along with this, isopropyl 
β-D-1 thiogalactopyranoside solution (IPTG) (0.5 mM) and bromo-chloro-indolyl-
galactopyranoside (X-gal) (80 µg/mL) were also filtered and added to the LB agar. 
X-gal as added to aid selection due to the presence of lacZ gene on the plasmid. 
The contents were mixed and plates poured. Agar was allowed to solidify and 
plates were surface spread with transformed E. coli cells. After overnight 
incubation at 37 ºC, blue and white colonies were observed. White colonies, which 
represented successful ligation of product to the vector were selected and 
inoculated in LB broth with ampicillin (100 µg/mL) and incubated at 37 ºC overnight 
on shaker. Recombinant plasmids from these cells were extracted and purified 
using Qiagen’s Qiaprep spin Miniprep kit (Qiagen). PCRs were performed using 
the purified plasmid and the vector primers as well as the designed gene primers. 
Amplicons were electrophoresed at 100 volts on an agarose gel to confirm the 
presence of the expected product. The products were either gel extracted or 
purified using Qiagen’s gel extraction kit or PCR product purification kit and sent for 
sequencing.  
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2.2.12 Sequencing PCR products  
The identity of the obtained PCR product was confirmed by sequencing.  
Principle: Single stranded primer binds to a strand of dsDNA to be sequenced and 
the primer is extended by addition of nucleotides complementary to the DNA 
strand. As a convention the top and the bottom strands of DNA are represented as 
5’ to 3’ and 3’ to 5’, respectively. The forward primer binds to and thus reads the 
bottom strand of DNA and the reverse primer binds to and thus reads the top 
strand of DNA; both reads are given to the customer in 5’ to 3’ direction.   
 
Methodology: PCR products for sequencing were purified either using Qiagen’s 
gel extraction kit or Qiagen’s PCR product purification kit, as per manufacturer’s 
instructions. The concentration and purity of DNA was checked using a Nanodrop 
3.1 (Thermo Scientific, UK) and sent to the Wolfson Institute for Biomedical 
Research (University College London) or GATC-Biotech (London, UK) for 
sequencing, as per their respective specifications. Forward and backward reads for 
a product were requested. Characterised sequences were accessed and analysed 
using Applied Bio systems sequence scanner v 1.0. The forward and backward 
reads were aligned using blastn at NCBI to obtain the most clearly sequenced 
section of the DNA. This section of sequence was then used to find its matches in 
the NCBI database. 
 
2.2.13 Determination of iron saturation of holotransferrin  
In order to check the iron saturation of holotransferrin used in iron supplementation 
experiments, a urea gel assay was performed.  
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Principle: Transferrin is a bi-lobed protein. The N-lobe corresponds to the amino 
terminus of the protein and the C-lobe corresponds to the carboxyl terminus of the 
protein. Each lobe can accommodate up to one Fe3+ ions. Transferrin can thus 
exist in 4 different forms : holotransferrin, when both the lobes of transferrin are 
occupied by Fe3+; monoferric transferrin, when only one of the two lobes of 
transferrin is occupied with Fe3+ and apotransferrin when no Fe3+  is bound to 
transferrin (Makey and Seal, 1976).   
 
Since apotransferrin is iron-free, it is easily unfolded by 6 M urea and thus runs 
slowly on the gel. On the contrary, iron bound to transferrin does not allow urea to 
unfold the protein structure. Since the protein remains intact, iron bound transferrin 
runs at a comparatively faster rate than apotransferrin. Thus the 4 forms of 
transferrin have different mobilities on a 6 M urea gel and this allows identification  
of the different forms (Evans and Williams, 1978)(Makey and Seal, 1976).  
 
Methodology: Solutions of holotransferrin (SCIPAC LTD, Kent, UK) 5 g/L and  
apotransferrin (SCIPAC LTD, Kent, UK)  were prepared in 0.01 mM sodium 
bicarbonate. The concentrations and preparation of buffers and solutions are 
mentioned in appendix II. Briefly, two 400 cm2 glass plates were prepared with  
1 mm spacers between the two plates. Acrylamide gel solution was prepared and 
poured in between the glass plates and allowed to set with a comb of wells. The 
gel was then pre-equilibrated with stock buffer in the appropriate tank.  
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Samples for loading were prepared by adding 20 L of transferrin solutions to  
30 L of sample buffer. From this, 40 L of sample was loaded into each well of 
the gel and 110 volts current was applied for 16 hours. Gels were then removed 
from the glass plates and stained overnight with coomassie blue solution with 
gentle agitation. This was followed by overnight destaining in 10 % acetic acid and 
10 % methanol. The gel was placed on a scanner and a photograph was taken. As 
seen in Fig. 2.4 the vast majority of the protein was holotransferrin, as expected, 
with some proportions of monoferric transferrins. 
 
 
 
 
 
 
 
 
 
 
2.2.14 Pre-iron supplementation optimisations 
For the iron supplementation experiment it was important that the iron supplied to 
the cells was of a defined concentration, type, and the sole source of iron available 
to the cells. Since FCS, which is a component of normal maintenance medium, 
may contain inorganic iron as well as holotransferrin, it was necessary to ensure 
that the iron supplementation studies were performed in a serum-free medium. 
Fig. 2.4  A 6 M urea gel assay 
Lane 1: Apotransferrin  
Lane 2: Holotransferrin (SCIPAC) 
1          2 
Monoferric transferrin 
 
 Monoferric transferrin 
Holotransferrin  
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However, the survival of cells without FCS for a long period of time would be 
difficult. Hence bovine serum albumin (BSA) was chosen as a substitute for FCS. 
Since iron can bind to albumin (Silva and Hider, 2009), BSA was checked for the 
presence of any bound iron through the ferrozine assay described in section 
2.2.17.1. Results revealed that there was no detectable iron in 4 % BSA prepared 
in deionised water (appendix III). Thus it was concluded that the BSA was iron-free 
and the holotransferrin supplementation prepared in a medium containing BSA 
would be the only source of iron available to the cells. 
 
Following this, cells were grown in different BSA concentrations (1 % BSA to 8 % 
BSA made in serum-free EMEM) to check the minimum concentration of BSA that 
would support cell survival in the absence of FCS throughout the duration of an 
iron supplementation experiment. The medium of choice was EMEM as it does not 
contain any inorganic iron. Cell viabilities were determined (section 2.2.16) after 6 
hours, 24 hours and 48 hours and the results were compared to the cells growing 
in normal maintenance medium with FCS at that time point. Viability studies along 
with cell morphology observations suggested that the BSA-free and serum-free 
medium was the most suitable for the cells up to 48 hours (appendix IV). 
 
Hence for the iron supplementation experiments, the cells were treated with the 
desired concentration of holotransferrin prepared in serum-free and BSA-free 
EMEM. Throughout the thesis, the term 'iron overdose' refers to the treatment of 
the cells whereas 'iron overload' refers to high intracellular iron content.  
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Also, before every experiment, the difference between the Wt HepG2 cells and rec-
TfR1 HepG2 cells was established by growing the cells in 500 µg/mL hygromycin B 
in one well of a 6 well plate. The recombinant HepG2 cells survived in hygromycin 
B due to the presence of the hygromycin B resistance gene in the pCEP4 plasmid 
whereas the Wt HepG2 cells died after 5-7 days. This confirmed the cell type. 
Images of HepG2 cells grown under different conditions are shown in Fig. 2.5. 
        
                 
 
 
 
2.2.15 Iron supplementations 
For the iron supplementation experiments, cells were seeded at a density of 3 X 
105 per well in a 24 well plate or 5 X 105 per well in a 6 well plate in maintenance 
medium with hygromycin B (for rec-TfR1 HepG2 and HepG2 (p) cells) and without 
hygromycin B (for Wt HepG2 and CHO TRVb1 cells). The medium was changed 
every 48 hours until the cells reached 60 % - 70 % confluence. For the next 24 
hours all cells were incubated in fresh hygromycin-free maintenance medium. 
Following the 24-hour hygromycin-free incubation the cells were washed twice with 
warm PBS to remove traces of FCS. This was followed by holotransferrin 
treatments (1 g/L to 5 g/L for 30 min, 2, 4, 6, 24 and 48 hours). These 
Fig. 2.5  Effect of hygromycin B on HepG2 cells 
A: Wt HepG2 cells in maintenance medium without hygromycin B.  
B: Rec-TfR1 HepG2 cells in maintenance medium with 500 µg/mL hygromycin B.  
C: Wt HepG2 cells in maintenance medium with 500 µg/mL of hygromycin B. 
A B C 
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holotransferrin treatment solutions were prepared in BSA-free, serum-free and 
hygromycin-free EMEM, denoted as 0 g/L. Alongside the holotransferrin 
treatments, cells were also treated with 0g/L which represented the untreated 
control, as well as the maintenance medium to enable comparisons between 
different conditions.  
 
Cells were incubated for the required period of time and assessed for viability (as 
per section 2.2.16), intracellular iron concentration (as per section 2.2.17) and 
gene expression (as per sections 2.2.18 and 2.2.19). 
 
2.2.16 Viability assay  
Following the experimental treatments, cell viability was assessed using the MTT 
assay (Mosmann, 1983).  
Principle: Live cells possess active reductase enzymes. The enzymes convert   
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), a yellow 
tetrazolium salt, into purple coloured insoluble formazan crystals. The formazan 
crystals are dissolved by DMSO and the solution is read spectrophotometrically. 
Since these enzymes are only found in active mitochondria, this conversion only 
occurs in live cells. Hence, the higher the absorbance, the higher the viability of 
cells, compared to the control.  
Methodology: To compare the viability of cells in between different treatments,  
2.5 X 104 cells were seeded per well of a 96 well plate in maintenance medium. 
The plate was incubated overnight at 37 ºC in a humidified atmosphere with 5 % 
CO2. The following day, the maintenance medium was removed and the cells were 
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washed twice with warm PBS to remove traces of the maintenance medium. 
Treatment media were then added to each well and the plates were again 
incubated at 37 ºC in a humidified atmosphere with 5 % CO2. On completion of the 
treatment exposure period, the old media were replaced with 200 µL of fresh media 
per well. This was followed by addition of 5 µL per well of 5 mg/mL of MTT 
prepared in PBS. The plates were incubated at 37 °C  for 2 hours, the media were 
removed and 100 µL DMSO was added to each well. Plates were incubated at RT 
for 15 min, vortexed for 30 sec and absorbances were read at 550 nm using a 
spectrophotometer. The absorbance values of blanks (medium only) were 
subtracted from controls and treated samples. 
 
2.2.17 Determination of cellular iron and protein content  
In order to determine the intracellular iron level, cells were washed twice with ice 
cold PBS and the plates were frozen at -20 ºC to induce cell lysis. After overnight 
incubation, to each well, 200 µl (in a 24 well plate) or 500 µl (in a 6 well plate) of 50 
mM sodium hydroxide was added. Cells were detached by rocking on a plate 
shaker for 2 hours and collected in sterile 1.5 mL tubes. Cell lysis was further 
promoted by vortexing and one freeze-thaw cycle. The samples (i.e. cells) were 
dissolved in 50 mM NaOH, syringed using a 25 G needle and centrifuged for 10 
min at 13,000 rpm (16,060 x g) at 4 ºC. The supernatant was collected in a 1.5 mL 
tube, from which 100 µL was used in the ferrozine assay for iron determination and 
5 µL was used in the Bradford assay for protein quantification. The iron content 
determined through the ferrozine assay was expressed as nmoles of iron per mg of 
protein. 
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2.2.17.1 Determination of cellular iron content by the ferrozine assay 
Principle: In an acidic environment and reducing conditions, iron is detached from 
the proteins to which it is bound and converted from Fe3+ to Fe2+. The iron 
detection reagent contains ferrozine, a chromophore with an aromatic ring 
structure, which binds to Fe2+ iron and gives a purple colour, which is measured 
spectrophotometrically. 
 
Methodology: Iron standards were prepared (10 µM to 150 µM or 5 µM to 20 µM)  
from an iron atomic absorption standard solution (Fig. 2.6). The ferrozine assay 
was modified from Riemer et al. (2004). The supernatant of the cell lysate was 
used for the ferrozine assay. Additionally, 45 µL of iron detection reagent was 
added to the samples and the samples were incubated for 1 hour at RT in the dark. 
The intensity of the colour was measured spectrophotometrically at 550 nm.  
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2.2.17.2 Determination of cellular protein content by the Bradford assay 
Principle: The dye Brilliant Blue G present in the Bradford reagent binds to the 
proteins in the solution to form blue coloured complexes. These complexes cause 
Fig. 2.6  A typical iron standard curve 
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a shift in the absorption maximum of the dye from 465 to 595 nm. The higher the 
absorbance, the more protein present in the sample.  
 
Methodology: The Bradford assay was performed as per the manufacturer’s 
guidelines (Sigma-Aldrich, Gillingham, UK) using the BSA protein standard liquid in 
the range from 0 -1.4 mg/mL. 
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2.2.18 RNA extraction and complementary DNA (cDNA) synthesis 
In order to understand gene expression under treatment conditions, RNA was 
extracted from cells, converted to cDNA and used as a template in real time PCR.  
Principle: TRI reagent lyses the cells and keeps the RNA stable to be processed. 
Addition of 1-bromo-3-chloropropane facilitates phase separation, i.e. separation of 
RNA from DNA and proteins. The supernatant which contains RNA is treated with 
isopropanol to precipitate RNA. 
 
Methodology: RNA was extracted from cells with TRI reagent using the 
manufacturer’s protocol (Sigma-Aldrich, Gillingham, UK), which was modified as 
Fig. 2.7  A typical protein standard curve 
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described as follows. The entire process was performed on ice, except when 
indicated otherwise. Cells were washed with warm PBS. TRI reagent was directly 
added dropwise to the cells: 1 mL for 25 cm2 flask, 200 µL for a well of a 24-well 
plate and 500 µL for a well of a 6-well plate. In the case of 24-well plates, TRI 
reagent-cell suspensions were pooled together to increase the RNA concentration. 
The cell suspensions were collected in 1.5 mL tubes and stored overnight at -80 ºC 
to prevent RNA degradation. The next day, tubes were thawed on ice and 
incubated at RT for 15 min. 150 µL of 1-bromo-3-chloropropane was added per 
500 µL of cell suspension in the TRI reagent, mixed by inverting the tubes and 
incubated at RT for 3 min. For phase separation, tubes were centrifuged at 4000 
rpm (1,523 x g) for 15 min at 4 ºC. The resultant top layer containing RNA was 
aliquoted into a separate tube. Isopropanol, at 1/4th this volume, was added and 
RNA was precipitated overnight at -20 ºC. The following day, tubes were 
centrifuged at 13,000 rpm (16,060 x g) for 15 min at 4 ºC. To the RNA pellet, 500 
µL of 70 % ethanol was added and centrifuged at 10,000 rpm (9,520 x g) for 10 
min at 4 ºC. The supernatant was removed completely and tubes were allowed to 
dry on ice. The RNA was suspended in 30 µL of DEPC-treated nuclease-free water 
and stored at -80 ºC. Reverse transcription and cDNA synthesis from this RNA was 
performed according to Qiagen’s QuantiTect reverse transcription kit protocol. All 
RNA preparations used in cDNA conversions had a 260/280 ratio >1.7. Once the 
cDNA was prepared, it was immediately analysed through real time PCR to 
prevent any degradation.  
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2.2.19 Real time PCR using SYBR green as detector 
Principle: Real time PCR (RT PCR) measures the amount of product formed 
during a PCR in real time. In the SYBR green real time PCR, the fluorescent dye 
SYBR green binds to the minor grooves of DNA and binds only to double stranded 
(ds) DNA. As the cycles progress, an increase in fluorescence is measured by the 
machine which provides a set of CT (threshold cycle) values. CT is a cycle at which 
there is a significant detectable increase in the amount of fluorescence. Hence, the 
higher the initial starting template cDNA, the earlier the fluorescence will reach a 
certain threshold and lower will be the CT value. These CT values are then 
mathematically processed further for biological interpretations. 
 
Methodology: All real time PCRs were performed using Qiagen’s Quantifast 
SYBR green kit, as per manufacturer’s protocol (Table 2.5). cDNA equivalent to 
100 ng RNA was used in each reaction, except when performing standard dilution 
curves as described in the following section. The reactions were carried out in the 
Rotor-gene Q machine (Qiagen, Crawley, UK) and results were analysed using 
Rotor-gene software series 1.7. Products were electrophoresed on 1 % agarose 
gel to ensure product formation of the expected size.  
Contents Volume  Real time PCR cycle steps  
Nuclease free water 4 µL 1. Initial denaturation temperature: 95 ºC for 10 min  
2. Denaturation: 94 ºC for 10 sec  
3. Annealing:  60 ºC for 15 sec (or 12 sec)  
4. Extension: 72 ºC for 20 sec (or 15 sec)  
5. Repeat step 2 to 4, 39 times or 34 times  
 
 
SYBR green master 
mix 
10 µL 
5 µM Forward primer 2 µL 
5 µM Reverse primer 2 µL 
cDNA equivalent to 
100 ng RNA. 
2 µL 
Total volume 20 µL 
 
 
Table 2.5  SYBR real time PCR protocol and cycles 
The table describes standard real time PCR protocol. The cycling steps described represent the 
default cycle, except when modified for optimisations as indicated in the brackets. 
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2.2.19.1 Standard dilution series  
Firstly, a PCR was performed to confirm the presence of all genes of interest in the 
cell line of interest. Amplicons obtained were sent for sequencing to confirm the 
sequence identity of each gene (appendix V). This was followed by a pilot real time 
temperature gradient PCR to ensure that the default annealing temperature was 
the most appropriate for product formation (appendix VI).  
 
Amplification efficiencies of all genes of interest were determined by setting up a 2- 
fold dilution series of the cDNA template with the respective primers. The starting 
amount of the template was cDNA equivalent to 100 ng RNA. As an example, the 
TfR1 gene is analysed in Fig. 2.8. The standard curves showing the amplification 
efficiencies and analysis of all other genes of interest are in appendix VII.  
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Fig. 2.8  Analysis of TfR1 standard curve 
A : Melt curve: shows the presence of a single peak, indicating unique product formation 
without any detectable primer dimers. 
B : Cycling curve: a sigmoidal curve of cycle number vs. fluorescence. The shape suggests 
that as the substrates are depleted over the course of cycles and thus the curve flattens 
towards the end. The line of threshold is placed above the negative controls (nuclease-free 
water). This displays a set of CT values which are used by the software to plot the efficiency of 
the reaction, as seen in part C.  
C : Efficiency curve: displays the efficiency of the reaction.  
 
A B C 
Temperature ºC Cycle number Concentration 
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2.2.19.2 Analysis of real time PCR data 
The CT values obtained from a particular experiment were analysed by the 
comparative method, also referred to as the Delta-Delta CT (∆∆CT) relative 
quantification. Essentially, the method is based on the following calculations:  
(I)   ∆ CT of sample = CT of target gene  -  CT of reference gene (in this study it 
was glyceraldehyde 3-phosphate dehydrogenase, GAPDH) 
(II)    ∆ CT of untreated  = CT of target gene  -  CT of reference gene 
(III)   ∆∆ CT = ∆ CT of sample - ∆ CT of untreated   
(IV) Normalised target gene expression of sample=  2-∆∆ CT 
 
2.2.20 Detection of transferrin receptor on cell surface  
The effect of holotransferrin treatments on the cell surface expression of TfR1 was 
studied using flow cytometry. 
Principle: The human transferrin receptor, to be detected, binds to a 
complementary primary antibody. A fluorescein isothiocyanate (FITC)-labelled 
secondary antibody binds to the primary antibody and this label is detected by the 
flow cytometer. The higher the fluorescence detected, the higher would be the 
number of transferrin receptors present on the cell surface.  
 
Method: Cells were seeded at a density of 5 X105 cells per well in a 6 well plate. 
After 24 hours, the cells were washed with PBS to remove traces of the 
maintenance medium. Following this, the cells were either serum deprived for 24 
hours followed by addition of the treatment medium or the treatment medium was 
added immediately after washing the cells without any period of serum deprivation. 
 56 
 
The cells were then incubated with the treatment medium for the desired period of 
time and harvested for flow cytometry. Cell harvesting was accomplished by 
dissociation of cells with 500 µL of TrypLE Express (ThermoFisher Scientific, UK), 
per well of a 6 well plate for 7 min, followed by centrifugation for 4 min at 1000 rpm 
(89 x g). Cells were suspended in PBC (PBS containing 0.15 % BSA and 1 mM 
calcium chloride) and 200 X 103 cells from each well were transferred to a 96 well 
plate. Cells were washed 3 times with PBC by centrifugation at 3800 rpm (~ 1,263 
x g) for 30 sec, on slow acceleration and no brake. Then, to each well, 20 µL of 
blocking IgG (i.e. γ-globulins from human blood) was added at the concentration of 
16 mg/mL prepared in PBC.  
 
The primary antibody, in this study the human transferrin receptor antibody (Abcam 
Cambridge, UK), was prepared at the optimised concentration of 5 µg/mL in PBC. 
20 µL of this solution was added to each of the test wells whereas the control wells 
were supplemented with 20 µL of PBC. The controls cells without the primary 
antibody and the treated cells with the primary antibody were incubated for 45 min 
on ice. The cells were then washed with PBC, as previously described, to remove 
any non-specifically bound primary antibody. A FITC-labelled secondary antibody 
STAR9B, rabbit F (ab')2 anti-mouse IgG (ABD Serotec Kidlington,UK) was added, 
at a concentration of 10 µg/mL; 40 µL was added to each well. The cells were 
incubated for 30 min on ice and washed twice with PBC and once with PBS, as 
previously described. The cell layer formed at the bottom of each well was 
resuspended in 200 µL of PBS. At the time of analysis using the flow cytometer, 
this 200 µL of cell suspension was transferred to a tube already containing 200 µL 
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of PBS. Thus for each sample 400 µL of cell suspension was analysed. All 
samples were kept on ice during analysis. Fig. 2.9 shows a typical analysis of cell 
surface TfR1 via flow cytometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.21 Detection of human TfR1 in CHO TRVb1 cells 
The presence of human TfR1 protein in the CHO TRVb1 cells was checked using 
dot blot chemiluminescence and Western blotting.  
Principle of chemiluminescence: Anti-human TfR1 antibody binds to the TfR1 
and a secondary antibody conjugated to horseradish peroxidase (HRP) binds to 
Fig. 2.9  Analysis of cell-surface TfR1 in Wt HepG2 cells by flow cytometry 
A and B : Cells without the primary antibody (negative control) 
C and D : Cells treated with primary antibody (test) 
 
          C           D 
        A 
        B 
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the primary antibody. The HRP produces luminescence on exposure to 
chemiluminescent substrates, the proportion of luminescence being directly 
proportional to the amount of protein. 
 
Methodology: Wt CHO and CHO TRVb1 cell lines were grown in a 25 cm2 flask in 
the maintenance medium. On reaching 70 % confluence, cells were trypsinised as 
normal. The supernatant was removed and the cell pellet was resuspended in 100 
µL of PBS. To this, 100 µL of 2X loading buffer (800 µl of milliQ water, 2 mL of 0.5 
M tris pH 6.8, 1.6 mL glycerol, 3.2 mL of 10% SDS, 0.5 mL of 0.1 % bromophenol 
blue) was added. The mixture was vortexed for 5 sec and 5 µL of each cell extract 
was applied as a dot on a nitrocellulose membrane (Bio-Rad, UK) and allowed to 
dry for 5 min at RT. Following this, the nitrocellulose membrane was blocked 
overnight at 4 ºC on a shaker, in 5 % milk prepared in PBST (0.05% Tween 20 in 
PBS). 
 
On the following day, the milk was removed and the membrane was washed with 
distilled water. Then the membrane was placed in a clean tray prior to the addition 
of the antibody. The primary antibody, human TfR1 antibody (Cell science) (100 
µg/mL), was diluted 1:2000 in PBS containing 1 % BSA. This antibody solution was 
added onto the membrane and incubated for 1 hour at 37 ºC on a shaker. After 
incubation, the membrane was washed three times for 10 min each wash on a 
shaker with PBST followed by a final wash with PBS for 10 min.  
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A rabbit anti-mouse HRP-conjugated secondary antibody (Dako UK Ltd, UK) was 
diluted 1:1000 by using 1 % BSA in PBS. This was added onto the nitrocellulose 
membrane and the membrane was incubated at RT for 1 hour on a shaker. After 
incubation the membrane was washed with distilled water once, followed by two 10 
min washes with PBST and one wash with distilled water for 10 min.  
 
A mixture of 750 µl of each of the ECL™ Western Blotting Detection Reagents 
(Amersham, GE healthcare, UK) was prepared in a tube and mixed thoroughly and 
added onto the membrane. Two Ryman films were placed on the nitrocellulose 
membrane like a “sandwich” such that the nitrocellulose membrane was in the 
middle and the two films were on either side. One X-ray film was placed on top of 
the sandwich and this assembly was put in a cassette and developed in the dark 
for 10 min. The luminescent signal was thus captured on the film.  
 
SDS PAGE and blotting was performed using the MINI- Protean-3 cell system 
(Laemmli buffer system) and Bio-Rad's Ready Gel, precast gels (BIO-RAD, UK) as 
per manufacturer’s recommendation. The samples for SDS PAGE were prepared 
by addition of dithiothreitol (DTT) at a final concentration of 10 mM to the 
previously prepared cell extract in loading buffer. The samples were boiled for 5 
min at 100 ºC and 20 µL was loaded per well. The samples were subjected to 
electrophoresis and immunoblotting was performed with the antibodies used in the 
dot blot. The concentrations of the primary and secondary antibody as well as the 
detection system were the same as those used in the dot blot.  
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2.2.22 Determination of hepcidin peptide concentrations  
The concentration of hepcidin-25 in the medium was measured by 
radioimmunoassay in collaboration with Dr. Mark Busbridge, Imperial college, 
London UK (Busbridge et al., 2009). 
 
2.2.23 Restriction digest  
pEGFPN1 plasmid constructs containing preprohepcidin derivatives were obtained 
from Dr. Sebastien Farnaud. In order to identify these plasmid constructs, each 
was digested with the restriction enzymes BamHI (Promega, UK) and Hind III 
(Promega, UK), as per the manufacturer’s restriction digest protocol. Prior to 
digestion, the yield of the plasmid was increased by transformation of each of the 
recombinant plasmid constructs into E.Coli XL1 blue cells as explained in section 
2.2.11, except that here 50 µg/mL of kanamycin sulphate (Fisher BioReagents) 
was used as a selection antibiotic (since the plasmid possesses a kanamycin 
resistance gene) without the addition of X-gal and IPTG in the agar plates. 
Following this, the purified plasmids were subjected to single and double restriction 
digest. Essentially, 1.5 µg of plasmid per 20 µL of the digestion reaction was added 
and the reaction mix was incubated at 37 ºC for 1 hour. An aliquot (2 µL) of loading 
buffer was added to 10 µL of the reaction mixture and electrophoresed on 2 % 
agarose gel at 100 V to check for post-digestion products. The host plasmid is 
shown in the Fig. 2.10. 
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2.2.24 Localisation studies of preprohepcidin derivatives 
Localisation studies were performed by transfecting Wt HepG2 cells with the 
recombinant pEGFPN1 plasmid containing the ‘pre-pro’ construct of 
preprohepcidin. The transfection reagent used, Lipofectamine LTX and Plus 
reagent (Life technologies), is specially formulated to transfect the difficult-to-
transfect HepG2 cells.  
Principle of transfection:  Lipid globules surround the plasmids. These  
lipid-coated globules fuse with the cell membranes and the lipid-coated plasmids 
are uptaken by the cells.  
 
Methodology:  HepG2 cells were seeded at a cell density 2 x 105 cells per well of 
a 6 well plate and the transfection procedure was performed using the 
Lipofectamine LTX and PLUS reagent, adapted from the manufacturer’s 
recommendation. Essentially, the Wt HepG2 cells growing in maintenance medium 
Fig. 2.10  Cloning vector pEGFP-N1 plasmid 
Restriction sites for enzymes HindIII and BamHI  
are located within the multiple cloning site. The 
figure is adapted from Clonetech available at 
http://www.liv.ac.uk/physiology/ncs/catalogue/Cloni
ng/pEGFP-N1.htm 
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were trypsinised and seeded into 6 well plates at a cell density of 2 X 105 cells per 
well. After overnight incubation, the transfection procedure was initiated. A 
transfection mix containing 2.5 µg of pEGFPN1 plasmid, 500 µL of Optimem I 
medium and 2.5 µL of PLUS reagent was prepared and incubated for 10 min at 
RT. Following this, 10 µL lipofectamine LTX was added to this preparation and 
incubated for a further 25 min at RT. Once the transfection mix was ready, the 
maintenance medium from the cells was aspirated and replaced with 2.5 mL of 
maintenance medium without antibiotics and 100 µL of transfection mix per well. 
The plate was gently rocked and incubated at 37º C for 24 hours. Cell fixation was 
performed by washing the cells with PBS followed by addition of 2 mL of ice cold 
paraformaldehyde (4%) and incubation at 37º C for 20 min. The paraformaldehyde 
was then removed and 2 mL PBS was added to each well, followed by wrapping 
the plates with foil and storing the plates at 4º C. Prior to analysis by confocal 
microscopy, the PBS was removed and the cells were washed 2 times with fresh 
PBS. The cells were permeabilised using Triton-X 100 (0.1% in PBS) for 10 min at 
RT and washed 3 times with PBS. This was followed by incubation with the nuclear 
staining dye TO-PRO-3 (1 µM in PBS) for 20 min. After washing the cells with PBS, 
2 mL of fresh PBS was added to the cells followed by observation by confocal 
microscopy. 
 
2.2.25 Statistical analysis 
Statistical analysis of the data was carried out using one-way or two-way ANOVA, 
accompanied by post-hoc analysis using the software SPSS, version 19. The level 
of significance was set at p<0.05. 
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Chapter 3  
Effect of iron supplementation on hepcidin expression in recombinant 
Chinese hamster ovary cells 
3. 1 Introduction  
Although in humans and in animal models systemic iron excess leads to a rise in 
hepcidin production (Lin et al., 2007, Pigeon et al., 2001), these results have not 
been replicated in cell lines and primary hepatocytes. Iron overdose to cells 
resulted in variable hepcidin mRNA expression in different cell types as explained 
in chapter 1 section 1.7. This may partly be attributed to TfR1 on the cell surface 
which regulates iron uptake by the cells and thus limits the increase in intracellular 
iron levels. To overcome this limitation, in this study, modified Chinese hamster 
ovary (CHO) cells were used which are devoid of the endogenous TfR1 and 
instead over-express the human TfR1 (McGraw et al., 1987). Due to this specific 
property it was hypothesised that the cells would permit intracellular iron overload 
upon iron overdose and the resultant effect on gene expression could be studied. 
Also, the mechanisms involved in the transferrin cycle in CHO cells have been well 
described and have similar properties to other cell types (Yamashiro et al., 1984). 
Hence these cells were considered suitable for studies related to transferrin-bound 
iron uptake.  
 
The gene sequence of hepcidin and other iron-related genes in the CHO cells have 
not yet been determined. Therefore, it was necessary to first characterise these 
gene sequences to enable expression analyses in real time and thus establish the 
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CHO cells as a model system to study hepcidin and iron regulation. The other iron-
related genes in CHO cells chosen for this study were ferroportin, Hfe and Irp2.  
 
3.1.1 Aims and objectives 
Aim: To characterise iron-related genes in CHO cells.  
Since the hamster species is a rodent it was expected to have high genomic 
similarities with the mouse, rat and human genome. Hence, primers designed 
based on conserved nucleotides between these three species should also bind to 
the CHO genome. This would enable product formation and subsequent 
sequencing of the previously unknown gene sequences. 
 
Objectives:  
1. To identify conserved nucleotides between human, mouse and rat in the gene 
of interest and design primers based on these conserved regions.  
2. To probe the CHO genome with the designed primers and optimise PCR 
conditions to facilitate maximum product formation. 
3. To sequence CHO genes and analyse these using blastn at NCBI to confirm 
sequence identity and compare it to the pre-characterised sequences in the 
database.  
4. To study the effect of iron overdose on hepcidin expression in CHO TRVb1 
cells.  
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3.2  Approach and optimisations  
3.2.1 Concept behind primer design and sequence acquisition  
The aim of characterisation of previously unknown gene sequences in CHO cells 
was based on the hypothesis that there were genomic similarities between the 
hamster and human, mouse and rat. To confirm this, some pre-characterised 
hamster mRNA sequences were compared to corresponding transcripts in human, 
mouse and rat. As seen in table 3.1, the hamster genes showed high sequence 
similarity with the corresponding genes in the mentioned three species.  
Genes in Cricetulus griseus 
(hamster)   
Human  Mouse  Rat  
Transferrin receptor 82% 
99% 
87% 
100% 
87% 
100% 
Dihydrofolate reductase 83% 
65% 
86% 
75% 
97% 
28% 
Heat shock protein 89% 
96% 
93% 
90% 
93% 
90% 
Ferritin 87% 
88% 
91% 
99% 
90% 
99% 
Transferrin 82% 
99% 
88% 
100% 
88% 
100% 
Alpha tubulin 93% 
83% 
95% 
83% 
94% 
99% 
 
 
 
Using this principle, for a particular iron-related gene of interest, primers were 
designed based on conserved nucleotides between human, mouse and rat mRNA 
sequences. These primers were used to probe the CHO genome to obtain a partial 
sequence of that gene. This was the 1st round of sequencing. This partially 
characterised gene sequence was compared to corresponding pre-characterised 
gene sequences in the NCBI database and the identity of the CHO sequence was 
Table 3.1  Similarities between hamster, human, mouse and rat genomes 
The NCBI accession numbers of genes are in appendix VIII.  
Key to table: 
• Sequence similarity with CHO genes 
• Sequence coverage   
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confirmed. Following this, primers were designed again based on the partially 
characterised CHO sequence obtained from the 1st round of sequencing and 
conserved nucleotides between the mentioned three species. These primers, one 
CHO-specific and another based on conserved nucleotides, were used to probe 
the CHO genome to obtain a CHO gene product. This was the 2nd round of 
sequencing. Thus, as explained through Fig. 3.1, the concept of “PCR walking” 
was employed to characterise previously uncharacterised genes in the CHO cells. 
 
 
 
 
 
 
                                                                                                    
 
                                                                                                 
 
 
 
 
 
 
At every round of sequencing, the gene specificity of each designed primer was 
checked using blastn at NCBI. The characterised gene sequences of CHO cells 
5’ 
5’ 
3’ 
3’ 
CHO sequence 
obtained from 1st 
round of 
sequencing 
based on 
conserved 
nucleotide 
between 
human/mouse 
and rat  
CHO sequence obtained from 
2nd round of sequencing 
CHO sequence obtained from 
2nd round of sequencing 
Primer designed based on 
conserved nucleotides 
between human /mouse and 
rat sequences 
Primer designed based on 
conserved nucleotides 
between human/mouse and rat 
sequences  
Fig. 3.1  Concept of “PCR walking” used for CHO gene sequencing    
Primers based 
on the 
characterised 
CHO gene 
sequence 
obtained from 1st 
round of 
sequencing  
Primers in 5’ to 3’ 
direction, designed for 
the 2nd round of 
sequencing 
Double stranded DNA 
Key to figure:  
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were further used to design CHO-specific and exon spanning primers for real time 
PCR. To identify conserved regions, mRNA and protein multiple sequence 
alignments were created using ClustalW2 (available at www.ebi.ac.uk). As an 
example, Fig. 3.2 demonstrates the approach used to design primers and the 
resultant gene sequence acquired for ferroportin gene in CHO cells.   
                                                                         5’ CTT 
HumanSLC40A1_      -----CTAGGCTCGGACGACCTGCTGAGCCTCCCAAACCGCTTCCATAAGGCTTTGCCTT 120 
MouseSlc40a1_      -----CTGCGGCCGG---------TGGATCCTCCAACCCGCTCCCATAAGGCTTTGGCTT 99 
RatSlc40a1_        -----CTGCGGCCGG---------TGGACCCTCCAACCCGCTTCCATAAGGCTTTAGCTT 61 
                   -----**  *  ***         **   *  **** ***** ************  *** 
 
                 5’TCCAACTTCAGCTACAGTGTT >>> 3' 
                   TCCAACTTCAGCTACAGTGTT >>> 3' 
HumanSLC40A1_      TCCAACTTCAGCTACAGTGTTAGCTAAGTTTGGAAAGAAGGAAAAAAGAAAATCCCT-GG 179 
MouseSlc40a1_      TCCAACTTCAGCTACAGTGTTAGCTAAGTTTGGAAAGAAGACAAAAAGAAGACCCCG-TG 158 
RatSlc40a1_        TCCAACTTCAGCTACAGTGTTAGCTAAGTTTGGAAAGAAGACATAAAGAAGACCCCGGTG 121 
                   ****************************************  * ****** * ***   * 
                                                                   5’ATCGGATGTG >>> 
HumanSLC40A1_      ----------TTCCTTCTCTACCTTGGTCATTCTCTCTCTACTTGGGGAGATCGGATGTG 476 
MouseSlc40a1_      ----------TTCCTCCTCTACCTTGGCCACTCTCTCTCCACTTGGGGGGATCGGATGTG 456 
RatSlc40a1_        ----------TTCCTCCTCTACCTTGGCCACTCTCTCTCCACTTGGGGGGATCGGATGTG 416 
                   ----------***** *********** ** ******** ******** *********** 
                   GCACTTTGC >>> 3’ (F)  
HumanSLC40A1_      GCACTTTGCGGTGTCTGTGTTTCTGGTAGAGCTCTATGGAAACAGCCTCCTTTTGACAGC 536 
MouseSlc40a1_      GCACTTTGCAGTGTCTGTGTTTCTGGTGGAACTCTATGGAAACAGCCTTCTCTTGACAGC 516 
RatSlc40a1_        GCACTTTGCAGTGTCTGTGTTTCTGGTGGAACTCTACGGAAACAGCCTCCTCTTGACAGC 476 
                   ********* ***************** ** ***** *********** ** ******** 
                                                              AGCCTCCTCTTGACAGC 
                                                     3’<<< AGGAGAACTGTCG 
                  
HumanSLC40A1_      AGTCTACGGGCTGGTGGTGGCAGGGTCTGTTCTGGTCCTGGGAGCCATCATCGGTGACTG 596 
MouseSlc40a1_      TGTCTATGGACTGGTGGTGGCAGGCTCTGTTCTGGTCCTGGGAGCCATCATTGGTGACTG 576 
RatSlc40a1_        TGTCTACGGGTTGGTGGTGGCAGGCTCTGTTCTGGTCCTGGGAGCCATCATTGGTGACTG 536 
                    ***** **  ************* ************************** ******** 
 
                   TGTCTACGGGCTGGTGGTAGCAGGCTCTGTTCT  
               <<< ACAGATGC 5’   5' TAGCAGGCTCTGTTCTGG >>>3' 
 
                     3’<<< TCTTACGNTCTGAATTTCACCG 5’ (R)  
HumanSLC40A1_      GGTGGACAAGAATGCTAGACTTAAAGTGGCCCAGACCTCGCTGGTGGTACAGAATGTTTC 656 
MouseSlc40a1_      GGTGGATAAGAATGCCAGACTTAAAGTGGCCCAGACGTCACTGGTGGTTCAGAATGTGTC 636 
RatSlc40a1_        GGTGGATAAGAATGCCAGACTTAAAGTGGCCCAGACGTCCCTGGTGGTTCAGAATGTATC 596 
                   ****** ******** ******************** ** ******** ******** ** 
                                           AGTGGCGCAGACTTCACTGGTGGTGCAGAACGTCTC 
HumanSLC40A1_      AGTCATCCTGTGTGGAATCATCCTGATGATGGTTTTCTTACATAAACATGAGCTTCTGAC 716 
MouseSlc40a1_      CGTCATCCTCTGCGGAATCATCCTGATGATGGTTTTCCTACACAAGAATGAGCTCCTGAC 696 
RatSlc40a1_        AGTCATTCTCTGCGGGATCATCCTGATGATGGTTTTCTTACACAAGAATGAGCTTCTGAA 656 
                    ***** ** ** ** ********************* **** **  ******* ****  
                   CGTCATTCTCTGCGGGATCATCCTGATGATGGTTTTCTTACACAAAAACGAGCTTCTGAC 
HumanSLC40A1_      CATGTACCATGGATGGGTTCTCACTTCCTGCTATATCCTGATCATCACTATTGCAAATAT 776 
MouseSlc40a1_      CATGTACCATGGATGGGTCCTTACTGTCTGCTACATCCTGATCATCACTATTGCAAACAT 756 
RatSlc40a1_        CATGTATCATGGATGGGTCCTTACTGTCTGCTACATCCTGATCATCACCATTGCAAACAT 716 
                   ****** *********** ** ***  ****** ************** ******** ** 
                   CATGTATCATGGATGGGTGCTCACTGTCTGCTACATCCTGATCATCACGATTGCAAACAT 
                        5’ ATGGGTGCTCACTGTCTGCTA 3'>>> (FPN for CHO F) 
 
HumanSLC40A1_      TGCAAATTTGGCCAGTACTGCTACTGCAATCACAATCCAAAGGGATTGGATTGTTGTTGT 836 
MouseSlc40a1_      TGCAAATTTGGCCAGTACTGCCACTGCGATCACAATCCAAAGGGACTGGATTGTTGTTGT 816 
RatSlc40a1_        TGCGAATTTGGCCAGTACTGCCACTGCAATTACAATCCAAAGGGACTGGATTGTTGTCGT 776 
                   *** ***************** ***** ** ************** *********** ** 
                   TGCAAATCTGGCCAGTACTGCTACTGCAATCACGATCCAAAGGGACTGGATTGTTGTTGT 
(F1a) 
(F1b) 
(F2) 
(R1) 
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HumanSLC40A1_      TGCAGGAGAAGACAGAAGCAAACTAGCAAATATGAATGCCACAATACGAAGGATTGACCA 896 
MouseSlc40a1_      GGCAGGAGAAAACAGGAGCAGATTAGCAGACATGAATGCTACCATTAGAAGGATTGACCA 876 
RatSlc40a1_        AGCAGGAGAAAACAGGAGCAGATTAGCAGACATGAATGCTACCATTAGAAGGATTGACCA 836 
                    ********* **** **** * ***** * ******** ** **  ************* 
                   GGCGGGAGAGAACAGAAGCAGATTAGCAGATATGAATGCTACCATCAGAAGGATTGACCA 
         (FPN for CHO R) <<<  3’ CTTCGTCTAATCGTCTATACTTACG 5’ 
 
HumanSLC40A1_      GTTAACCAACATCTTAGCCCCCATGGCTGTTGGCCAGATTATGACATTTGGCTCCCCAGT 956 
MouseSlc40a1_      GCTAACCAACATCCTGGCCCCCATGGCTGTCGGCCAGATTATGACATTTGGTTCTCCAGT 936 
RatSlc40a1_        GCTAACCAACATCCTGGCCCCCATGGCTGTTGGCCAGATTATGACATTCGGTTCCCCAGT 896 
                   * *********** * ************** ***************** ** ** ***** 
                   GCTAACCAACATCCTGGCCCCCATGGCTGTCGGCCAGATTATGACATTCGGTTCCCCAGT 
 
HumanSLC40A1_      CATCGGCTGTGGCTTTATTTCGGGATGGAACTTGGTATCCATGTGCGTGGAGTACGTTCT 1016 
MouseSlc40a1_      CATTGGCTGTGGTTTTATTTCCGGTTGGAATTTGGTGTCCATGTGTGTGGAGTACTTCTT 996 
RatSlc40a1_        CATTGGCTGTGGTTTCATTTCTGGTTGGAATTTGGTGTCCATGTGTGTGGAGTACTTCTT 956 
                   *** ******** ** ***** ** ***** ***** ******** ********* *  * 
                   CATTGGCTGTGGTTTCATTTCGGGGTGGAATTTGGTGTCCATGTGTGTGGAGTACTTCTT 
 
HumanSLC40A1_      GCTCTGGAAGGTTTACCAGAAAACCCCAGCTCTAGCTGTGAAAGCTGGTCTTAAAGAAGA 1076 
MouseSlc40a1_      GCTCTGGAAGGTTTACCAGAAGACCCCTGCTCTGGCTGTAAAAGCTGCTCTCAAGGTAGA 1056 
RatSlc40a1_        GCTCTGGAAGGTTTACCAGAAGACCCCTGCTCTGGCTGTAAAAGCTGCTCTCAAGGTAGA 1016 
                   ********************* ***** ***** ***** ******* *** ** * *** 
                   GCTCTGGAAGGTTTACCAGAAAACCCCTGCTCTGGCTGTGAAAGCTGTTCTCAAAGTAGA 
 
HumanSLC40A1_      GGAAACTGAATTGAAACAGCTGAATTTACACAAAGATACTGAGCCAAAACCCCTGGAGGG 1136 
MouseSlc40a1_      GGAGTCAGAACTGAAGCAGCTGACCTCACCTAAAGATACTGAGCCAAAACCTTTGGAGGG 1116 
RatSlc40a1_        GGAGTCAGAACTGAAGCAGCTGACCTCACCTAAAGATACTGAGCCAAAACCTTTGGAGGG 1076 
                   ***  * *** **** *******  * **  ********************  ******* 
                   GGAGGCAGAACTGAAGCAACTGAACTTACCTAAAGACACTGAGCCAAAATCTCTGGAGGG 
 
HumanSLC40A1_      AACTCATCTAATGGGTGTGAAAGACTCTAACATCCATGAGCTTGAACATGAGCAAGAGCC 1196 
MouseSlc40a1_      AACTCATCTAATGGGTGAGAAAGACTCCAACATCCGTGAACTTGAATGTGAACAAGAGCC 1176 
RatSlc40a1_        AACTCACCTAATGGGTGAGAAAGACTCTAACATCCGTGAACTTGAATGTGAACAAGAACC 1136 
                   ****** ********** ********* ******* *** ******  *** ***** ** 
                   AACTCATCTTATGGGTGAGAAAGACTCCAACATCCGTGAACTTGAACATGAGCAAGAGTC 
 
HumanSLC40A1_      TACTTGTGCCTCCCAGATGGCTGAGCCCTTCCGTACCTTCCGAGATGGATGGGTCTCCTA 1256 
MouseSlc40a1_      CACCTGTGCCTCCCAGATGGCAGAGCCCTTCCGCACTTTCCGAGATGGATGGGTCTCCTA 1236 
RatSlc40a1_        CACCTGTGCCTCCCAGATCGCAGAACCCTTCCGCACTTTTCGAGATGGATGGGTCTCCTA 1196 
                    ** ************** ** ** ******** ** ** ******************** 
                   TACGTGTGCCTCCCAGATCGCTGAGCCCTTCCGCACCTTTCGAGATGGGTGGGTCTCCTA 
 
HumanSLC40A1_      CTACAACCAGCCTGTGTTTCTGGCTGGCATGGGTCTTGCTTTCCTTTATATGACTGTCCT 1316 
MouseSlc40a1_      CTATAACCAGCCAGTGTTTCTGGCTGGCATGGGCCTGGCTTTCCTCTATATGACAGTCCT 1296 
RatSlc40a1_        CTATAACCAGCCCGTATTTTTGGCTGGCATGGGCCTGGCTTTCCTCTATATGACAGTCCT 1256 
                   *** ******** ** *** ************* ** ******** ******** ***** 
                   CTATAACCAGCCAGTGTTTCTGGCTGGCATGGGCCTGGCCTTCCTCTATATGACAGTCCT 
 
HumanSLC40A1_      GGGCTTTGACTGCATCACCACAGGGTACGCCTACACTCAGGGACTGAGTGGTTCCATCCT 1376 
MouseSlc40a1_      GGGCTTTGACTGTATCACTACAGGGTACGCCTACACTCAGGGGCTGAGTGGATCCATCCT 1356 
RatSlc40a1_        GGGCTTCGACTGTATCACCACAGGATATGCTTACACTCAGGGACTGAGTGGTTCCATCCT 1316 
                   ****** ***** ***** ***** ** ** *********** ******** ******** 
                   GGGCTTTGATTGCATCACCACAGGGTACGCCTACACTCAGGGACTAAGTGG 
 
                              3’<<<CGTAGTCGNTATTGACCTTATTACC 5’ 
                               3’<<CGTAGTCGNTATTGACCTTATTA   5’ 
HumanSLC40A1_      CAGTATTTTGATGGGAGCATCAGCTATAACTGGAATAATGGGAACTGTAGCTTTTACTTG 1436 
MouseSlc40a1_      TAGTATTTTGATGGGAGCATCAGCAATAACTGGAATAATGGGAACTGTGGCCTTCACCTG 1416 
RatSlc40a1_        CAGTGTTTTGATGGGAGCATCAGCAATAACTGGAATAATGGGAACTGTGGCCTTCACTTG 1376 
                    *** ******************* *********************** ** ** ** ** 
 
 
 
 
 
(F2a)R b
Fig. 3.2  Partial alignment of ferroportin mRNA sequences  
Key to alignment: 
• Ferroportin gene sequence in CHO cells characterised by primers (F) and (R) in 1st round of 
sequencing.  
• Ferroportin gene sequence in CHO cells characterised by primers (F2) and (R2a) in 2nd round of 
sequencing  
• CHO-specific primers, FPN for CHO forward and FPN for CHO reverse, were based on the 
characterised CHO sequence. These primers span exon–exon boundaries in other species, as 
shown by downward arrows on the alignment. 
 
(R2a)
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The NCBI accession numbers of all gene sequences used to design primers are 
listed in appendix VIII. Transcripts alignments and other information on sequencing 
of ferroportin, Hfe and Irp2 genes are in appendices IX, X and XI, respectively. 
 
3.2.2 PCR optimisations 
The CHO cells were maintained in cell culture as described in methods sections 
2.2.1 and 2.2.2, whereas DNA was extracted as per methods section 2.2.5. In all 
PCRs, rat liver DNA and/or mouse kidney were used as positive controls as these 
would yield gene products of expected sizes with the respective primers. Nuclease-
free water was used as a negative control and here no product was expected since 
there was no template in this reaction.  
 
To identify the most appropriate annealing temperature which would facilitate 
unique product formation in high amounts, temperature gradient PCRs were 
performed as described in methods sections 2.2.8 and 2.2.9. This optimisation was 
performed with each primer pair designed for every gene for the 1st round of 
sequencing (table 2.1 and appendix XIII). An example of the temperature gradient 
PCR for ferroportin gene in the 1st round of sequencing is shown in Fig. 3.3. In this 
case, the appropriate annealing temperature that yielded a single product of the 
expected size was identified as 51 ºC and multiple PCR reactions were set at  
51 ºC. The PCR products from these multiple tubes were pooled together, purified 
and sent for sequencing (section 2.2.12) to confirm sequence identity. 
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3.3 Results 
3.3.1 Characterisation of CHO gene sequences  
Using the concept explained in section 3.2.1 and PCR optimisations described in 
section 3.2.2, previously unknown sequences of iron-related genes in CHO cells 
were characterised. As a representation, CHO gene products obtained from the 1st 
round of sequencing are shown in Fig. 3.4.  
1   2  3  4   5   6  7   8  9 10  11 12    1   2  3   4   5   6  7   8  9 10 11 12    
1   2  3   4   5   6  7    8   9 10 11 12    
Fig. 3.3  Temperature gradient PCR for 1st round of CHO ferroportin gene sequencing 
with primers ferroportin (F) and (R) 
DNA was extracted from the CHO TRVb1 cells (as per methods section 2.2.5) and amplified 
under different annealing temperatures (as described in sections 2.2.8 and 2.2.9). cDNA 
synthesis from mouse kidney was performed as described in section 2.2.18.  
 
In all figures:  
Lanes 1,5,9 = mouse kidney cDNA; expected product size=160 bp  
Lanes 2,6,10 = rat liver DNA, expected product size=160 bp 
Lanes 3,7,11 = negative control 
Lanes 4,8,12 = CHOTRVb1 DNA 
 
1   2  3  4    
51 ºC         52 ºC         53 ºC 54 ºC         55 ºC         56 ºC 
58 ºC         59 ºC         60 ºC 61 ºC         
100 bp 
200 bp 200 bp 
100 bp 
100 bp 
200 bp 
100 bp 
200 bp 
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The characterised CHO gene sequences of products encircled in Fig. 3.4, were 
compared to the corresponding pre-characterised gene sequences in other species 
and their identities were studied. For example, the characterised CHO-ferroportin 
sequence shares 92 % identity with the human-ferroportin gene sequence, as 
shown below.  
 
>ref|NG_009027.1|  Homo sapiens solute carrier family 40 (iron-regulated 
transporter), member 1 (SLC40A1),  
 
 Score = 78.8 bits (86),  Expect = 2e-12 
 Identities = 49/53 (92%), Gaps = 0/53 (0%) 
 Strand=Plus/Plus 
 
CHO Ferroportin        1 CAGCCTCCTCTTGACAGCTGTCTACGGGCTGGTGGTAGCAGGCTCTGTTCTGG  53 
                              ||||||||| |||||||| ||||||||||||||||| ||||| |||||||||| 
Human Ferroportin   10548 CAGCCTCCTTTTGACAGCAGTCTACGGGCTGGTGGTGGCAGGGTCTGTTCTGG  10600 
 
 
     1      2      3     4     1     2     3     4     1    2    3    4     
Fig. 3.4  Amplicons generated for 1st round of CHO gene sequencing 
Encircled products were purified and their sequence identity was confirmed as described in 
methods section 2.2.12. 
 
A: Amplicons of ferroportin gene in rodents and CHO cells with primers ferroportin (F) and (R); 
expected size of controls= 160 bp   
B: Amplicons of HFE genes in rodents and CHO cells with primers HFE (F) and (R); 
expected size of controls= 185 bp 
C: Amplicons of IRP2 gene in rodents and CHO cell lines with primers IRP2 (F) and (R);           
expected size of controls= 215 bp 
 
Lane 1= rat liver DNA (control) 
Lane 2= mouse liver DNA (control) 
Lane 3= CHO TRVb1 DNA 
Lane 4= negative control 
 
A B C 
100 bp 
200 bp 
100 bp 
200 bp 
100 bp 
200 bp 
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Following this, the 2nd round of CHO gene sequencing was initiated with primers 
listed in table 2.1. Coincidently, for all genes of interest, the primers F1 & R1 
showed minimal product formation, whereas primers F2 & R2 (R2a for ferroportin 
and Irp2 genes) yielded a comparatively higher amount of product (appendix XIII). 
Hence these were used for subsequent sequencing reactions. 
 
Percentage identities between the characterised CHO gene sequences and pre-
existing gene sequences in the database were tabulated (Table 3.2). Data showed 
that the iron-related genes bore very high level of genomic similarities between the 
hamster and human, mouse and rat, as hypothesised.  
Genes CHO sequence characterised in     
1st  round of sequencing 
CHO sequence characterised in 
 2nd round of sequencing 
 Human  Mouse  Rat Human  Mouse  Rat 
Ferroportin 92 % 92 % 96 % 89 % 93 % 92 % 
Hfe 86 % 91 % 87 % 80 % 88 % 88 % 
Irp2 95 % 94 % 96 % 92 % 97 % 96 % 
 
 
 
 
3.3.2 Functional analysis of characterised gene sequences 
In order to understand the link between the genome and proteome and whether 
genomic similarities seen in table 3.1 inferred proteomic similarities, the 
characterised CHO gene sequences were translated to protein sequences and 
compared to corresponding protein sequences in other species. Fig. 3.5 shows 
functionally significant amino acids in ferroportin in different species. 
 
Table 3.2  Percentage identity between characterised CHO gene sequences and other 
species 
The table shows identities between the characterised CHO gene sequences and the pre-
characterised gene sequences of other species in the NCBI database. Full details on the 
sequencing data on characterised CHO gene sequences for ferroportin, HFE and IRP2 
genes are in appendices IX, X and XI, respectively. 
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HumanSLC40a1        MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLL 60 
MouseSlc40a1        ------------------------------------------------------------ 
RatSlc40a1          MTKSRDQTHQEGCCGSLANYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNGLLL 60 
CHOFerroportin      --------------------------------------------------------SLLL 4 
                                                                                 
HumanSLC40a1        TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHEL 120 
MouseSlc40a1        TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 60 
RatSlc40a1          TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 120 
CHOFerroportin      TAVYGLVVAGSVLVA-----------------QTSLVVQNVSVILCGIILMMVFLHKNEL 47 
                    **************                  *************************:** 
 
HumanSLC40a1        LTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRI 180 
MouseSlc40a1        LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 120 
RatSlc40a1          LNMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 180 
CHOFerroportin      LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 107 
                    *.******** **********************************:**:**:******** 
                                         N144H            V162∆  
          
HumanSLC40a1        DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLK 240 
MouseSlc40a1        DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 180 
RatSlc40a1          DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 240 
CHOFerroportin      DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAVLK 167 
                    ****************************************.**************** ** 
 
 
HumanSLC40a1        EEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWV 300 
MouseSlc40a1        VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQMAEPFRTFRDGWV 240 
RatSlc40a1          VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQIAEPFRTFRDGWV 300 
CHOFerroportin      VEEAELKQLNLPKDTEPKSLEGTHLMGEKDSNIRELEHEQESTCASQIAEPFRTFRDGWV 227 
                     **:*****.  ******.******** *****:*** ***.*****:************ 
                               K253 
 
HumanSLC40a1        SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 360 
MouseSlc40a1        SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 300 
RatSlc40a1          SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSVLMGASAITGIMGTVAF 360 
CHOFerroportin      SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLS---------------------- 265 
                    **************************************                       
                     Y302,Y303              C326 
  
 
 
The translated HFE CHO gene sequences when alignme with the previously  
 
It can be seen that the CHO proteome bears a high degree of proteomic similarly 
with other species. The transmembrane region (De Domenico et al., 2008, Wallace 
et al., 2009) as well as the amino acids involved in binding hepcidin (De Domenico 
et al., 2008) are conserved. The amino acid C326 lies in the hepcidin binding 
domain in the extracellular environment and is consistent with its role in binding to 
hepcidin (Wallace et al., 2009). A mutation C326Y affects binding of hepcidin to 
Fig. 3.5  Functional significance of the characterised CHO-ferroportin sequence  
The characterised gene sequence of ferroportin in CHO cells was translated using the functional 
tool “translate” available at web.expasy.org, and compared to ferroportin protein sequences of 
different species..  
Key to alignment:                       
• Transmembrane region  
• Hepcidin binding domain  
• K253,Y302,Y303 : amino acids affecting ferroportin degradation and internalisation  
• N144H, V162 ∆: Mutations that disruption ferroportin function 
• * represents conserved amino acid between species 
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ferroportin, reflecting the significance of this amino acid in ferroportin degradation 
and internalisation (De Domenico et al., 2008). This amino acid is also conserved 
in the CHO cells within the hepcidin binding domain. Binding of hepcidin to 
ferroportin leads to phosphorylation of either Y302 or Y303 followed by ferroportin 
internalisation (De Domenico et al., 2007) and degradation, involving K253 (De 
Domenico et al., 2006). Interestingly, these amino acids in the CHO proteome lie in 
the same position relative to other amino acids, as in human, mouse and rat 
proteomes. Additionally, in the CHO cells, the amino acids N144 and V162 are 
conserved, which if mutated, exhibit hepcidin insensitivity (Wallace et al., 2009). 
Also, the cysteines which form disulphide bonds and usually play a significant role 
in the folding and stability of proteins (Sevier and Kaiser, 2002), are well conserved 
in the characterised CHO-ferroportin sequence. Similarly, functional analysis of the 
characterised CHO-Hfe sequence was performed (Fig. 3.6). 
HumanHFE        ----MGPRAR-PALLLLMLLQTAVLQGRLLRSHSLHYLFMGASEQDLGLSLFEALGYVDD 55 
MouseHFE        MSLSAGLPVR-PLLLLLLLLWSVAPQALPPRSHSLRYLFMGASEPDLGLPLFEARGYVDD 59 
RatHFE          MDRSAGLPVRLLLLLLLLLLWSVAPQALRPGSHSLRYLFMGASKPDLGLPFFEALGYVDD 60 
CHOHFE          -----------------------------------------------------AMGYVDD 7 
                                                                     * ***** 
 
HumanHFE        QLFVFYDHESRRVEPRTPWVSSRISSQMWLQLSQSLKGWDHMFTVDFWTIMENHNHSK-- 113 
MouseHFE        QLFVSYNHESRRAEPRAPWILEQTSSQLWLHLSQSLKGWDYMFIVDFWTIMGNYNHSKVT 119 
RatHFE          QLFVSYNHESRRAEPRAPWILGQTSSQLWLQLSQSLKGWDYMFIVDFWTIMGNYNHSKVT 120 
CHOHFE          QLFVSYNHENRRAEPRAPWI---TSSQLWLQLSQSLKGWDHMFIVDFWNIMDNYNHSKGS 64 
                **** *:**.**.***:**:    ***:**:*********:** ****.** *:****   
                     H63D 
 
HumanHFE        ------ESHTLQVILGCEMQEDNSTEGYWKYGYDGQDHLEFCPDTLDWRAAEPRAWPTKL 167 
MouseHFE        KLGVVSESHILQVVLGCEVHEDNSTSGFWRYGYDGQDHLEFCPKTLNWSAAEPGAWATKV 179 
RatHFE          KLRVVPESHILQVILGCEVHEDNSTSGFWKYGYDGQDHLEFCPKTLNWSAAEPRAWATKM 180 
CHOHFE          KLGVMPESHILQVILGCEVHEDNSTSGIWKYGYDGQDHLEFCPTTLEWRAAEPGAWTTKV 124 
                      *** ***:****::*****.* *:************* **:* **** **.**: 
 
HumanHFE        EWERHKIRARQNRAYLERDCPAQLQQLLELGRGVLDQQVPPLVKVTHHVTSSVTTLRCRA 227 
MouseHFE        EWDEHKIRAKQNRDYLEKDCPEQLKRLLELGRGVLGQQVPTLVKVTRHWASTGTSLRCQA 239 
RatHFE          EWEEHRIRARQSRDYLQRDCPQQLKQVLELQRGVLGQQVPTLVKVTRHWASTGTSLRCQA 240 
CHOHFE          EWEEHKIRTRQNKDYLERDCPEQLK----------------------------------- 149 
                **:.*:**::*.: **::*** **:                                    
 
 
 
Fig. 3.6  Functional significance of the characterised CHO-Hfe sequence  
Translation of CHO-Hfe sequence was carried out as described in legend of Fig. 3.5.  
Key to alignment: 
• α 1 and α 2 : domains of HFE protein involved in interaction with transferrin 
• H63D : mutation that leads to haemochromatosis in humans 
• * represents conserved amino acid between species. 
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The alignment in Fig. 3.6 reveals high conservation of the alpha 1 and alpha 2 
regions of Hfe protein. These regions are known to interact with the transferrin 
receptor and play a role in transferrin-bound iron uptake (reviewed in Fleming, 
2009). Also, the characterised Hfe gene sequence in CHO cells showed the 
presence of histidine H63 at the same relative position as other species. A 
mutation (H63D) leads to the development of hereditary haemochromatosis in 
humans (reviewed in Pietrangelo, 2006).  
 
The iron regulatory proteins IRP1 and IRP2 play a significant role in maintaining 
cellular iron levels by binding to IREs on transcripts of various genes (reviewed in 
Muckenthaler et al., 2008). It has been proposed that IRP2 acts as an iron sensor 
within cells (Kang et al., 2003). Functional analysis of the characterised CHO-Irp2 
revealed the presence of important amino acids proposed to be involved in iron 
binding (Kang et al., 2003), as shown in Fig. 3.7. 
 
 
 
 
 
  
 
  
HumanIRP2 AIQNAPNPGGGDLQKAGKLSPVKVQPKKLPCRGQTTCRGSCD 179 
MouseIRP2 AIQNAPNPGGGDLQKAGKLSPLKVQSKKLPCRGQTTCRGSCD 180 
RatIRP2   AIQNAPNPGGGDLQKAGKLSPLKVQPKKLPCRGQTTCRGSCD 180 
CHOIRP2   -----------------------VQPKKFPCRGQTTCRGSCD 19 
                                 **.**:************* 
 
 
Fig. 3.7  Functional significance of the characterised CHO-Irp2 sequence  
Translation of CHO-Irp2 gene sequence was carried out as described in legend of Fig. 3.5. 
A: The encircled amino acids have been proposed to be involved in iron binding.  
B: The proposed amino acids are conserved in the CHO proteome in the same relative position, 
as in other species. * represents conserved amino acid between species. 
  
B 
A 
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3.3.3 CHO specific primers and preliminary real time PCR 
The purpose of characterising gene sequences in the CHO cells was to enable 
gene expression analysis upon iron overdose and thus using the CHO cells as a 
model system to study iron regulation. To serve the purpose, CHO-specific primers 
were designed based on the characterised CHO gene sequences. While designing 
these primers the exon–exon boundaries in the human, mouse and rat genomes 
were taken into consideration; assuming that these boundaries would be similar in 
the hamster genome (appendices IX-XI). These CHO-specific primers were used 
to amplify the CHO cDNA to confirm their appropriateness for use in real time PCR 
(appendix XIII). The resultant CHO gene products obtained were sequenced to 
confirm sequence identity.    
 
For the Hfe gene in CHO cells, three CHO-specific primers were designed, one 
forward and two reverse primers Hfe-for-CHO-Rx and Hfe-for-CHO-Ry. Both 
primer pairs yielded unique products of expected sizes (appendix X). The primer 
Hfe-for-CHO-Rx spans the exon-exon boundary in other species and therefore was 
initially considered appropriate for the real time PCR as it would eliminate the 
possibility of binding to DNA. However, the product size obtained with this primer 
(319 bp) was more than that recommended for an ideal real time PCR (<200 bp). 
Conversely, although the primer Hfe-for-CHO-Ry did not span exon-exon boundary, 
the product size formed (167 bp) is considered ideal for the real time PCR. Hence, 
despite formation of a single product of the expected size with both the reverse 
primers, the primer Hfe-for-CHO-Ry was used to amplify the CHO-Hfe gene.  
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On confirming gene identity, it was used in the subsequent standardisation of RT 
PCR (Fig. 3.8).     
 
Selection of a reference gene is crucial for the analysis of real time PCR data. 
Ideally, the expression levels of the reference gene should stay relatively stable on 
exposure to different stimuli. However, many studies have observed fluctuations in 
the expression levels of these genes and also that this variability was species-, 
cell- and tissue-specific and at times was dependent on the experiment conditions 
(reviewed in Bahr et al., 2009).  
 
In this context, Bahr et.al., (2009) validated the use of some reference genes for 
CHO cells. From this group, beta actin, that has been traditionally used as a 
reference gene and pabpn1 gene were chosen for this study. The pabpn1 gene 
encodes for a poly (A) binding protein which functions in the nucleus, unlike the 
actins which are found in the cytoplasm. The intention behind this selection was to 
normalise the genes of interest against two reference genes which function in 
different cell locations. This would improve the reliability of the real time PCR data.  
 
On performing a PCR with the designed primers (Table 2.1) formation of unique 
products confirmed the appropriateness of the primers of reference genes 
(appendix XIV) and the designed CHO-specific primers for genes of interest 
(appendix XIII). Following this, a preliminary real time PCR was performed, as 
shown in Fig. 3.8, to confirm the uniqueness of products formed and the 
appropriateness of the designed primers.  
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As seen in Fig. 3.8, the melt curve (A) shows the presence of two peaks with the 
Irp2 primers. This suggested the formation of a non-specific product, as was 
confirmed by agarose gel electrophoresis of the real time PCR products ((B) lane 
3). Thus the Irp2 primers required redesigning. Secondly, although the pabpn1 
primers showed single product formation in the melt cure (A), agarose gel 
electrophoresis revealed the presence of another product, as detected in (C) lane 5. 
Hence the beta actin gene product seen in (B) lane 4 was sequenced. On 
confirming its identity it was concluded that beta actin should be used as reference 
gene instead of pabpn1 for further real PCR with CHO cells. The Hfe and 
ferroportin genes showed unique product formation, confirming their 
appropriateness for further real time PCRs.  
 
 1  2  3 4  5  6  7   8  9 10   
Fig. 3.8  Preliminary real time PCR with CHO-specific primers  
CHO TRVb1 cDNA was probed with different primer pairs (Table. 2) in a real time PCR, as 
described in methods section 2.2.19. 
A: Melt curve, shows formation of two peaks with the Irp2 primers Irp2-for CHO (F) and (R).  
B: Amplicons from real time PCR, CHO TRVb1 cDNA and CHO specific primers 
electrophoresed on agarose gel. 
Lane 1= Primers HFE for CHO (F) and (Ry); expected product size= 167 bp 
Lane 2= Primers FPN for CHO (F) and (R); expected product size= 147 bp 
Lane 3= Primers Irp2 for CHO (F) and (R); expected product size= 177 bp 
Lane 4= Primers beta actin (F) and (R); expected product size= 187 bp 
Lane 5= Primers pabpn1 (F) and (R); expected product size~200 bp 
Lanes 6-10= negative controls with respective primers  
A B 
100 bp 
500 bp 
 
 200 bp 
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Before performing gene expression analysis the amplification efficiencies of the 
genes are required to be determined to ensure that the efficiencies between the 
gene of interest and the reference gene closely match each other. Hence 
amplification efficiencies of Hfe and beta actin genes were determined, as shown 
in Fig. 3.9.  
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Fig. 3.9  Standard dilution curves of Hfe and beta actin genes in CHO cells 
In order to check the amplification efficiencies of genes, serial dilution of CHO cDNA 
were prepared (1:2) and probed with respective primers of each gene, as described 
in methods section 2.2.19.  
A and C: Fluorescence curves of Hfe and beta actin genes, respectively  
C and D: Efficiency curves of Hfe and beta actin genes, respectively 
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3.3.4 Hepcidin gene sequencing in CHO cells 
Partial sequencing of ferroportin, Hfe and Irp2 genes in CHO cells was successful, 
as represented by Fig. 3.4. Comparisons between characterised CHO genes and 
corresponding genes in human, rat and mouse showed that there is high degree of 
genomic similarity between these species (Table 3.1). Using the same approach, 
attempts were made to obtain the hepcidin gene sequence in CHO cells. 
Accordingly, conserved nucleotides on hepcidin mRNA alignment between mouse 
and rat (appendix XII), were identified and hepcidin primers (F) and (R) were 
designed. PCRs with these primers and CHO DNA could not yield a unique 
product at any of the annealing temperatures (appendix XIII). Hence, a new 
reverse primer R1a was designed which allowed more flexibility in binding the 
template than the previous reverse primer and a combination of hepcidin F and 
R1a was probed with the CHO DNA (Fig. 3.10). As previously observed, this 
combination of primers also resulted in multiple products. 
 
                         
 
The encircled predominant product of ~400 bp (lane 3) was gel purified and sent 
for sequencing. However the sequence of this product could not be obtained.   
Fig. 3.10  Amplicons of CHO genome obtained with 
hepcidin primers (F) and (R1a)  
DNA was extrcated as described in methods section 2.2.5 
and amplified with hepcidin primers, as listed in Table. 2.  
Lane 1 = rat liver DNA; lane 2 = mouse liver DNA,  
excepted size of products for lanes 1 and 2 =~1500bp 
Lane 3=CHO TRVb1 DNA, Lane 4 = negative control 
 1    2   3   4  
200 bp 
400 bp 
800 bp 
1000 bp 
 600 bp 
1500 bp 
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3.3.4.1 Magnesium chloride gradient PCR 
To facilitate sequencing, a new forward primer hepcidin F1 was designed and used 
in combination with primer R1a. This combination showed the presence of two 
prominent products (Fig. 3.11, lane 1) of sizes ~1000 bp and 500 bp. In order to 
increase specificity of product formation and reduce non-specific binding of primers, 
a magnesium chloride gradient PCR was performed, ranging from 1.5 mM to 4 mM. 
 
 
 
 
 
 
 
It was observed that as the concentration of magnesium chloride increased, 
products A and B, seen in Fig. 3.11, lane 1, could not be formed and instead, two 
other products of sizes ~ 900 bp and 700 bp increased in intensity. Gel purification 
of these predominant products A, B and C followed by sequencing could not yield 
the sequence of any of these products. Thus increasing magnesium chloride 
concentration could not help the purpose of obtaining hepcidin gene sequence.  
Fig. 3.11  Amplicons of CHO DNA under MgCl2 gradient 
using hepcidin primers (F1) and (R1a) 
Increased specificity of product formation was obtained (as 
per methods section 2.2.9) when a series of PCR reactions 
were set up with increasing concentrations of MgCl2. 
Encircled products were gel purified and sent for sequencing 
(as described in methods section 2.2.12). 
Lanes 1 to 6 = 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM and 4 
mM MgCl2, respectively. Lane 7 = rat liver DNA (1.5mM 
MgCl2), expected product size ~1500 bp. Lane 8 = negative 
control  
         1    2    3    4     5    6           7          8            
A 
B 
C 
100 bp 
200 bp 
500 bp 
1000 bp 
1500 bp 
2000 bp 
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3.3.4.2 Amplification of amplicon to increase product yield 
It was observed that one of the reasons for not acquiring the hepcidin gene 
sequence was the inability of primers to yield products in large amounts. Hence to 
increase product yield and facilitate sequencing, PCR products were reused as 
templates in subsequent PCRs. Thus products A and B observed in Fig. 3.11 were 
gel purified and used as templates in PCRs (Fig. 3.12-X).  
 
 
 
 
 
 
 
 
 
 
 
Gel electrophoresis of the products on 2 % agarose gel (Fig. 3.12X, boxed) 
identified the presence of a double band B1-B2. Products A, B1-B2, B1 and B2 
were gel purified and electrophoresed (Fig. 3.12Y) before sequencing to confirm 
the presence of products. However, sequences of none of these products could be 
obtained. The reason for sequencing problems with the dual product segment B1-
B2 could be attributed to multiple priming as these products had very similar sizes.   
A 
B1-B2 
B1 
B2 
 
A 
B1-B2 B1 B2 
X 
Y 
100 bp 
200 bp 
500 bp 
500 bp 
1000 bp 
500 bp 
  1      2      3     4      5      6      
8            
Fig. 3.12  Amplification of amplicon to increase product yield 
The PCR products obtained from the 1st round of amplification were used as templates in 
the 2nd round of PCR to increase product yield. Purified products of each lane were sent for 
sequencing as described in methods section 2.2.12. 
X: Amplicons of CHO TRVb1 DNA obtained using hepcidin primers F1 and R1a 
Product A was obtained when gel extracted band A, seen in Fig 27, was used as template.  
Products B1-B2 were obtained when gel extracted band B, seen in Fig 27 was used as a 
template.  
Y: Confirmation of presence of product before sequencing  
Lane 1 = CHO TRVb1 DNA; lane 2= Wt CHO DNA;  
lanes 3,4,5,6 = gel purified products of A, B1-B2, B1 and B2, respectively.  
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3.3.4.3 Cloning of DNA fragment 
Since the size of the products B1and B2 were similar to the size of the 
predominant product observed in Fig. 3.10 (lane 3) and Fig. 3.11 (lane1), it was 
decided to sequence the products B1 and B2 first, followed later by sequencing the 
product A. The products B1 and B2 were closely spaced on the gel due to similarity 
in sizes. Hence to separate the products B1 and B2 and then sequence these, the 
product segment B1-B2 was gel purified and cloned into a pGEM-T easy vector 
system. This was followed by transformation into competent E.coli XL-1 Blue cells. 
The recombinant plasmids were extracted, purified and amplified using the 
designed hepcidin primers and vector primers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1   2  3  4  5   6  7  8  9 10 11  12     
  1   2   3  4   5   6   7  8   9 10                    
A B 
500 bp 
500 bp 
Fig. 3.13  Amplification of cloned plasmids  
The dual segment product B1-B1 seen in Fig. 3.12 was gel purified and cloned into pGEM-T 
Easy vector system as described in methods section 2.2.11. The yield of plasmid was increased 
by transformation of the recombinant plasmid into E.coli XL-1 Blue cells. Plasmids were purified 
from selected colonies of recombinant cells and amplified with hepcidin and vector primers as 
shown in the figure. Encircled products were gel purified and sent for sequencing as described 
in methods section 2.2.12.  
 
A: Amplicons of cloned plasmids obtained using hepcidin primers F1 and R1a 
Lanes 1 to 10 = Amplicons of 10 random recombinant plasmids obtained from 10 different 
recombinant colonies. Expected size of products = ~ 450 bp. Lane 11 = Wt CHO DNA. 
Lane 12= negative control.  
B: Amplicons of cloned plasmids obtained using pGEM-T easy vector primers pGEM-T easy 
forward and reverse. Expected size of products = ~ 450 bp including the vector sequence. 
 
 
 84 
 
Fig. 3.13A shows that separation of the products B1 and B2 was successful via 
cloning, as indicated by the presence of two distinct bands of different sizes 
(encircled in Fig. 3.13A, lanes 1 and 2). Sequencing of the product in lane 1 was 
successful. Although the sequence did not match the hepcidin gene sequence, 5 % 
coverage of the characterised sequence matched a DNA binding protein in rat, as 
shown below.  
 
CHO sequence characterised (5% coverage)     78 AATCACTAGTGAATTCGCGGCCG 400 
                                                ||||||||||||||||||||||| 
[Rattus norvegicus]GENE ID:64470 Ddb1      3769 AATCACTAGTGAATTCGCGGCCG 3791 
Damage-specific DNA binding protein-1   
 
 
This suggests a potential role of this sequence in entering the nucleus to bind DNA. 
The other product seen in Fig. 3.13A lane 2, could not be sequenced, possibly 
because it still comprised two products, as seen in Fig. 3.13B, lane 2.  
 
3.3.4.4 Reverse primers with unique hepcidin specificity  
To improve the specificity of primer binding and encourage unique product 
formation, a new reverse primer, hepcidin R1b was designed, part of which 
indicated unique specificity for hepcidin gene at the NCBI–blastn. PCR conditions 
were optimised with hepcidin primer pairs F1 and R1b (appendix XIII). Results 
showed formation of diffused products in minimal amounts, which could be due to 
the degeneracy of the reverse primer. As this primer pair did not give a unique 
product, this combination of primers was not used any further.  
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3.3.4.5 Primer specificity  
Since attempts made so far could not yield the hepcidin gene sequence and the 
primers F1 and R1a resulted in multiple products (Fig. 3.11 and Fig. 3.12), the 
specificity of the primers was checked by using only one of the primers of the 
primer pair in separate PCR reactions, i.e. using only the forward primer F1 and 
only the reverse primer R1a for amplification, as shown in Fig. 3.14A. This should 
not yield products. 
                            
                
 
 
Amplification of CHO DNA using only the forward primer resulted in a product of  
~ 900 bp (Fig. 3.14A, lane 1). This suggested that the forward primer also 
functioned as a reverse primer by binding to a region in CHO DNA ~ 900 bp away 
from where it was originally designed to bind. This region could be within an intron 
and would be complementary and reverse of a section of the top DNA strand, as 
explained through Fig. 3.14B. Hence it was concluded that this was the product “A” 
seen in figures 3.11 and 3.12 and that this was a non-specific product and should 
Fig. 3.14 A  Amplification of 
CHO DNA with only the 
forward primer F1  
Lane 1 = Wt CHO DNA 
Lane 2 = CHO TRVb1 DNA 
Lane 3 = rat liver DNA 
Lane 4 = mouse liver DNA 
Lane 5 = negative control  
1      2      3     4   5                     
Fig. 3.14 B  Probable position of 
binding of forward primer F1, to 
function as a reverse primer  
1000 bp 
500 bp 
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not be sequenced. Thus, the forward primer required to be redesigned. On using 
only the reverse primer, no product was observed (results not shown for brevity).  
 
3.3.4.6 Hepcidin primers for other species 
Previously it was seen that the hamster genomes bears high genomic similarities 
with the genomes of human, mouse and rat (Tables 3.1 and 3.2). Hence published 
hepcidin primers used for these species (Table 2.2) were used to amplify the 
unknown CHO-hepcidin gene (Fig. 3.15). The resultant PCR products were 
electrophoresed on 2 % agarose gels to facilitate the separation of any closely-
sized products. It was observed that amplification of CHO DNA with mouse 
hepcidin-1 primers (A), rat hepcidin primers-x (A) and rat hepcidin primers-y (B), 
resulted in either no product or non-specific products. Also, human hepcidin 
primers (C) showed non–specific product formation with the CHO DNA.  
 
 
 
    
 
 
 
 
3.3.4.7 Primers designed with human hepcidin transcript into alignment 
   1  2 3 4  5        6  7 8 9 10   
A 
Fig. 3.15  Amplification of CHO genome with hepcidin primers used for other species 
A: Amplicons of CHO DNA obtained with rat hepcidin primers (x) and mouse hepcidin-1 primers   
Lanes 1-5 = Products obtained with rat hepcidin primers (x) 
Lanes 6-10 = Products obtained with mouse hepcidin-1 primers   
Expected product size of lane 1 (rat Liver DNA) = 95 bp  
Expected product size of lane 7 (mouse liver DNA) = 120 bp  
B: Amplicons obtained with rat hepcidin primers (y)  
Expected product size of lane 1 (rat Liver DNA) = 95 bp  
C: Amplicons obtained with human hepcidin primers FF and RR 
Lane H = HepG2 DNA, expected product size = 300 bp 
In all figures:  
Lanes 1,6 = rat liver DNA;   Lanes 2,7 = mouse liver DNA;   Lanes 3,8 = WT CHO DNA; 
Lanes 4,9 = CHO TRVb1 DNA;  Lanes 5,10= negative control.  
 
C 
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 1    2    3    4    5       H  1   2   3   4   5      
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Since the amplification of CHO DNA using mouse, rat and human hepcidin primers 
did not yield a specific product within the CHO genome (Fig. 3.15) and also due to 
the non-specificity of the forward hepcidin primer (Fig. 3.14), new hepcidin primers 
were designed based on conserved nucleotides between hepcidin transcripts of 
mouse, rat and human (appendix XII). One forward (F2) and two reverse primers 
(R2a and R2b) were designed and used to amplify CHO DNA. PCR products were 
electrophoresed on a 3 % agarose gel to enable separation of any closely sized 
products (Fig. 3.16).  
 
 
 
 
 
 
 
 
 
 
 
 
Here the reverse primer R2a yielded one prominent product (Fig. 3.16A, lane 1) 
whereas reverse primer R2b yielded two products (Fig. 3.16B, lane 1). Hence it 
was concluded that the hepcidin primer pair F2 and R2a was more specific and 
was used in subsequent PCRs. 
Fig. 3.16  Amplification of CHO genome with hepcidin primers designed on human transcript 
Since primers designed based on conserved regions between mouse and rat hepcidin could not 
characterise CHO-hepcidin, primers were redesigned based on conserved regions between the 
human, mouse and rat hepcidin transcript alignment. The CHO genome was amplified with these 
primers. 
 
A: Amplicons obtained using hepcidin primers F2 and R2a 
B: Amplicons obtained using hepcidin primers F2 and R2b 
Lane 1 = WT CHO DNA;    Lane 2 = rat liver DNA;    Lane 3 = HepG2 DNA;  
Lane 4 = WT CHO DNA with only forward primer; Lane 5 = WT CHO DNA with only reverse primer; 
Lane 6 = negative control.  Expected sizes of products in lane 2 and 3 ~1400 bp 
 
 
    1    2      3    4    5     6              
 
   1       2       3       4       5       6        
A B 
500 bp 
1000 bp 
500 bp 
1000 bp 
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3.3.4.7 cDNA usage for sequencing 
So far in this study, sequencing the hepcidin gene using the DNA had presented 
various challenges. Thus, although the approach used to sequence hepcidin 
mRNA (cDNA) was more expensive, it was concluded that this would be more 
fruitful than sequencing hepcidin DNA. Accordingly, Wt CHO cDNA was amplified 
with hepcidin primers F2 and R2a.  
 
  
 
 
 
 
 
 
 
 
  
As seen in the Fig. 3.17A, lane 2, the Wt CHO cDNA yielded a product of ~ 400 bp, 
similar to the product observed in figures 3.10-3.13. Hence multiple tubes of 
reaction in lane 2 were set up. Before sequencing, the presence of the product was 
confirmed (Fig. 3.17B, lane 2). However, sequence of the purified product could 
not be obtained, possibly because of two closely sized products (Fig. 3.17B, lane 
2). This suggested that cloning the cDNA products and then sequencing would be 
an alternative strategy. 
 
   
     1                    2             1     2    3    4       5     6             
A 
B 
1000 bp 
400 bp 
1500 bp 
500 bp 
1000 bp 
Fig. 3.17  Amplicon of Wt CHO cDNA obtained with hepcidin primers F2 and R2a  
CHO cDNA amplified with selected hepcidin primer pair is shown in the figure. The encircled product 
was sent for sequencing as described in methods section 2.2.12.  
 
A: Lane 1 = WT CHO DNA; lane 2 = WT CHO cDNA;  lane 3 = HepG2 DNA; 
Lane 4= HepG2 cDNA;  Lane 5= rat liver DNA (expected size ~1400 bp); lane 6= negative control 
B: Purified WT CHO cDNA before sequencing.  
Lane 1 = WT CHO DNA; lane 2 = WT CHO cDNA 
 89 
 
3.3.4.8 Cloning of cDNA fragment 
The cDNA product (Fig. 3.17B, lane 2) was cloned into the pGEM-T easy vector 
system. The recombinant plasmids containing Wt CHO cDNA were amplified with 
vector primers and hepcidin primers (Fig. 3.18). 
 
                   
 
 
 
 
 
Fig. 3.18A (lanes 3 and 4) showed products of different sizes indicating that the 
two products seen in Fig. 3.17B had been successfully separated via cloning. The 
encircled product in Fig. 3.18A was gel purified and sequenced with vector primers. 
However, instead of the expected hepcidin sequence, the characterised sequence 
matched a section of RNA splicing factor 3a, as shown in table 3.3. 
NCBI Accession Description Query 
coverage 
Max 
identity 
XM_003502240.1 PREDICTED: Cricetulus griseus splicing factor 3a,  99% 100% 
BC092058.1 Mus musculus splicing factor 3a, subunit 3 99% 95% 
NM_001025698.1 Rattus norvegicus splicing factor 3a, subunit 3  97% 95% 
BC011523.1 Homo sapiens splicing factor 3a, subunit 3 97% 89% 
Fig. 3.18  Amplification of cloned Wt CHO cDNA 
With the aim of sequencing hepcidin mRNA in the CHO cells, the cDNA from Wt CHO 
cells was synthesised as described in methods section 2.2.18 and amplified with vector 
and hepcidin primers, as shown in the above figure.  
 
A: Amplicons of cloned plasmids obtained on using pGEM-T easy vector primers, 
pGEM- T easy forward and reverse. 
B: Amplicons of cloned plasmids obtained on using hepcidin primers F2 and R2a. 
Excepted size of products ~ 450 bp, including the vector sequence 
Lanes 1 to 6 = Amplicons of 6 different recombinant plasmids obtained from 6 different 
recombinant colonies.  
 
A B 
Table 3.3  Sequence similarities between the characterised CHO sequence and other species  
   1    2    3    4    5   6    1    2    3   4    5   6   
400 bp 500 bp 400 bp 
500 bp 
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Since the gene sequence of hepcidin in the CHO cells could not be characterised, 
gene expression analysis of hepcidin upon iron exposure was hampered. Hence 
studies apart from gene expression analysis were conducted which focussed on 
the iron uptake mechanisms and the consequent effect on hepcidin peptide 
production by the CHO TRVb1 cells. These studies included confirmation of human 
TfR1 at mRNA and protein levels under steady state conditions followed by 
analysis of cell surface TfR1, intracellular iron levels and finally measurements of 
hepcidin peptide levels upon iron overdose to cells.  
 
3.3.5 TfR1 transcript status in CHO TRVb1 cells  
The presence of human TfR1 at mRNA level in the CHO TRVb1 cells under steady 
state conditions was checked, as shown in Fig. 3.19.  
 
                                                   
    
 
 
 
 
 
 
 
Fig. 3.19  Amplicons of TfR1 transcript in CHO cells   
cDNA from CHO TRVb1 and Wt CHO cells was extracted and amplified as 
described in methods sections 2.2.18 and 2.2.8, respectively, using the 
CHO-endogenous and human-TfR1 primers (Table 2.1).  
 
A: Amplicons obtained on using CHO-endogenous TfR1 primers  
Lane 1= Wt CHO cDNA; expected size of product= 230 bp (appendix XV) 
Lane 2= CHO TRVb1 cDNA; no expected product  
B: Amplicons obtained on using human TfR1 primers 
Lane 1= Wt CHO cDNA; no expected product 
Lane 2= CHO TRVb1 cDNA; expected product size= 179 bp (appendix XV) 
 
B A 
 1   2 
  1   2 
300 bp  300 bp 
200 bp 
100 bp 
200 bp 
100 bp 
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As seen in Fig. 3.19A (lane 1), the CHO-endogenous TfR1 transcript was amplified 
by CHO-specific TfR1 primers whereas CHO TRVb1 cDNA in lane 2 showed the 
absence of the CHO-endogenous TfR1 transcript. Likewise, human TfR1 primers 
were unable to form a product with the Wt CHO cDNA, but successfully formed a 
product with CHO TRVb1 cDNA, as expected (Fig. 3.19B). Together this confirmed 
the presence of human TfR1 mRNA and the absence of CHO-endogenous TfR1 
mRNA in the CHO TRVb1 cells.  
 
3.3.6 TfR1 protein status in CHO TRVb1 cells 
The status of TfR1 protein in the CHO TRVb1 cells under steady state conditions 
was checked, as shown in Fig. 3.20.  
 
                                                                
 
 
 
 
Fig. 3.20  TfR1 protein expression in CHO TRVb1 cells  
CHO TRVb1 cells were grown in maintenance medium and the cell pellet was 
probed with human TfR1 antibody, as described in methods section 2.2.21.  
 
A : Dot blot detected human TfR1 protein in CHO TRVb1 cells 
Lane 1= Cell extract of CHO TRVb1 cells 
Lane 2= Cell extract of Wt CHO cells  
B : Western blot detected humanTfR1 protein in CHO TRVb1 cells 
Lane 1= CHO TRVb1 cells under non reducing conditions 
Lane 2= CHO TRVb1 cells under reducing conditions  
Lane 3= Wt CHO cells under non reducing conditions  
Lane 4= Wt CHO cells under reducing conditions  
The marker is in kDa.  
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The CHO TRVb1 cells expressed human TfR1 protein, as seen by the dot blot in 
Fig. 3.20A (lane 1) and Western blot in Fig. 3.20B (lanes 1 and 2). Here, under 
non-reducing conditions human TfR1 protein showed a prominent band of 
approximately 180 kDa (Fig. 3.20B, lane 1), and under reducing conditions a band 
of smaller size, approximately 85-90 kDa was observed (Fig. 3.20B, lane 2), as 
previously shown by Turkewitz et al. (1988). No human TfR1 protein was detected 
in Wt CHO cells. This confirmed the suitability of CHO TRVb1 cells for iron-related 
experiments upon holotransferrin treatment as required to be conducted in this 
study.   
 
3.3.7 Iron overdose and CHO TRVb1 cells  
The CHO TRVb1 cells were treated with holotransferrin (5 g/L) and the resultant 
effect of treatment on cell surface expression of TfR1 is shown in Fig. 3.21. Here, 
Wt HepG2 cells, which express the endogenous TfR1 of human origin, were also 
treated simultaneously and the effect on the two cell types were compared. Each 
treatment undergone by the CHO TRVB1 cells is represented by figures 3.21 (A), 
(B) and (C). It was observed that under steady state conditions i.e. in the 
maintenance medium, CHO TRVb1 cells express approximately twice the levels of 
TfR1 protein on the cell surface than the Wt HepG2 cells (Fig. 3.21D). Iron 
overdose for a period of 48 h caused a significant gradual decrease (p<0.03) in 
surface expression of TfR1 in the Wt HepG2 cells, whereas the CHO TRVb1 cells 
showed constant levels of cell-surface TfR1 (Fig. 3.21E). This implied that CHO 
TRVb1 cells not only displayed higher levels of TfR1 than the Wt HepG2 cells 
under basal conditions but also under iron overload.  
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Under the same experimental conditions, hepcidin peptide levels in the treatment 
medium were measured. Data revealed that the CHO TRVb1 cells increased the 
production of hepcidin peptide with an increase in extracellular holotransferrin 
levels over time (Fig. 3.22). Iron overdose for 24 h significantly induced an 
approximately 4-fold increase in hepcidin peptide production and increased by 
approximately 7-fold after 48 h (p<0.01). 
Fig. 3.21  TfR1 response of CHO TRVb1 cells on iron overload  
CHO TRVb1 and Wt HepG2 cells were treated with 5 g/L holotransferrin and analysed 
for cell-surface TfR1 by flow cytometry as described in methods sections 2.2.15 and 
2.2.20, respectively. Flow cytometry images of CHO TRVb1 cells before treatment i.e. 
time 0 (A) and after holotransferrin treatment for 24 h (B) and 48 h (C) are shown.  
D : Cell-surface TfR1 under steady state conditions (maintenance medium). 
E : Cell-surface TfR1 after 5 g/L holotransferrin treatment. 
Time 0 represent cells under steady state conditions. 
Data is presented as mean ± SEM (n=3).  
* p<0.03 compared to time 0, ** p<0.01, # p<0.03 compared to 24 h. 
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To further understand hepcidin peptide production by the CHO TRVb1 cells within 
a shorter time exposure to iron overdose, cells were treated with 5 g/L 
holotransferrin for up to 4 h. To ensure that the cells received the planned 
overdose, iron levels in the treatment media were determined (Fig. 3.23).  
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Fig. 3.22  Holotransferrin overdose and hepcidin 
peptide production by CHO TRVb1 cells  
CHO TRVb1 cells were treated with holotransferrin 
overdose and hepcidin peptides secreted into the 
medium after treatment were measured as described 
in methods section 2.2.22. 
Time 0 represent cells under steady state conditions 
i.e. in maintenance medium. Data is presented as 
mean ± SEM (n=3). * p<0.01 compared to time 0, # 
p<0.01 compared to 24 h. 
Fig. 3.23  Iron content in CHO TRVb1 
treatment media 
Iron levels in the media used to treat the CHO 
TRVb1 cells were measured by the ferrozine 
assay as described in methods section 2.2.17.1.  
0 g/L represents serum-free and holotransferrin-
free maintenance medium whereas 5 g/L 
represents serum-free maintenance medium 
supplemented with 5 g/L holotransferrin. Data is 
presented as mean ± SEM (n=3).  
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The effect of holotransferrin treatment on cell viability was studied using the MTT 
assay. Results showed that iron overdose in the form of 5 g/L holotransferrin for a 
period of 4 h reduced cell viability by approximately 10-15 %, as compared to the 
untreated controls (Fig. 3.24). However, the data also showed that cell viability was 
approximately 30 % higher in a medium deprived of FCS and iron (0 g/L) than the 
maintenance medium (10%FCS).  
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Following holotransferrin treatments it was observed that there was no significant 
increase in intracellular iron content in the CHO TRVb1 cells; levels generally 
remained constant under serum deprivation and maintenance medium (Fig. 3.25).  
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Fig. 3.24  Viability studies in CHO TRVb1 cells  
CHO TRVb1 cells were treated with 5 g/L holotransferrin and the viability of the cells was 
studied by MTT assay as described in methods sections 2.2.15 and 2.2.16, respectively.  
10%FCS represent cells in maintenance medium.  
Data is presented as mean ±SEM (n=3).  
 
Fig. 3.25  Intracellular iron levels in CHO TRVb1 cells upon iron supplementation 
CHO TRVb1 cells were treated with 5 g/L holotransferrin up to 4 h. Intracellular iron levels 
were determined by ferrozine assay as described in methods section 2.2.17 and shown in 
the figure. 10% FCS represent normal maintenance medium. Data is presented as mean 
±SEM (n=3).  
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When in the maintenance medium, the CHO TRVb1 cells released constant levels 
of bioactive hepcidin up to 4 h (Fig. 3.26). A slight but significant decrease in 
hepcidin levels (p<0.03) was observed after 2 h, however, after 4 h hepcidin levels 
increased to those detected at time 0 and 30 min. Compared to the untreated 
control 0 g/L, hepcidin peptide production significantly increased upon 
holotransferrin overdose after 30 min and 2 h (p<0.03), although it appeared that 
the effect of holotransferrin gradually decreased with time. Serum and iron 
deprivation did not significantly decrease hepcidin production over the 4 h 
treatment period. 
 
3.4 Discussion   
Chinese hamster ovary cells have been used over the last 20 years in the 
biopharmaceutical industry for the production of therapeutic recombinant proteins 
for human use (reviewed in Bahr et al., 2009). Successful productions of such 
proteins include those offered for rheumatoid arthritis, colorectal cancer and 
Fig. 3.26  Hepcidin peptide secretion by CHO TRVb1 cells upon iron supplementation 
CHO TRVb1 cells were treated with 5 g/L holotransferrin up to 4 h. Hepcidin peptides 
released at various time points after treatment were measured as described in section 
2.2.22 and shown in the figure. 10% FCS represent normal maintenance medium 
Data is presented as mean ± SEM (n=3). * p <0.03 compared to the untreated controls at 
respective time points. # p<0.03 compared to hepcidin released at 30 min when in 
maintenance medium.  
* * 
# 
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anaemia, as reviewed in Warner, (1999). The CHO TRVb1 cells are unique in that 
they are devoid of the endogenous hamster TfR1, and additionally over-express 
the human TfR1 (McGraw et al., 1987). Due to this characteristic these cells can 
be of immense use for iron-related studies and eventually can be valuable in the 
biopharmaceutical industry. In the present work, studies were conducted to 
understand iron-related responses exhibited by the CHO TRVb1 cells. 
 
Previous studies relating to hepcidin gene expression following iron overdose to 
cell lines have given inconsistent results, primarily due to the lack of a suitable cell 
model for iron overdose experiments. This issue has been addressed in this study 
by using the CHO TRVb1 cells. Since the CHO TRVb1 cells over-express the 
human TfR1 (McGraw et al., 1987), it was hypothesised that this characteristic 
should enable the cells to take up large amounts of iron via holotransferrin and the 
resultant effects on cells could be examined.  
 
Accordingly, an objective of this project was to study the effect of iron overdose via 
holotransferrin on the expression of iron-related genes, particularly hepcidin. 
However, many iron-related genes in the hamster have not been characterised yet 
and this limits experimental work with this cell line. If the gene sequence 
information was known, then this would aid in expression analyses of genes via 
real time PCR. This, along with the fact that the CHO cells are easy to transfect 
and widely used, it would then be possible to establish the CHO TRVb1 cells as a 
model system to study iron regulation.  
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In order to characterise the unknown sequences of genes of interest, the concept 
of genome similarities between species was exploited. It was seen that the 
hamster, being a rodent, bore genomic similarities with the human, mouse and rat 
genomes (Table 3.1). Hence, primers were designed based on conserved 
nucleotides between the human, mouse and rat genomes. These were used to 
amplify the CHO DNA and the PCR products obtained were sequenced. The 
partially characterised CHO sequences of genes ferroportin, Hfe and Irp2 showed 
high similarity with the corresponding pre-characterised gene sequences in the 
database (Table 3.2). This reconfirmed that indeed the hamster genome 
resembled the human, mouse and rat genomes. Also, the sizes of the CHO-gene 
products were very similar to gene products of the rat and mouse. For example, as 
seen in Fig. 3.4, in case of Hfe, Irp2 and ferroportin genes, the size of the CHO-
gene product was very similar to those of the rat liver DNA and mouse kidney 
cDNA. This suggests similarity in exon sizes and a probable similarity in exon-
intron boundaries between the three species.  
 
Since the objective behind sequencing iron-related genes in CHO cells was to 
perform gene expression studies through real time PCR, ideally the cDNA would 
have been a better choice to perform the preliminary PCRs. However the cDNA 
was not chosen because the basal mRNA levels of some genes may be low and 
hence it would be difficult to observe a product on the gel using the cDNA. In 
contrast, performing a PCR with DNA and visualising the product on the gel would 
at least confirm the presence of the gene and also indicate its probable size in the 
previously uncharacterised CHO cells. Secondly, PCR optimisations with cDNA 
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would be more expensive than using the DNA. An additional factor is the labile 
nature of RNA. Since RNA has a higher rate of degradation than the DNA, it is 
more difficult to optimise conditions with cDNA than with DNA.  
 
In order to optimise PCR conditions, temperature gradient PCRs were performed 
with all the designed primers (appendix XIII). This helped to identify the most 
appropriate annealing temperature which would give unique products and following 
this, all subsequent PCRs for sequencing were performed at the chosen 
temperature. Generally, lower temperatures produced more products than higher 
temperatures. This is due to the non-specific binding of the primers to the template. 
Also, high temperatures such as 60 ºC - 61 ºC resulted in fraying of DNA or even 
complete loss of product, as seen in Fig. 3.3D. This suggests that although the 
specificity of primer binding increased with increasing annealing temperature, there 
was a certain optimum functional range for a particular primer pair which led to 
maximum product formation. Since all the primer pairs were designed to possess 
similar properties (described in methods section 2.2.17), most primer pairs yielded 
a single specific product around an annealing temperature 58 ºC.   
 
3.4.1   Summary of ferroportin, Hfe and Irp2 gene sequencing in CHO cells 
• Partial characterisation of Hfe, ferroportin and Irp2 genes in CHO cells has 
been achieved, as represented by Fig. 3.4. The characterised gene 
sequences matched closely the corresponding gene sequences in other 
species (Table 3.2)  
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• Not only the gene sequences but also the translated protein sequences bear 
high resemblance to the corresponding proteins of other species, as seen in 
figures 3.5 - 3.7. These multiple sequence alignments of proteins showed 
conservation of many functionally significant motifs within the CHO 
proteome.  
• CHO-specific primers were designed based on the characterised CHO gene 
sequences and real time PCR was optimised with the CHO-specific primers 
for the genes ferroportin, Hfe and beta actin (Fig. 3.8 and Fig. 3.9).  
 
3.4.2   Hepcidin gene sequencing in CHO cells 
In order to enable studies related to hepcidin gene expression in the CHO TRVb1 
cells, here, attempts were made to acquire the previously unknown hepcidin gene 
sequence in CHO cells.  
 
Since the ferroportin, Hfe and Irp2 genes in CHO cells were successfully 
characterised, the same approach was used to acquire the CHO-hepcidin gene 
sequence. Accordingly, primers were designed based on conserved nucleotides 
between rat and mouse hepcidin transcripts. However, sequencing attempts using 
these primers could not yield the hepcidin gene sequence. Following this, several 
approaches were used to resolve the issue. These included redesigning primers    
(Fig. 3.10), using magnesium chloride to increase primer specificity (Fig. 3.11), 
increasing product yield to facilitate sequencing (Fig. 3.12), cloning of the DNA 
fragment (Fig. 3.13) and the cDNA fragment (Fig. 3.18) in order to separate and 
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then sequence closely sized products. None of these approaches yielded the 
desired sequence. Since the hamster showed high genomic and proteomic 
similarities to other species (Tables 3.1 and 3.2; Figures 3.5 - 3.7), published 
hepcidin primers used for these species were used to amplify the CHO DNA (Fig. 
3.15). This was to check if one of the primer pairs could yield a unique product 
which could be hepcidin. However, no specific product was obtained. The lack of 
product formation could be either due to the specificity of the hepcidin gene in CHO 
cells or primer specificity.  
 
The concept of the hepcidin gene in CHO cells being species-specific is related to 
genomic differences between these species. The existence of such differences is 
supported by the result that rat hepcidin primers could not amplify the mouse 
genome (Fig. 3.15B, lane 2). Also, using only the forward primer for amplification 
resulted in a product with hamster DNA but not with rat and mouse liver DNA (Fig. 
3.14A, lanes 4 and 5). Together, these results point at the overall genomic 
differences between the hamster and other rodents. However, the reason for the 
lack of product formation in these examples may also be due to intronic variation 
between hamster and other rodents as opposed to overall genomic differences. 
Indeed, there are mRNA similarities between these species but introns in different 
species may vary considerably. The concept of primer specificity mentioned earlier 
reflects on the specificity of PCR reactions. Along this line, it has been reported 
that when primers specific for hepcidin-1 and hepcidin-2 for mice were probed with 
the mouse hepcidin cDNA, there was no amplification after 25 cycles, eventually 
implying high specificity of this particular PCR reaction (Ilyin et al., 2003). 
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Whether the hamster is genetically close to other rodents or humans can be 
examined. As seen in Fig. 3.15B, the rat hepcidin primers yielded multiple products 
with CHO DNA (Fig. 3.15B, lanes 3, 4) but not with the mouse DNA. This suggests 
that the hamster genome bears more resemblance to the rat genome than the 
mouse genome. As seen in Fig. 3.15C, lanes 3 and 4, on using human hepcidin 
primers to amplify CHO DNA, two prominent products were obtained. These were 
of sizes approximately 700 bp and 250 bp. The 700 bp product matched closely in 
size to rat and mouse products (lanes 1 and 2) whereas the 250 bp product 
matched in size to the human DNA product (lane H). Together, this suggests that 
the hamster genome bears resemblance to humans and rodents but this is only at 
specific locations, again pointing at the specificity of the hepcidin gene.  
  
One major reason for the difficulties encountered in obtaining the sequence of the 
hepcidin gene arose from the fact that preprohepcidin is a small peptide of 84 
amino acids in human and rat (Park et al., 2001) and 83 amino acids in mouse 
(Pigeon et al., 2001). Thus the transcripts’ sizes are very small which offers fewer 
sections of conserved nucleotides to design primers. This was one of the 
constraints which led to designing degenerate primers. Such degenerate primers 
would be less specific and may bind to multiple regions in the genome to give 
multiple products, one of which could be a part of the hepcidin gene sequence.  
 
It is interesting to note that amplification of hamster DNA and cDNA with similar but 
different primer pairs resulted in two closely-sized products. This suggests that, 
there may be two hepcidin genes in hamster, like the mouse (Pigeon et al., 2001) 
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and the fish (Kim et al., 2005). These genes could be very similar in size and 
sequence. Since the designed hepcidin primers are degenerate, they may bind to 
both these genes giving two different products, barely separated on a gel.  
 
The natural ligand for hepcidin is ferroportin (Nemeth et al., 2004). Conservation of 
the hepcidin binding domain in the CHO cells accompanied by conservation of 
C326 which is implicated in binding to hepcidin (De Domenico et al., 2008) strongly 
suggested that the hepcidin gene should exist in the CHO cells, but it is probably 
highly specific. Thus further work needs to be done to obtain the hepcidin gene 
sequence in CHO cells so that the CHO TRVb1 cells which over-express human 
TfR1 can be proven to be a valuable model for iron-related studies. 
 
3.4.3 Effect of iron supplementation on CHO TRVb1 cells  
This study confirmed the presence of human TfR1 at mRNA and protein levels in 
the CHOTRVb1 cells (Fig. 3.19 and 3.20). Here, it was shown for the first time that 
regardless of iron overdose the CHO TRVb1 cells expressed stable levels of  
cell-surface TfR1 up to a period of 48 h (Fig. 3.21E). Since the TfR1 in these cells 
is not devoid of its iron-sensitive IRE, the constant levels of TfR1 reflect the 
inherent characteristic of TfR1 over-expression in these cells. This led to a large 
number of receptors being present on the cell surface at a particular time point. 
Notably, the CHO TRVb1 cells express approximately 150,000 receptors on their 
cell surface whereas its Wt counterpart displays only 65,000 receptors (McGraw et 
al., 1987). Conversely, the Wt HepG2 cells showed not only lower levels of surface 
TfR1 than the CHO TRVb1 cells, but also showed a decrease in expression over 
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time upon iron overdose as seen in figures 3.21 (D) and (E). This response implied 
a regulated mechanism of iron uptake by the TfR1 which was sensitive to 
intracellular iron levels and decreased TfR1 levels on surface on reaching cellular 
iron sufficiency. The Wt HepG2 cells were surrounded by an iron-rich environment 
and thus demonstrated an iron-regulated TfR1 response. 
 
In the CHO TRVb1 cells, unlike the TfR1 levels which remained constant, iron 
overdose caused a significant rise in hepcidin peptide production over the period of 
48 h (p<0.01). As seen in Fig. 3.22, this increase in bioactive hepcidin on 
increasing extracellular holotransferrin levels was demonstrated in this study for 
the first time and correlates with the normal physiological response exhibited by 
humans under the influence of increased circulating iron levels.  
 
To further understand if such a response could be observed within a short time of 
exposure to iron, the CHO TRVb1 cells were exposed to holotransferrin overdose 
up to 4 h. Data showed that despite the over-expression of TfR1 protein on the cell 
surface, intracellular iron concentrations in these cells were not significantly raised 
upon increasing extracellular iron levels (Fig. 3.25). Essentially, iron overdose to 
cells did not result in intracellular iron overload in the CHO TRVb1 cells. Hence it 
was concluded that the abundance of TfR1 on cell surface does not necessarily 
lead to intracellular iron overload, primarily because the TfR1 mRNA in these cells 
is regulated at transcription level by its IRE region (Casey et al., 1988) and this 
controls the uptake of iron by the cells.  
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Regardless of the overall stability in intracellular iron levels, holotransferrin 
treatments led to a significant 1.4- and 1.5-fold increases in hepcidin peptide 
secretion at 30 min and 2 h, respectively (Fig. 3.26), compared to the untreated 
controls. Within the 4 h treatment period, cells were the most responsive to 
extracellular iron levels at the 2 h time point. Together, the data suggested that a 
significant intracellular iron overload was not a prerequisite for an increase in 
hepcidin peptide levels by the CHO TRVb1 cells and that the levels of bioactive 
hepcidin could be raised by increasing extracellular iron levels which may have 
caused minor variation in intracellular iron levels.  
 
As shown in Fig. 3.23, iron levels in the maintenance medium and 5 g/L 
holotransferrin medium were determined. Correlating the iron levels in treatment 
media with hepcidin peptide production, it was seen that approximately 7 µM of 
iron present in the maintenance medium led to approximately 3.7 ng/mL of 
hepcidin whereas 105 µM of iron in 5 g/L of holotransferrin induced approximately 
6.9 ng/mL of hepcidin. This meant that 16-fold higher iron levels in 5 g/L 
holotransferrin could only lead to a 1.9-fold increase in bioactive hepcidin. FCS 
thus showed a better potential to induce hepcidin production than high iron levels 
in the holotransferrin treatment medium. This is not surprising as FCS may contain 
an array of growth factors, proteins, cytokines and interferons and these cytokines, 
particularly IL-6, IL1 alpha and IL1 beta are known to induce hepcidin synthesis 
(Nemeth et al., 2003, Darshan and Anderson, 2009). Also, interferon gamma has 
been shown to induce hepcidin expression (Frazier et al., 2011).  
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As seen earlier, the hepcidin gene sequence in the CHO TRVb1 cells could not be 
characterised despite assuming its similarity with the human hepcidin gene 
sequence. However, the hepcidin peptide in CHO TRVb1 cells was detectable by 
the rabbit anti-human hepcidin antibody (figures 3.22 and 3.26) which has 
successfully detected bioactive hepcidin in human serum (Busbridge et al., 2009). 
This suggests that although the gene sequence of hepcidin in the CHO cells may 
be unique and may have dissimilarity with the human hepcidin gene sequence, the 
peptide sequence of hepcidin in the two species is probably similar. This is 
supported by the fact that the hepcidin peptide sequence is highly conserved 
amongst different species, as discussed in chapter 1 and shown in the below 
alignment. 
 
Human             1 DTHFPICIFCCGCCHRSKCGMCCKT 25 
Mouse hepcidin-1  1 DTNFPICIFCCKCCNNSQCGICCKT 25 
Mouse hepcidin-2  1 DINFPICRFCCQCCNKPSCGICCEE 25 
Rat               1 DTNFPICLFCCKCCKNSSCGLCCIT 25 
Dog               1 DTHFPICIFCCGCCKTPKCGLCCKT 25 
Pig               1 DTHFPICIFCCGCCRKAICGMCCKT 25 
Zebrafish         1 QSHLSLCRFCCKCCRNKGCGYCCKF 25 
                    : ::.:* *** **.   ** **   
 
Since in the CHO TRVb1 cells intracellular iron overload upon iron overdose was 
not achieved, whether intracellular iron levels influenced hepcidin transcription and 
peptide production remained a question. Another question was whether the 
increase in hepcidin peptide production, as observed here, was restricted only to 
the CHO cells under these specific cell culture conditions; particularly in the scene 
of variability in hepcidin transcription observed by other groups. Some of these 
issues were addressed via experiments conducted in the following chapter.  
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Chapter 4  
Effect of iron overload on TfR1-recombinant HepG2 cells 
4.1 Introduction 
An objective of this research was to understand the effect of iron overload on 
hepcidin gene expression, for which initially the CHO TRVb1 cells were chosen. 
However, characterisation of the hepcidin gene sequence in these cells could not 
be achieved which prevented gene expression studies from being carried out. 
Hence, experiments investigating hepcidin peptide production were conducted. 
Results showed that the CHO TRVb1 cells increased hepcidin peptide production 
upon overdose of extracellular holotransferrin (chapter 3). However, the lack of 
intracellular iron overload in these cells restricted the understanding of whether 
excess iron within the cells would make an impact on hepcidin expression. In order 
to study the effect of iron overload on hepcidin gene and peptide expression, a cell 
line was required which could facilitate intracellular iron overload and also 
possessed a characterised hepcidin gene sequence to enable mRNA expression 
studies.   
 
To achieve this, the human liver carcinoma cell line, HepG2 was utilised. This was 
principally because the gene sequences of hepcidin and other iron-related genes 
have been pre-characterised which can enable gene expression analysis through 
real time PCR. Also, since it is a mammalian cell line it would provide a better 
understanding of cellular processes occurring in humans, as compared to the 
hamster ovarian cell line. For instance the HepG2 cells demonstrate many features 
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of hepatocytes including the ability to produce liver-specific proteins like albumin 
and transferrin (Bokhari et al., 2007). Another major advantage of these cells is 
that they are of hepatic origin and the liver acts as a main site for iron storage as 
well as hepcidin production (Kohgo et al., 2008). Considering these advantages, 
HepG2 cells were chosen for further studies and were cloned such that these 
would express an IRE-independent TfR1 mRNA (methods section 2.2.3.2) which 
therefore would be insensitive to an increase in intracellular iron levels. 
 
4.1.1 Aims and objectives 
Aim: To study the effect of iron overload on gene expression of hepcidin and other 
iron-related genes using the TfR1-recombinant HepG2 cells (rec-TfR1 HepG2) 
which constitutively express human TfR1 on the cell surface. It was hypothesised 
that upon iron supplementation the rec-TfR1 HepG2 cells would continuously 
uptake iron through holotransferrin causing intracellular iron overload. This would 
lead to increased hepcidin gene expression and peptide production. The resultant 
effect on gene expression of hepcidin and other iron-related genes in the rec-TfR1 
HepG2 cells was compared to the wild type HepG2 and the HepG2 (p) cells 
(HepG2 cells transfected with empty plasmid), both of which express unmodified 
iron-regulated TfR1 mRNA. 
 
Objectives: 
1. To ascertain the cell-surface expression of TfR1. 
2. Confirmation of the presence of iron-related genes in HepG2 cells. 
3. Upon iron supplementation, to perform:  
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a. Viability studies 
b. Confirmation of iron uptake by cells 
c. Gene expression analysis through real time PCR 
d. Determination of the levels of secreted bioactive hepcidin  
 
4.2 Results 
4.2.1 Cell-surface expression of TfR1 in HepG2 cells 
The requirement of the rec-TfR1 HepG2 cells was that these cells expressed a 
greater amount of TfR1 on the cell surface as compared to the Wt HepG2 cells and 
also continuously uptake iron regardless of excess intracellular iron levels. To 
ascertain this, Wt and rec-TfR1 HepG2 cells were treated with holotransferrin (5 
g/L) for 48 h and cell-surface TfR1 was analysed. Each treatment undergone by 
the rec-TfR1 HepG2 cells is shown in figures 4.1 (A), (B) and (C). Here, 
fluorescence is depicted in R2 and the resultant effect on expression of cell-surface 
TfR1 is depicted in figures 4.1 (D), (E) and (F).  
 
Data showed that the rec-TfR1 HepG2 cells displayed significantly higher basal 
levels of TfR1 on the cell surface than the Wt HepG2 cells (Fig. 4.1D). When 
subjected to iron overdose, Wt HepG2 cells showed a slight but significant up-
regulation of TfR1 expression after 24 h (p<0.02) and a plateau at 48 h (Fig. 4.1E). 
In contrast, the rec-TfR1 HepG2 cells showed constant levels of cell-surface TfR1 
irrespective of holotransferrin overdose over time (Fig. 4.1F).  
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To further understand the TfR1 response, cells growing in the maintenance 
medium were treated with holotransferrin (5 g/L) without any period of serum 
starvation before the treatment. A representative cell response of each treatment 
undergone by the rec-TfR1 HepG2 cells is shown in Fig. 4.2 (A), (B) and (C) 
overleaf and the effect of the treatments is summarised in Fig. 4.2 (D) and (E).  
Fig. 4.1  Effect of holotransferrin overdose on cell-surface expression of TfR1 
Wt and rec-TfR1 HepG2 cells were serum starved for 24 h (time 0) followed by treatment with 5 
g/L holotransferrin for 48 h, as described in methods section 2.2.15. Cell-surface expression of 
TfR1 was studied at various time points after treatment as described in methods section 2.2.20. 
Flow cytometry images of serum starved rec-TfR1 HepG2 cells before treatment i.e. time 0 (A) 
and after holotransferrin treatment for 24 h (B) and 48 h (C) are shown.  
 
D: Cell-surface TfR1 in rec-TfR1 HepG2 cells relative to Wt HepG2 cells before treatment (time 
0). E and F: Cell-surface TfR1 in Wt HepG2 cells and rec-TfR1 HepG2 cells upon iron overdose, 
respectively, relative to time 0. Data is presented as mean ± SEM (n=3). * p<0.02, ** p<0.01 
compared to Wt HepG2 cells. 
 
A B C 
* 
** 
D E F 
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Under steady state conditions i.e. in the maintenance medium, there was no 
significant difference between the cell-surface expression of TfR1 in Wt HepG2 
and HepG2 (p) cells (Fig. 4.2D). On the other hand, rec-TfR1 HepG2 cells 
expressed approximately 2-fold higher levels of TfR1 on the cell surface than Wt 
HepG2 and HepG2 (p) cells (p<0.01). On treating the Wt HepG2 and the HepG2 (p) 
cells with 5 g/L holotransferrin, TfR1 expression in these cells decreased with time 
whereas in the rec-TfR1 HepG2 cells, a significant increase in expression of  
cell-surface TfR1 was observed (Fig. 4.2E). 
Fig. 4.2  Effect of iron overdose on TfR1 cell-surface expression in HepG2 cells 
Wt and rec-TfR1 HepG2 cells were treated with 5 g/L holotransferrin up to 48 h and cell-surface 
expression of TfR1 before (time 0) and after treatment was studied, as described in methods 
section 2.2.20. Flow cytometry images of rec-TfR1 HepG2 cells before treatment i.e. time 0 (A) 
and after holotransferrin treatment for 24 h (B) and 48 h (C) are shown. 
D: Cell-surface TfR1 of HepG2 (p) and rec-TfR1 HepG2 cells, relative to Wt HepG2 cells (n=3). 
E: HepG2 TfR1 responses upon iron overdose, relative to time 0.  
Data is presented as mean ± SEM. * p<0.02 compared to time 0 and ** p<0.01, # p<0.05 
compared to 24 h.  
* 
** 
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4.2.2 Iron-related genes in rec-TfR1 HepG2 cells  
Prior to gene expression analysis via real time PCR, the expression of genes of  
interest at the mRNA level in the rec-TfR1 HepG2 cells was confirmed by 
amplifying the cDNA with the designed primers and those published by other 
research groups (appendix V). Each amplicon observed in Fig. 4.3 was sent for 
sequencing to confirm its identity before proceeding with expression analysis 
(appendix V). As observed by other groups (Fein et al., 2007, Kulaksiz et al., 2004), 
here through Fig .4.3, it was shown that HepG2 cells express hepcidin.   
       
 
 
 
 
 
 
 
 
 
 
 
4.2.3 HepG2 cells under steady state conditions: 48 h study 
The viability of Wt and rec-TfR1 HepG2 cells under steady state conditions (i.e. in 
the maintenance medium) increased with time (figures 4.4 A and B). This indicated 
growth of cells and increase in cell numbers, although the increase in cell numbers 
1   2   3   4    5        6   7   8   9  1011 12  
100 bp 
200 bp 
300 bp 
Fig. 4.3  Amplicons of transcripts of iron-related genes in rec-
TfR1 HepG2 cells 
cDNA from rec-TfR1 HepG2 cells was synthesised as explained in 
methods section 2.2.18 and amplified by PCR as described in 
methods section 2.2.8. Primers (Table 2.3) used to amplify the rec-
TfR1 cDNA as seen in each lane, were as below: 
Lane 1= TfR1 (F) and (R); expected product size= 179 bp 
Lane 2= TFR1-IRE (F Ib) and (R I); expected product size= 210 bp 
Lane 3= Hepcidin (FI) and (RI); expected product size= 189 bp 
Lane 4= Ferroportin (FI) and (RI); expected product size= 260 bp 
Lane 5= GAPDH (F) and (R); expected product size= 131 bp 
Lane 6 = HFE (FI) and R (I); expected product size=77 bp 
Lanes 7-12 = negative controls with respective primers 
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in rec-TfR1 HepG2 cells was at a slower rate than Wt HepG2 cells from 24 to 48 h. 
This slow growth rate could be due to the presence of plasmid in the rec-TfR1 
HepG2 cells. Such plasmid-possessing recombinant cells may utilise a significant 
amount of the cell’s resources to maintain the plasmid; the plasmid being a 
metabolic burden on the cells (Glick, 1995). Intracellular iron content was 
determined which showed that basal levels of iron in the rec-TfR1 HepG2 cells 
were higher than those in the Wt HepG2 cells (figures 4.4 C and D). 
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Fig. 4.4  Viability studies and iron content in HepG2 cells 
under steady state conditions 
Wt and rec-TfR1 HepG2 cells growing in maintenance medium 
were assessed for viability and intracellular iron content at 
various time points, as described in methods section 2.2.16 and 
2.2.17, respectively. Viabilities were expressed relative to the 6 
h time point.   
 
A and B : Cell viabilities of Wt HepG2 cells (n=2) and rec-TfR1 
HepG2 cells (n=2), respectively. 
C and D : Intracellular iron levels in Wt HepG2 cells (n=2) and 
rec-TfR1 HepG2 cells (n=3), respectively. 
Data is presented as mean± SEM  
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In the preliminary RNA expression analysis of iron-related genes via real time PCR, 
three reference genes actin, GAPDH and 18s  were chosen. The CT values of the 
genes showed that GAPDH was the most suitable under varying experimental 
conditions as it was the most stable (appendix XVI). Hence GAPDH was chosen as 
a reference gene to normalise expression of all the iron-related genes under study.  
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Gene expression analysis showed that in Wt HepG2 cells TfR1 levels significantly 
decreased after 24 h (Fig. 4.5A). Although no significant change in hepcidin mRNA 
was observed after 24 h, ferroportin expression showed a significant decrease, the 
cells aiming to retain intracellular iron levels. On the other hand, the rec-TfR1 
HepG2 cells showed a significant increase in TfR1 mRNA expression at 24 h and 
then a reduction after 48 h (Fig. 4.5B). However, the level at 48 h was higher than 
Wt HepG2 cells, despite the higher intracellular iron content than Wt HepG2 cells, 
as seen in Fig. 4.4D. This showed that the TfR1 in the rec-TfR1 HepG2 cells were 
insensitive to high intracellular iron concentration, as expected, due to the absence 
Fig. 4.5  Basal mRNA expression of iron-related genes in HepG2 cells  
Wt and rec-TfR1 HepG2 cells growing in the maintenance medium were analysed for basal 
mRNA expression of iron-related genes of interest. RNA expression analysis was carried out 
as described in methods sections 2.2.18 and 2.2.19, and was expressed relative to the 6 h.   
 
A and B : Expression of iron-related genes in Wt HepG2 cells and in rec-TfR1 HepG2, 
respectively. Data is presented as mean ± SEM (n=1-3). * p<0.05, ** p<0.02 and  
*** p<0.01 compared to the previous time point. 
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of the iron-regulated IRE element in the modified TfR1 in these cells. Also, in the 
rec-TFR1 HepG2 cells the mRNA of TfR1-IRE, which is a reflection of the 
endogenous iron regulated-TfR1, decreased at 24 h and 48 h (Fig. 4.5B) reflecting 
the cells’ high intracellular iron status. In this situation the endogenous TfR1 mRNA 
is expected to be down-regulated to prevent any further iron uptake.  
 
The high intracellular iron status of rec-TfR1 Hep2 cells was reflected in the 
increased levels of ferroportin mRNA at 6 h followed by a drop at 24 h and then 
again a rise at 48 h, mirroring the pattern of intracellular iron levels seen in Fig. 
4.4D. A similar pattern of HFE gene expression was observed. Although hepcidin 
mRNA levels were generally maintained, hepcidin expression appeared to be at a 
higher level than in the Wt HepG2 cells at the same time points. 
 
4.2.4 Iron overdose and Wt HepG2 cells : 48 h study     
On treating the Wt HepG2 cells with 1 g/L and 5 g/L holotransferrin, both the 
concentrations decreased cell viability by ~ 20 % at 6 h, remained stable at 24 h 
and increased by 50 % at 48 h with respect to the untreated control at each time 
point (Fig. 4.6A). A 24 h period of serum and iron deprivation did not have a major 
impact on cell viability but viability decreased by 40 % when deprivation was for 48 
h (Fig. 4.6B). Intracellular iron levels were generally maintained regardless of the 
high circulating holotransferrin concentration (Fig. 4.6C), implying the regulatory 
effect of TfR1-IRE, which controlled iron uptake by the cells under high 
extracellular iron environment.  
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Fig. 4.7 shows the effect of holotransferrin treatments on mRNA expression of 
various iron-related genes in the Wt HepG2 cells. It was observed that TfR1 mRNA 
levels generally decreased upon holotransferrin treatment and increased by 
approximately 3-fold under serum and iron deprivation (Fig. 4.7A and B). Unlike 
TfR1, hepcidin mRNA levels increased upon iron exposure at 6 and 24 h, whereas 
24 h-holotransferrin treatment (1 g/L) resulted in an approximately 2.9-fold increase 
in hepcidin mRNA levels (Fig. 4.7C).  
A B
C
Fig. 4.6  Viability studies and intracellular iron levels in Wt HepG2 cells  
under holotransferrin treatments 
Wt HepG2 cells were treated with different concentrations of holotransferrin 
for 48 h as described in methods section 2.2.15. Cell viability and 
intracellular iron levels after treatments were determined as mentioned in 
legend of Fig. 4.4. Viability of treated cells (1 g/L and 5 g/L holotransferrin) 
was expressed relative to viability of untreated cells (0 g/L) at each time 
point. 
 
A and B: Effect of holotransferrin overdose and iron deprivation (0 g/L) on 
cell viability, respectively (6 h and 24 h: n=2; 48 h: n=1). 
C: Effect of holotransferrin overdose on intracellular iron levels (n=2). 
Data is presented as mean ± SEM. 
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Fig. 4.7 mRNA expression of iron-related genes in Wt HepG2 cells upon holotransferrin 
treatments  
Wt HepG2 cells were treated with different concentration of holotransferrin for 48 h as described 
in methods section 2.2.15. RNA expression analysis was per legend of Fig. 4.5. mRNA 
expression of treated cells (1 g/L and 5 g/L holotransferrin) was expressed relative to untreated 
cells (0 g/L) at each time point. 
 
A and B: TfR1 and TfR1-IRE expression upon holotransferrin treatment and under serum and 
holotransferrin deprivation (0 g/L), respectively; (6 h and 48 h: n=2; 24 h: n=3). 
C and D: Hepcidin and ferroportin expression upon holotransferrin treatment and under serum 
and holotransferrin deprivation (0 g/L), respectively; (6 h and 24 h: n=2; 48 h: n=1). 
E and F:  HFE expression upon holotransferrin treatment and under serum and holotransferrin 
deprivation (0 g/L), respectively; (n=1)  
Data is presented as mean ± SEM. * p<0.02 compared to untreated control. 
DC
E F
A B
* 
 
* 
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Ferroportin mRNA levels were generally maintained at constant levels throughout 
the treatment (Fig. 4.7C), similar to the intracellular iron levels seen in Fig. 4.6C. 
This implied that there was no excess iron within the cells and hence the cells 
retained iron. The increase in ferroportin expression by approximately 70 % after 
24 h of 1 g/L treatment may be to remove excess iron the cells have taken up. The 
down-regulation of ferroportin mRNA by approximately 20 % after 24 h in 5 g/L 
holotransferrin (compared to 0 g/L) was similar to that observed by Jacolot et al. 
(2008) on treatment of Wt HepG2 cells with 4.5 g/L of holotransferrin. 
 
Preliminary studies of HFE transcription showed that its level steadily increased 
upon increasing iron dosage but remained stable as compared to the untreated 
control after 24 h (Fig. 4.7 E). This is unlike the response reported by Jacolot et al. 
(2008) where HFE gene expression was slightly down-regulated on treatment with 
4.5 g/L of holotransferrin for 24 to 48 h.  
 
4.2.5 Iron overdose and rec-TfR1 HepG2 cells : 48 h study   
The viability of rec-TfR1 HepG2 cells generally remained steady over the period of 
48 h when under holotransferrin treatment and serum and iron deprivation (Fig 4.8 
A and B). Intracellular iron levels were determined which showed that in contrast to 
Wt HepG2 cells, the rec-TfR1 HepG2 cells showed a significant increase in iron 
uptake (p<0.01) with increasing holotransferrin concentration at 24 h (Fig. 4.8C).  
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Matching the pattern of iron uptake, TfR1 mRNA levels were up-regulated in rec-
TfR1 HepG2 cells upon increasing holotransferrin concentrations at 6 and 24 h (Fig. 
4.9A). Following 2 g/L (data not shown) and 5 g/L holotransferrin treatment for 24 h, 
these cells showed a 2-fold and ~3-fold rise in TfR1 mRNA (p< 0.04) (Fig. 4.9A). 
Thus, unlike the Wt HepG2 cells, the rec-TfR1 HepG2 cells showed insensitivity to 
high intracellular iron levels by preventing TfR1 mRNA down-regulation (Fig. 4.8 C). 
Fig. 4.8  Viability studies and intracellular iron levels in rec-TfR1 HepG2  
cells under holotransferrin treatments 
Rec-TfR1 HepG2 cells were treated with increasing concentrations of 
holotransferrin up to 48 h followed by measurement of cell viability and 
intracellular iron levels as described in legend of Fig. 4.6. Viability of treated 
cells (1 g/L and 5 g/L holotransferrin) was expressed relative to the viability of 
untreated cells (0 g/L) at each time point. 
 
A and B: Effect of holotransferrin overdose and serum and iron deprivation (0 
g/L) on cell viability, respectively (n=3). 
C: Effect of holotransferrin overdose on intracellular iron levels (0g/L: n=6;  
1 g/L and 5 g/L: n=3). Data is presented as mean ± SEM. * p<0.01 compared to 
untreated control, # p<0.01 compared to 1 g/L treatment.  
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Fig. 4.9  mRNA expression of iron-related genes in rec-TfR1 HepG2 cells upon 
holotransferrin treatment  
Rec-TfR1 HepG2 cells were treated with increasing concentrations of holotransferrin and mRNA 
expression was analysed as mentioned in legend of Fig. 4.7. mRNA expression of treated cells (1 
g/L and 5 g/L holotransferrin) was expressed relative to untreated cells (0 g/L) at each time point. 
 
A and B: TfR1 and TfR1-IRE expression upon holotransferrin treatments and under serum and 
holotransferrin deprivation (0 g/L), respectively; (6 h and 48 h: n=2; 24 h: n=3) 
C and D: Hepcidin and ferroportin expression upon holotransferrin treatments and under serum and 
holotransferrin deprivation, respectively (n=2). 
E and F: HFE expression upon holotransferrin treatments and under serum and holotransferrin 
deprivation, respectively (n=2). 
Data is presented as mean ± SEM. * p<0.01 compared to untreated control. 
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Under serum and iron deprivation, like the Wt HepG2 cells, the rec-TfR1 HepG2 
cells increased TfR1 mRNA levels, but unlike the Wt HepG2 cells the TfR1-IRE 
was either down-regulated or remained stable (Fig.49B), displaying a feature of 
regulated iron uptake. Also, unlike the Wt HepG2 cells, hepcidin and ferroportin 
mRNA expression did not show any significant change upon holotransferrin 
treatments at any time points (Fig. 4.9C). HFE expression levels decreased with 
increasing iron overdose after 6 h and 24 h (Fig. 4.9E), completely opposite to the 
pattern of iron uptake in these cells as seen in Fig. 4.8C. 
 
In conclusion, the results showed that the 48 h period of iron overdose to the rec-
TfR1 HepG2 cells, caused an intracellular iron overload but did not lead to a rise in 
hepcidin mRNA expression, as was hypothesised. Hence to determine if the 
expected increase in hepcidin mRNA expression occurred earlier than 6 h, the 
“time window” of measurements was changed in the subsequent experiments. 
Since previous results showed that the Wt and the rec-TfR1 HepG2 cells differed 
strikingly in their responses when treated with 5 g/L holotransferrin (figures 4.7A 
and 4. 9A, 4.6C and 4.8C), the effect of iron supplementation on cell responses 
was studied within 4 h of 5 g/L holotransferrin treatment. Responses exhibited by 
rec-TfR1 HepG2 cells were compared to those of Wt HepG2 cells and HepG2 (p) 
cells i.e. Wt HepG2 cells with empty plasmid, in which the endogenous TfR1 was 
unchanged and hence were expected to demonstrate regulated iron uptake like the 
Wt HepG2 cells. 
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4.2.6 HepG2 cells under steady state condition : 4 h study 
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Fig. 4.11  Viability and iron uptake in HepG2 cells under steady state 
conditions : 4 h study 
Wt HepG2, HepG2 (p) and rec-TfR1 HepG2 cells growing in maintenance medium 
were assessed for viability and intracellular iron content at various time points, as 
mentioned in legend of Fig. 4.4. Viabilities were expressed relative to the 1st time 
point of the assay (time 0).  
 
A, B, and C: cell viabilities of Wt HepG2, HepG2 (p) and rec-TfR1 HepG2 cells, 
respectively. 
D, E and F: Intracellular iron levels in Wt HepG2, HepG2 (p) and rec-TfR1 HepG2 
cells, respectively. 
Data is presented as mean ± SEM (n=3). * p<0.01 compared to time 0. 
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In the maintenance medium the viability of all cells generally remained stable within 
the 4 h period. Intracellular iron levels were also maintained at constant levels by 
the Wt HepG2 and HepG2 (p) cells, whereas rec-TfR1HepG2 cells showed a 
pattern of increasing iron uptake which significantly increased by 70 % after 4 h 
(p<0.01) (Fig. 4.11F). Iron levels in the Wt HepG2 cells measured in this study (3-4 
nmoles/mg protein) are similar to those measured by Gu et al.,(2008).  
 
The mRNA expression levels of various iron-related genes in the HepG2 cells in 
maintenance medium (i.e. under steady state) were analysed as shown in Fig.4.12. 
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Fig. 4.12  Basal mRNA expression of iron-related genes in HepG2 cells : 4 h study  
Wt HepG2, HepG2 (p) and rec-TfR1 HepG2 cells growing in the maintenance medium were 
analysed for basal mRNA expression of iron-related genes of interest. RNA expression 
analysis was carried out as mentioned in legend of Fig. 4.5 and expressed relative to time 0. 
mRNA expression studies of iron-related genes in A: Wt HepG2 cells; B: HepG2 (p) cells; C 
and D : Rec-TfR1 HepG2 cells. Data is presented as mean ± SEM (n=3).  
* p<0.01 compared to time 0. 
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In the Wt HepG2 cells there was no significant change in gene expression over the 
4 h period, except the rise in hepcidin mRNA expression after 4 h (Fig. 4.12A). In 
the HepG2 (p) cells the increase in TfR1 and hepcidin mRNA within the first 30 min 
followed a gradual stabilisation after 2 h and 4 h (Fig. 4.12B). The rec-TfR1 HepG2 
cells showed a notably different pattern of gene expression than the cells of Wt 
origin i.e. Wt HepG2 cells and HepG2 (p) cells. While the expression of HFE and 
hepcidin mirrored each other, these cells showed significantly high ferroportin 
mRNA levels (p<0.01) as seen in figures. 4.12 C and D.  
 
4.2.7 Effect of iron overdose on HepG2 cells : 4 h study 
In order to ensure that the cells had received a high dosage of iron via 
holotransferrin, iron levels in the treatment media were measured. The results 
showed that iron levels in 5 g/L holotransferrin treatment media were 15-20 fold 
higher than those in the maintenance medium (Fig. 4.13).   
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Fig. 4.13  Iron levels in treatment media for HepG2 cells 
Iron levels in the treatment media used to treat HepG2 cells were detected as per methods 
section 2.2.17.1.  
A: Wt HepG2 cells; B: HepG2 (p) cells; C: Rec-TfR1 HepG2 cells 
10%FCS represent maintenance medium. Data is presented as mean ± SEM (n=3) 
A B C
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Viability studies revealed that holotransferrin treatment of 5 g/L up to 4 h did not 
have a major impact on the viabilities of any of the cell lines (figures 4.14, A, B  
and C). 
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Fig. 4.14  Viability studies and iron uptake in HepG2 cells under holotransferrin 
treatment : 4 h study 
HepG2 cells were treated with 5 g/L holotransferrin for 4 h as described in methods section 
2.2.15. Cell viability and intracellular iron levels after treatments were determined as 
described in legend of Fig. 4.4. Viability of treated cells (5 g/L holotransferrin) was expressed 
relative to viability of untreated cells (0 g/L) at each time point. 
 
A, B and C : Effect of holotransferrin treatment on viability of Wt HepG2, HepG2 (p) and rec-
TfR1 HepG2 cells, respectively. 
D, E and F : Effect of holotransferrin treatment on intracellular iron levels in Wt HepG2, 
HepG2 (p) and rec-TfR1 HepG2 cells, respectively.  
Data is presented as mean ± SEM (n=3). * p<0.05, ** p<0.01 compared to untreated control 
at respective time points. 
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Likewise, the Wt HepG2 and HepG2 (p) cells generally showed constant levels of 
intracellular iron regardless of high extracellular iron highlighting that the iron 
uptake regulatory mechanisms in these cells were functional (figures 4.14, D and 
E). In comparison, the rec-TfR1 HepG2 cells not only showed considerably higher 
basal levels of iron but also significantly increased iron uptake upon holotransferrin 
treatment for 2 and 4 h by approximately 1.4- and 2.1-fold, respectively (Fig. 4.14F), 
a feature of these cells as observed earlier (Fig. 4.8C). 
 
Gene expression analysis under holotransferrin treatments in the three HepG2 cell 
lines under study has been captured in figures 4.15-4.17. In the Wt HepG2 cells 
(Fig. 4.15), holotransferrin treatment did not significantly affect the mRNA 
expression of TfR1, ferroportin and HFE genes in the first 30 min. When the 
duration of treatment increased to 2 h and 4 h, the expression of TfR1 significantly 
decreased (p<0.02 and p<0.01, respectively) compared to the untreated control at 
each time point. This was expected as the Wt HepG2 cells express IRE-regulated 
TfR1 mRNA which made the cells sensitive to intracellular iron levels and 
prevented any further iron uptake on reaching cellular iron sufficiency by down- 
regulation of TfR1. While the other genes were stably expressed, hepcidin mRNA 
levels were up-regulated by 0.7-, 0.4- and 0.6-fold after 30 min, 2 h and 4 h of 
holotransferrin overdose, respectively, compared to the untreated control at each 
time point.  
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The HepG2 (p) cells generally showed a similar pattern of gene expression to the 
Wt HepG2 cells (Fig. 4.16). Although these cells appeared to show increased 
hepcidin and ferroportin expression upon iron overdose, it was observed that these 
increases resulted from the changes in expression of the reference gene in these 
cells rather than changes in expression of hepcidin and ferroportin (appendix XVI). 
This conclusion was based on the CT values of hepcidin and ferroportin as well as 
the products observed on the gel, which remained unchanged under untreated and 
treated conditions at all time points.    
 
* 
TfR1 
TfR1-IRE 
Hepcidin 
Ferroportin 
HFE 
GAPDH 
 0 g/L   5 g/L   0 g/L   5 g/L   0 g/L   5 g/L  
Fig. 4.15  Effect of holotransferrin treatment on gene expression in Wt HepG2 cells 
Wt HepG2 cells were treated with 5 g/L holotransferrin up to 4 h and their mRNA 
expression analysis was per legend of Fig. 4.7. mRNA expression of treated cells (5 g/L 
holotransferrin) was expressed relative to untreated cells (0 g/L) at each time point. 18 µL 
of RT PCR products were electrophoresed on 1-1.5 % agarose gel.  
Data is presented as mean ± SEM (n=3).* p<0.02, ** p<0.01 compared to untreated 
control at respective time points.  
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The rec-TfR1 HepG2 cells displayed their typical characteristic of up-regulation of   
TfR1 mRNA under holotransferrin treatment (Fig. 4.17) as previously observed in 
Fig. 4.9A. Although hepcidin and HFE expression did not significantly change, 
ferroportin expression showed a pattern of increasing expression as the duration of 
treatment increased, similar to the pattern of iron uptake by these cells as seen in 
Fig. 4.14F.  
 
 
 
 
 
TfR1 
TfR1-IRE 
Hepcidin 
Ferroportin 
HFE 
GAPDH 
Fig. 4.16  Effect of holotransferrin treatment on gene expression in HepG2 (p) cells 
HepG2 (p) cells were treated with 5 g/L holotransferrin up to 4 h and their mRNA 
expression analysis was per legend of Fig. 4.7. mRNA expression of treated cells (5 g/L 
holotransferrin) was expressed relative to untreated cells (0 g/L) at each time point. 18 µL 
of RT PCR products were electrophoresed on 1.5 % agarose gel.  
Data is presented as mean ± SEM (n=3).  
 
 0 g/L   5 g/L   0 g/L   5 g/L   0 g/L   5 g/L  
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Although Wt HepG2 and HepG2 (p) cells showed similar patterns of gene 
expression with holotransferrin overdose over time, some differences surfaced with 
respect to hepcidin and ferroportin gene expression (figures 4.18 A and B). In Wt 
HepG2 cells, where hepcidin expression was down-regulated, the HepG2 (p) cells 
showed an elevated response after 30 min which gradually subsided after 4 h to a 
level similar to that in Wt HepG2 cells. Likewise, ferroportin mRNA levels were 
found to be generally up-regulated compared to the Wt HepG2 cells. The rec-TfR1 
HepG2 cells exhibited a different response (figures 4.18 C and D). Notably, after 
30 min, the cells showed increased TfR1-IRE, hepcidin, HFE and ferroportin 
expression. It was observed again that HFE and hepcidin expression mirrored 
* 
* 
** 
TfR1 
TfR1-IRE 
Hepcidin 
Ferroportin 
HFE 
GAPDH 
 0 g/L   5 g/L   0 g/L   5 g/L   0 g/L   5 g/L  
Fig. 4.17  Effect of holotransferrin treatment on gene expression in rec-TfR1 HepG2 cells 
Rec-TfR1 HepG2 (p) cells were treated with 5 g/L holotransferrin up to 4 h and their mRNA 
expression analysis was per legend of Fig. 4.7. mRNA expression of treated cells (5 g/L 
holotransferrin) was expressed relative to untreated cells (0 g/L) at each time point. 18 µL of RT 
PCR products were electrophoresed on 1-1.5 % agarose gel. Data is presented as mean ± SEM 
(n=3). * p<0.02, ** p<0.01 compared to untreated control at respective time points.  
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each other. At 2 h and 4 h, the rec-TfR1 HepG2 cells expressed HFE and 
ferroportin genes at higher levels than the Wt HepG2 cells at the same time points.  
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4.2.8 Iron overdose and hepcidin secretion by HepG2 cells  
Holotransferrin overdose to the HepG2 cells resulted in increased hepcidin 
peptide secretion (Fig. 4.19). As seen in the figure, Wt and rec-TfR1 HepG2 
cells increased hepcidin peptide secretion regardless of a prior 24 h period of 
serum deprivation. Fig. 4.19B shows that the Wt HepG2 cells significantly 
Fig. 4.18 Gene expression in HepG2 cells under holotransferrin overdose over time 
The figure shows changes in gene expression over time in 
A: Wt HepG2 cells; B : HepG2 (p) cells ; C and D : Rec-TfR1 HepG2 cells 
Data is presented as mean± SEM (n=3). * p<0.05, ** p<0.01, compared to time 0,  
# p<0.05 compared to 30 min.  
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B
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increased hepcidin secretion in the first 24 h exposure to holotransferrin 
overdose followed by a plateau in Wt HepG2 and HepG2 (p) cells. Unlike this, 
the rec-TfR1 HepG2 cells showed a significant steady increase in hepcidin 
peptide levels up to 48 h.  
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Similarly, holotransferrin overdose for a short period of 4 h resulted in increased 
hepcidin peptide secretion (~2-fold) by all the HepG2 cell lines (Fig. 4.20). In the 
case of rec-TfR1 HepG2 cells, the released levels of hepcidin were significantly 
higher than the untreated cells as well as cells in the maintenance medium. In the 
maintenance medium, the Wt and rec-TfR1 HepG2 cells secreted constant levels 
of hepcidin, although the secretion was decreased in rec-TfR1 HepG2 cells at 4 h 
Fig. 4.19  Effect of prolonged iron overdose on hepcidin peptide secretion by HepG2 
cells   
Wt and rec-TfR1 HepG2 cells were serum starved for 24 h (time 0) and treated with 5 g/L 
holotransferrin for 48 h, as described in methods section 2.2.15. Cell-surface expression of 
TfR1 was studied at various time points after treatment as described in methods section 
2.2.20. Determination of the level of hepcidin excreted in the treatment medium was as 
explained in methods section 2.2.22. 
 
A and B: Hepcidin peptide levels in HepG2 cells after a prior period of serum deprivation 
and without any period of serum deprivation, respectively. 
10% FCS represent maintenance medium. Data is presented as mean ± SEM. 
* p<0.05 compared to 24 h, ** p<0.01 compared to time 0, # p<0.01 compared to 24 h. 
** 
# * * 
A B
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(p<0.01). Serum and iron deprivation (0 g/L) up to 4 h resulted in a significant  
1.7-fold decrease in hepcidin peptide levels by the Wt HepG2 cells compared to 0 
g/L treatment for 2 h. 
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4.3 Discussion  
To date, experiments conducted by different groups showed that hepcidin mRNA 
expression varied on exposure to iron overdose (Gehrke et al., 2003, Jacolot et al., 
2008, Nemeth et al., 2003, Rapisarda et al., 2010). The observed variability in 
results was primarily due to the lack of an appropriate model system that would 
mimic human physiological conditions. In the present study, while trying to 
establish a suitable cell model for iron-related studies, iron overdose experiments 
were designed with the intention of observing the same effect on hepcidin 
expression as observed in human and animal models (Lin et al., 2007, Nemeth et 
al., 2003, Pigeon et al., 2001).  
Fig. 4.20  Effect of iron overdose on hepcidin peptide secretion by HepG2 cells  
HepG2 cells were treated with holotransferrin overdose for 4 h and the hepcidin peptide levels 
were measured as described in legend of Fig. 4.17. 10%FCS represent maintenance medium. 
Data is presented as mean ± SEM (n=3).* p 0.058 compared to 2 h 0 g/L, ** p<0.05 and  
*** p<0.02 compared to 0 g/L at respective time points.  # p<0.01 compared to 2 h in 
maintenance medium (10%FCS). 
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Hepcidin-25 has been shown to bind iron and it was proposed that iron may play 
an important role in regulating hepcidin expression (Farnaud et al., 2008). Based 
on this information, in the present study it was hypothesised that intracellular iron 
overload would cause a rise in hepcidin mRNA expression and that such an 
increase in HepG2 cells would not require the presence of other cell types. To 
check this hypothesis, mRNA expression of hepcidin and other iron-related genes 
were analysed upon iron exposure. Through this, the intention was to study how 
iron regulates hepcidin gene expression, which has not been previously 
understood. 
 
Before proceeding with iron supplementations, the proportion of holotransferrin in 
the transferrin treatment medium was determined by using a 6 M urea gel assay 
(section 2.2.13). Results showed that the transferrin preparation used for iron 
supplementation experiments possessed a high proportion (approximately 80%) of 
holotransferrin (Fig. 2.4). This confirmed that the cells would be surrounded by an 
iron-rich environment to enable intracellular iron overload. Holotransferrin 
concentrations ranging from 1g/L to 5 g/L were initially chosen for iron 
supplementations to cover the normal human physiological range of transferrin (2-4 
g/L) (Sternberg, 1986) and to create an iron-rich environment to facilitate 
intracellular iron overload.  
 
As seen in chapter 3 (Fig. 3.25) holotransferrin overdose to CHO TRVb1 cells did 
not lead to intracellular iron overload but increased the secretion of hepcidin 
peptide levels (Fig. 3.26). To investigate whether intracellular iron overload could 
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affect hepcidin gene expression, rec-TfR1 HepG2 cells were created such that they 
expressed an IRE-independent TfR1 mRNA to maximise iron uptake. Using these 
cells, hepcidin expression and several other genes and iron-related aspects were 
studied. 
 
4.3.1 Regulation of iron uptake by TfR1  
In order to confirm the expression of recombinant TfR1 on the cell membrane of 
rec-TfR1 HepG2 cells, the level of total TfR1 proteins on the cell-surfaces of Wt 
HepG2 and rec-TfR1 HepG2 cells were compared. As expected, the rec-TfR1 
HepG2 cells displayed higher basal levels of cell-surface TfR1 than Wt HepG2 
cells (figures. 4.1D and 4.2D).  
 
In the Wt HepG2 cells, serum deprivation followed by holotransferrin overdose 
resulted in an increased expression of TfR1 on the cell surface (Fig. 4.1E). Such a 
response reflected the cells’ necessity for increased iron uptake for survival and 
growth, particularly after a period of serum starvation. After 24 to 48 h the cells 
may have reached intracellular iron sufficiency and hence the plateau or a slight 
down-regulation of TfR1, as seen at the 48 h time point (Fig. 4.1E). The 
mechanism is supported by the results obtained when the Wt HepG2 cells were 
treated with holotransferrin overdose without any prior period of serum starvation; 
in this instance cell-surface TfR1 was found to be down-regulated (Fig. 4.2E). This 
was an expected response in which cellular iron sufficiency would lead to down-
regulation of TfR1 to prevent any further iron uptake. Both responses (i.e. up-
regulation of TfR1 following serum and iron deprivation and down regulation under 
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holotransferrin overdose), are expected and characteristic of the well characterised 
regulated mechanism in which iron uptake is regulated by the functional TfR1-IRE.  
 
In contrast, the rec-TfR1 HepG2 cells showed either constitutive or up-regulated 
levels of cell-surface TfR1 upon holotransferrin overdose (figures 4.1E and 4.2E). 
This was expected since the recombinant TfR1 construct in these cells was devoid 
of the IRE region. The result of such constitutive and high TfR1 expression on cell 
surface was that these cells showed higher basal levels of intracellular iron than 
the Wt HepG2 cells (figures. 4.4C and D). In addition, holotransferrin overdose led 
to increased iron uptake by the rec-TfR1 HepG2 cells, unlike the Wt HepG2 cells 
(figures 4.6C and 4.8C; 4.11D and F; 4.14D and F). Together, the results indicated 
that TfR1 in the rec-TfR1 HepG2 cells was insensitive to the increase in 
intracellular iron levels and therefore independent of the regulatory mechanisms 
exhibited by the IRE region.  
 
Correlating the TfR1 responses observed at protein levels to transcript levels, it 
was observed that the rec-TfR1 HepG2 cells showed higher basal levels of TfR1 
mRNA and increased TfR1 mRNA expression upon holotransferrin overdose, 
unlike the Wt HepG2 cells (figures. 4.5, 4.7A, 4.9A). Decreased TfR1 mRNA in the 
Wt HepG2 cells under holotransferrin treatments observed in this study is similar to 
that observed by Gehrke et al. (2003). The most striking difference between the Wt 
HepG2 and rec-TfR1 HepG2 cells was that 5 g/L holotransferrin treatment for 6 
and 24 h led to a down-regulation of TfR1 mRNA in Wt HepG2 cells (Fig.4.7A) and 
an up-regulation in the rec-TfR1 HepG2 cells (Fig. 4.9A). 
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Another observation was that, as expected, serum and iron deprivation increased 
TfR1 mRNA levels in both the Wt HepG2 (similar to that reported by Jacolot et al. 
(2008)) and the rec-TfR1 cells. However, the TfR1-IRE, which is a reflection of the 
endogenous TfR1, was up-regulated in Wt HepG2 cells but not to the same extent 
in rec-TfR1 HepG2 cells (figures. 4.7B and 4.9B). This could be explained as 
follows. Along with the IRE-independent TfR1 mRNA, the rec-TfR1 HepG2 cells 
possess the endogenous TfR1 with its regulatory IRE region. High cell-surface 
TfR1 (Fig. 4.2D) along with high basal intracellular iron levels in these cells 
prevented any major increase in the endogenous TfR1, i.e. TfR1-IRE mRNA. 
Hence it could be concluded that the up-regulation of TfR1 mRNA by the rec-TfR1 
HepG2 cells, under holotransferrin-free conditions (0 g/L) was more due to TfR1-
insensitivity towards the high intracellular iron levels rather than cellular necessity 
to uptake iron.  
 
Together these results highlighted the difference in iron uptake mechanisms 
between the Wt and rec-TfR1 HepG2 cells, eventually highlighting the significance 
of TfR1 in regulating iron uptake.  
 
4.3.2 Effect of intracellular iron overload on hepcidin expression  
Although intracellular iron levels in the Wt HepG2 cells were lower than rec-TfR1 
HepG2 cells and upon holotransferrin treatments did not show a significant 
increase in iron uptake (figures 4.4C and 4.6C), hepcidin mRNA was up-regulated 
at 6 h and 24 h in the Wt HepG2 cells (Fig. 4.7C). The approximately 2.9-fold 
increase in hepcidin mRNA upon 1 g/L holotransferrin treatment (24 h) by the Wt 
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HepG2 cells is similar to that reported by Lin et. al (2007) where 1 g/L 
holotransferrin treatment to mouse hepatocytes for 18-24 h led to a 2.5±0.6 fold 
increase in hepcidin mRNA compared to iron-free medium. Also, the 0.6-fold 
increase (24 h) and 0.8-fold decrease (48 h) in hepcidin mRNA upon 5 g/L 
holotransferrin treatment observed in this study is similar to that observed by 
Jacolot et al. (2008), where 24-48 h treatment with 4.5 g/L holotransferrin resulted 
in a 0.82-fold decrease in hepcidin mRNA. Likewise, an average 0.6-fold increase 
in hepcidin mRNA following 5 g/L holotransferrin treatment for 30 min, 2 and 4 h, 
was also observed in the Wt HepG2 cells (Fig.4.15).  
 
In comparison, although the rec-TfR1 HepG2 cells showed high basal intracellular 
iron levels and increased intracellular iron uptake upon holotransferrin treatments, 
the expected increase in hepcidin mRNA levels was not observed (Fig. 4.9C and 
4.17). Interestingly, 2 h of 5 g/L holotransferrin treatment caused a significant  
0.5-fold increase in hepcidin mRNA followed by significant increase in ferroportin 
mRNA expression after 2 h and 4 h (Fig. 4.17). This scenario proposes a two-stage 
response under intracellular iron overload. In the first stage hepcidin mRNA 
expression shows a subtle physiological increase (here 0.5-fold) in an attempt to 
regulate high extracellular iron levels. However, prolonged high extracellular iron 
exposure along with increased intracellular iron levels leads to an increase in 
ferroportin expression to remove the excess iron, rather than further increasing 
hepcidin mRNA levels in an attempt to regulate extracellular iron levels.  
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Thus, data suggests that under these experimental conditions a minor increase in 
intracellular iron levels led to an increase in hepcidin mRNA, as expected, but a 
major and further increase in intracellular iron levels did not lead to a further 
increase in hepcidin mRNA levels. The observed increase in hepcidin mRNA in the 
Wt HepG2 cells, where there was no significant increase in intracellular iron levels, 
suggests that hepcidin mRNA levels subtly increase only under physiologically 
relevant conditions (i.e. optimal intracellular iron levels along with minor increases 
in extracellular iron levels). 
 
To complement the hepcidin mRNA studies, hepcidin peptide levels secreted into 
the medium were measured. Unlike the mRNA levels, hepcidin peptides exhibited 
a different response to extracellular holotransferrin overdose. For the first time, 
through this study it was shown that hepcidin peptide levels significantly increased 
upon holotransferrin overdose (figures 4.19 and 4.20) and decreased upon iron 
deprivation in a cell culture system (Fig. 4.21), as observed in human and animal 
models (Lin et al., 2007, Nemeth et al., 2003, Pigeon et al., 2001).   
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Fig. 4.21  Hepcidin secretion by HepG2 cells 
under iron deprivation 
Effect of serum and iron deprivation (0 g/L) on 
hepcidin peptide secretion over time is shown.  
Data is presented as mean ± SEM (n=3) 
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Although holotransferrin overdose triggered hepcidin peptide production, it was 
observed that FCS had a better capacity to induce hepcidin peptide secretion than 
holotransferrin overdose. As shown in Fig. 4.22, compared to the maintenance 
medium, 17-fold higher iron levels could only lead to a 1.6-fold increase in hepcidin 
peptide production. Results reported by other groups showed that serum factors in 
the FCS played a significant role in triggering hepcidin transcription (Dzikaite et al., 
2006). In the present study, the influence of FCS was observed at peptide levels as 
well. This suggests that hepcidin peptide secretion is not only influenced by 
intracellular or extracellular iron status, but also by a combination of various factors.   
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4.3.3 Influence of holotransferrin concentration and exposure-time on 
hepcidin 
In this study it was observed that an increase in hepcidin transcription in Wt HepG2 
cells was not directly proportional to an increase in extracellular holotransferrin 
concentration (Fig. 4.23). A similar response has been reported where low dosage 
of Fe-NTA (1- 3 µM) induced hepcidin transcription and high dosage of 65 µM Fe-
NTA resulted in its down-regulation below basal levels (Fein et al., 2007). Since the 
purpose of hepcidin is to regulate circulating iron levels, such a response is an 
Fig. 4.22  Hepcidin induction by holotransferrin and 
maintenance medium 
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attempt by the cell to regulate high extracellular iron levels. Thus, Fig. 4.23 shows 
the influence of increasing holotransferrin concentration on hepcidin mRNA levels.  
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Where previous studies showed that recombinant hepcidin is secreted in the 
medium within 1 h of its synthesis (Wallace et al., 2006), in this study, hepcidin 
peptides showed an immediate response to holotransferrin overdose. Both, the 
HepG2 and the CHO TRVb1 cell lines secreted hepcidin into the medium within 30 
minutes of increased iron exposure (figures 3.15 and 4.20). This fast response is 
not surprising as hepcidin is a hormone and its secretion in the extracellular 
environment should be a rapid process to be able to exhibit a quick response. 
There could be two possible scenarios mediating this quick response. Firstly, 
transcription of hepcidin gene could occur even earlier than 30 min. A quicker 
generation of preprohepcidin at the mRNA level is possible because it is only 430 
bases long. Secondly, hepcidin could be quickly secreted from the proposed 
prohepcidin pools stored within the cells (Farnaud, personal communication). 
Since the Wt and rec-TfR1 HepG2 cells showed similar increases in hepcidin 
peptide secretion on iron overdose, both at shorter and longer exposure time to 
Fig. 4.23  Hepcidin mRNA response towards increasing 
holotransferrin concentrations  
Pattern of hepcidin mRNA levels exhibited by Wt HepG2 cells is shown. 
Data is presented as mean ± SEM (n=2) 
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holotransferrin overdose (figures 4.19 and 4.20), where their hepcidin mRNA levels 
were variable (figures 4.7C and 4.9C), secretion of hepcidin from prohepcidin pools 
is probable. 
 
The response of hepcidin was also seen to be influenced by exposure time to 
holotransferrin. Fig. 4.24 shows the effect of holotransferrin overdose on hepcidin 
secretion over time.  
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Both the recombinant cell types i.e., the CHO TRVb1 cells and the rec-TfR1 
HepG2 cells showed comparatively low hepcidin secretion at 24 h and an increase 
again at 48 h. This drop followed by an increase predicts the same pattern of 
hepcidin response by the Wt HepG2 cells. Accordingly, the drop in hepcidin levels 
in the cells of Wt origin as seen at 48 h may be followed by an increase at 72 h. 
Although the cells of Wt origin (i.e. Wt HepG2 and HepG2 (p) cells) showed similar 
pattern of hepcidin secretion, it was different from that of the recombinant cells (i.e. 
rec-TfR1 HepG2 and CHO TRVb1 cells). The reason for these differences in 
Fig. 4.24  Hepcidin peptide release under holotransferrin overdose over time 
Effect of 5 g/L holotransferrin on hepcidin peptide secretion over time is shown. Data is 
presented as mean ± SEM (n=3) 
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hepcidin responses could be attributed to TfR1 in these cells; the  CHO TRVb1 
possess over-expressed human TfR1 and the rec-TfR1 HepG2 cells possess over-
expressed TfR1 which is devoid of the IRE-region, unlike the Wt and HepG2 (p) 
cells. These results highlight the role of TfR1 in hepcidin induction, probably via the 
proposed HFE-TfR1 dissociation mechanism (Schmidt et al., 2008).   
 
4.3.4 Relationship between HFE and hepcidin  
The effect of TfR1-regulated iron uptake on hepcidin expression suggests a 
probable link between HFE and hepcidin expression. It has been shown that HFE 
influences hepcidin expression. The absence of HFE abolishes hepcidin mRNA up-
regulation in the HepG2 cells (Gao et al., 2009). Similarly in the case of HFE-
related haemochromatosis, the absence of HFE on the cell surface is linked to 
reduced hepcidin mRNA (Bridle et al., 2003). Since both hepcidin and HFE are 
predominantly expressed in hepatocytes (Holmstrom et al., 2003, Zhang et al., 
2004) an inter-dependence between an up-regulated hepcidin response and the 
level of HFE expression can be envisaged.   
 
In the present study the rec-TfR1 HepG2 system can be described as being  
“haemochromatotic” since it is characterised by high intracellular iron content 
which is the case in haemochromatosis, however, with a major difference. 
Haemochromatosis is characterised by low levels of circulating hepcidin which is 
suggested to be linked with a mutated HFE which does not reach the cell surface 
(Feder et al., 1996, Bridle et al., 2003)  and therefore cannot induce hepcidin  
 143 
 
synthesis. In contrast the rec-TfR1 HepG2 cells showed increased hepcidin 
peptide production on iron treatment (figures. 4.19 and 4. 20), possibly due to the 
presence of functional HFE on its cell-surface.  
 
Additionally, in this study, the expression of hepcidin and HFE genes mirrored 
each other at the mRNA level. Hepcidin mRNA expression increased only in the 
presence of stable or increased HFE mRNA expression (figures. 4.12C and 4.18C). 
Since hepcidin regulates systemic iron levels and HFE is necessary to exhibit a 
hepcidin response, it could be concluded that HFE contributes to the regulation of 
extracellular iron levels via hepcidin. Since a relation between hepcidin and HFE 
expression at mRNA and protein level is shown to exist, it is important to fully 
understand which one of the two, HFE and hepcidin, regulated the other. This 
issue has been addressed in the following chapter.  
 
Like hepcidin, the expression of HFE was also observed to be dependent on the 
duration of exposure to holotransferrin. Cell exposure to high holotransferrin levels 
for a shorter time span did not lead to any significant changes in HFE expression 
(figures 4.15-4.17). However, notable changes were observed at longer exposure 
times (figures. 4.7E and F; 4.9E and F). Correlating this to hepcidin peptide levels, 
hepcidin was induced regardless of the differences in HFE gene expression 
(figures. 4.19 and 4.20). Based on the proposed mechanism of hepcidin induction 
by Schmidt et al. (2008), it could be explained that high dosage of iron for a shorter 
time span (i.e. up to 4 h) led to hepcidin induction due to cell-surface dissociation 
of TfR1 from the HFE allowing free HFE to then bind to TfR2 to induce hepcidin 
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expression. However, when the cells were exposed for a long time (e.g. 6 to 24 h), 
the mechanism of cell-surface dissociation of HFE from TfR1 may not be sufficient 
to deal with increased extracellular iron. Hence notable changes in HFE mRNA 
expression were observed at the later time points. Thus, it could be concluded that 
the response of HFE to induce hepcidin was dependent on the time of iron-
exposure. 
 
4.3.5 Effect of intracellular and extracellular iron levels on HFE 
It has been shown that in mouse hepatocytes the function of HFE is to bind to TfR1 
and regulate iron uptake by the cells (Chua et al., 2008). In the present study it 
was observed that increasing iron overdose to Wt HepG2 cells led to increased 
HFE mRNA expression, particularly at 6 h (Fig. 4.25A). 
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This is an expected response when extracellular iron levels are high and the cells’ 
attempt to control iron uptake via the HFE-TfR1 association, as proposed (Fleming 
and Britton, 2006). Since the Wt HepG2 cells did not show intracellular iron 
overload, the increase in HFE mRNA could be attributed exclusively to the 
Fig. 4.25  HFE sense iron levels 
A: HFE in Wt HepG2 cells sense extracellular iron levels 
B: HFE in rec-TfR1 HepG2 cells sense intracellular iron levels under basal conditions.  
 A  B 
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increasing extracellular holotransferrin concentrations, suggesting that the HFE is 
sensitive to extracellular iron levels. On the other hand, the similarity in patterns of 
intracellular iron content, ferroportin and HFE gene expressions in rec-TfR1 HepG2 
cells when in maintenance medium possibly suggests that the HFE participated in 
sensing intracellular iron levels (Fig. 4.25B).  
 
However, the existence of high intracellular iron levels in the rec-TfR1 HepG2 cells 
implies that the expected regulatory function of HFE via HFE-TfR1 association 
could not be executed due to the over-expression of TfR1 on the cell surface of 
these cells. Probably a certain ratio of HFE and TfR1 on the cell surface is required 
for the physiological regulation of iron uptake by the cells, which would suggest 
that in the rec-TfR1 HepG2 cells the expression of HFE was not sufficient to 
interact with the high number of TfR1 receptors on the cell surface and perform its 
suggested function of limiting iron uptake. The disturbance in this normal ratio in 
rec-TfR1 HepG2 cells led to uncontrolled iron uptake by these cells. 
 
Unlike the Wt HepG2 cells, the HFE expression in rec-TfR1 HepG2 cells 
decreased with increasing holotransferrin concentration at the 24 h time point (Fig. 
4.26). This decrease in HFE expression was similar to the decrease inTfR1-IRE 
which sensed the increase in intracellular iron levels and therefore decreased its 
mRNA expression, as expected. Since no IREs have been identified on HFE as yet, 
it is likely that HFE sensed iron status via TfR1. This confirms a correlation 
between the HFE and TfR1 as previously shown where HFE expression in HepG2 
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cells which were devoid of HFE led to an increase in TfR1 mRNA (Gao et al., 
2008). 
 
0
0.5
1
1.5
2
2.5
0 g/L 1 g/L 2 g/L 5 g/L
Holotransferrin concentration
F
o
ld
 c
h
a
n
g
e
Iron levels
HFE
TfR1-IRE
 
 
 
If the proposition of iron sensing via HFE is correct, then the presence of an ‘iron 
insensitive’ TfR1 in the rec-Tfr1 HepG2 cells may have informed the HFE 
incorrectly of the intracellular iron status. Consequently, instead of increasing HFE 
expression to control iron uptake, the cells decreased HFE levels upon 
holotransferrin overdose despite the high intracellular iron content. This resulted in 
an uncontrolled iron uptake by the recombinant TfR1 on the cell surface. Thus this 
suggests that HFE controls and is controlled by intracellular iron levels via the TfR1. 
Essentially, when HFE is absent on the cell surface as in case of 
haemochromatosis, or present in lesser amounts compared to TfR1 as in the rec-
TfR1 HepG2 cells, regulated iron uptake by cells is abolished resulting in 
intracellular iron overload and prevention of increased hepcidin induction.   
 
 
 
Fig. 4.26  Iron sensing by HFE in rec-TfR1 HepG2 
cells under increasing holotransferrin concentrations 
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4.3.6 HepG2 cells have an iron holding threshold 
HepG2 cells belong to the cell lineage of hepatocytes which are known for their 
iron storing function. Hence these cells should be capable of accommodating large 
amounts of iron. However, increased ferroportin expression in the rec-TfR1 HepG2 
cells (figures. 4.12D, 4.17, 4.18D) showed that the cells were losing intracellular 
iron. Such up-regulation in hepatic ferroportin mRNA expression was also 
observed in haemochromatotic patients where intracellular iron levels were high 
(Bridle et al., 2003). This implies that the iron-storing cells can hold a large amount 
of iron but only up to a certain threshold and perhaps only under a normal 
physiological environment where the levels of iron are ‘manageable’ by the cells. 
Once the cells reach a certain iron-holding threshold, ferroportin expression would 
be raised to remove the excess intracellular iron to mediate intracellular iron 
homeostasis.  
 
In conclusion, it is certain that the homeostasis of extracellular/circulating iron 
levels is a complex process and it would be incorrect to state that hepcidin alone is 
the iron homeostasis regulator. As seen in this study, it involves an interaction 
between the key iron-related genes studied here and possibly may involve many 
more iron-related genes. Hepcidin would be synthesised, secreted and execute its 
function of maintaining iron homeostasis only if all interactions between genes and 
proteins function optimally. 
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Chapter 5 
Significance of preprohepcidin derivatives 
 
5.1 Introduction  
 
HFE-associated haemochromatotic patients as well as iron overloaded HFE -/-  
mice  showed decreased levels of hepcidin mRNA (Bridle et al., 2003). Thus it has 
been observed that HFE influences hepcidin synthesis. Parallel to this, in the 
current study the transcription of hepcidin and HFE genes mirrored each other 
where increased hepcidin mRNA levels accompanied increased HFE mRNA levels 
(chapter 4). Whether the HFE informed hepcidin synthesis or vice versa and 
whether this information was signalled by a direct physical interaction between 
HFE and derivatives of preprohepcidin remain to be elucidated.  
 
There are several aspects which support this putative interaction. Firstly, although 
HFE it is a pseudo major histocompatibility complex (MHC), it has been proposed 
that the binding groove of HFE is too narrow to accommodate a peptide for typical 
antigen presentation like the MHC class I molecule (Lebron et al., 1998).  
 
Fig. 5.1 Crystal structure of cytoplasmic region of HFE protein 
Alpha 1 and alpha 2 regions of the HFE protein as well as the alpha 
3 region which binds to beta-2 microglobulin protein are displayed. 
Structure adapted from Lebron et al. (1998). 
Beta-2 microglobulin 
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However, unpublished results (Moss, personal communication) suggest that the 
groove is large enough to accommodate a peptide. Additionally, the structural 
similarity between the HFE and MHC class I molecule (Lebron et al., 1998) support 
this proposed peptide binding. Secondly, the HFE and MHC I genes are located on 
the same chromosome (6p21.3 in humans) quite proximal to each other. Genes 
located on the same chromosome may belong to the same multigene family which 
by definition, are “a set of genes descended by duplication and variation from some 
ancestral gene” (King and Stansfield., 1990). This implies that the genes on the 
same chromosome, here the HFE and MHC I, may have a similar or the same 
function (i.e. peptide binding and its presentation on cell-surface). On the other 
hand, the fate of the 35-mer pro-region generated as a result of furin cleavage of 
prohepcidin is unknown.  
 
5.1.1 Aims and objectives 
Aim: The aim was to understand the significance of preprohepcidin derivatives. 
The pro-region of preprohepcidin may bear functional significance. Like the MHC 
class I molecule, binding of a peptide, possibly a part of the pro-region, may 
stimulate the HFE to traverse across the endoplasmic reticulum and present the 
peptide to the cell surface. The presence of a nuclear localisation signal within the 
pro-region suggests a functional role in the nucleus.  
Objectives: 
1. To understand the interaction between preprohepcidin derivatives and HFE 
in silico. 
2. To perform localisation studies with the preprohepcidin derivative in Wt 
HepG2 cells. 
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5.2 Results  
5.2.1 Identification of hydrophilic regions in preprohepcidin 
The hydrophilic regions in a protein are usually exposed on the surface of the 
protein to enable interactions with surrounding proteins whereas the hydrophobic 
amino acids are usually buried into the interior of a protein. In order to identify the 
region of hydrophilicity within the preprohepcidin peptide sequence, a Hopp-Woods 
hydropathy plot was created. As per the scaling pattern of the plot, for every amino 
acid, any value higher than 0 is considered as hydrophilic. In this case the C-
terminus of the pro-region was identified as the most hydrophilic (Fig. 5.2). Hence, 
this region is most likely to be exposed on the outer surface of the peptide and is 
thus the most potential protein-binding region within preprohepcidin.  
 
 
 
 
 
5.2.2 Putative binding of preprohepcidin derivatives to HFE 
Since the HFE bears structural similarity to MHC I molecule (referred as human 
leucocyte antigen, HLA in humans) (Feder et al., 1996), it was hypothesised that 
peptide binding to the HLA molecule should be similar to peptide binding to the 
MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASW MPMFQRRRRR DTHFPICIFCCGCCHRSKCGMCCKT 
<---Signal peptide---- > --------------Pro-region-35 mer ----------- ---hepcidin-25 mer--- 
<-------------------------------Prohepcidin-60 mer----------------------------------->  
Fig. 5.2  Hydrophilicity scale for human preprohepcidin  
A Hopp-Woods scale identifies the most hydrophilic regions in preprohepcidin; created at ‘Molecular 
toolkit’ (available at http://www.vivo.colostate.edu/molkit/hydropathy/index.html).  
 
Most hydrophilic region  
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HFE molecule. Hence, binding affinities of different serotypes of HLA molecules to 
different combinations of nonamers from preprohepcidin was assessed through 
bioinformatics software HLA_BIND at ExPASy. Only those interactions with scores 
of 100 or above 100 were plotted in the graph (Fig. 5.3). The figure shows the 
regions within preprohepcidin which may interact with an HLA and hence the HFE. 
Along with the test interactions, a positive control (i.e. a concatenated amino acid 
sequence suggested by the software), was also used which gave the highest 
binding score of 30,000 (data not shown for brevity).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The data shows that the nonamer RRRRRDTHF scored the highest binding score 
of 3,000 with the HLA molecule B_2705. This nonamer is located at the C- terminal 
region of pro-hepcidin and N-terminal region of bioactive hepcidin-25.  
Colour legends 
for nonamers: 
LLLLLLASL     
LASLTSGSV   
VFPQQTGQL  
AELQPQDRA  
AGARASWMP   
WMPMFQRRR  
RRRRRDTHF  
HRSKCGMCC  
SKCGMCCKT  
 
Fig. 5.3 Graphical representation of binding scores of HLA to different 
combinations of preprohepcidin nonamers 
Bioinformatics’ software HLA_BIND at ExPASy (available at 
http://bimas.dcrt.nih.gov/molbio/hla_bind) was used for prediction of MHC class I 
(HLA) binding to preprohepcidin protein derivatives. All triangles represent scores 
achieved by a particular nonamer of preprohepcidin with a particular HLA serotype.  
RRRRRDTHF 
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This is a part of the most hydrophilic region within preprohepcidin, as identified 
previously in Fig. 5.2. Other scores (represented by dark blue triangle) also 
suggest that the pro-region has a high possibility of interacting with the HLA and 
hence the HFE. In comparison to the pro-region, the regions in the signal peptide 
and bioactive hepcidin show the least likelihood of binding to HLA, as per the data 
extrapolated from the HLA_BIND software.  
 
5.2.3 Conservation of regions of potential interaction 
Since the α-1 and α-2 regions in the HFE molecule form a groove within which the 
proposed putative peptide binding may occur, conservation of these regions in 
different species was checked (Fig. 5.4). As seen in the alignment, the α -1 and α - 
2 regions are highly conserved amongst species, which strengthens the possibility 
of these regions being functionally significant and involved in peptide binding. 
HFE_HUMAN       ----MGPRAR-PALLLLMLLQTAVLQGRLLRSHSLHYLFMGASEQDLGLSLFEALGYVDD 55 
HFE_MOUSE       MSLSAGLPVR-PLLLLLLLLWSVAPQALPPRSHSLRYLFMGASEPDLGLPLFEARGYVDD 59 
HFE_RAT         MDRSAGLPVRLLLLLLLLLLWSVAPQALRPGSHSLRYLFMGASKPDLGLPFFEALGYVDD 60 
HFE_Rhino       ----MGPRAR-PALFFLILLRTVAAQGRPPRSHSLRYLFMGASERDHGLPLFEALGYVDD 55 
HFE_Chimp       ----MGPRAR-PALLLLMLLQTAVLQGRLLRSHSLHYLFMGASEQDLGLSLFEALGYVDD 55 
                     *  .*   *::*:** :.. *.    ****:*******: * **.:*** ***** 
 
HFE_HUMAN       QLFVFYDHESRRVEPRTPWVSSRISSQMWLQLSQSLKGWDHMFTVDFWTIMENHNHSK-- 113 
HFE_MOUSE       QLFVSYNHESRRAEPRAPWILEQTSSQLWLHLSQSLKGWDYMFIVDFWTIMGNYNHSKVT 119 
HFE_RAT         QLFVSYNHESRRAEPRAPWILGQTSSQLWLQLSQSLKGWDYMFIVDFWTIMGNYNHSKVT 120 
HFE_Rhino       ELFVAYNHESRRAESRAQWVLGEAHSQLWLQLSQSLKGWDHMFIVDFWTIMDNHNHSK-- 113 
HFE_Chimp       QLFVFYDHESRRVEPRTPWVSSRISSQMWLQLSQSLKGWDHMFTVDFWTIMENHNHSK-- 113 
                :*** *:*****.*.*: *:  .  **:**:*********:** ******* *:****   
 
HFE_HUMAN       ------ESHTLQVILGCEMQEDNSTEGYWKYGYDGQDHLEFCPDTLDWRAAEPRAWPTKL 167 
HFE_MOUSE       KLGVVSESHILQVVLGCEVHEDNSTSGFWRYGYDGQDHLEFCPKTLNWSAAEPGAWATKV 179 
HFE_RAT         KLRVVPESHILQVILGCEVHEDNSTSGFWKYGYDGQDHLEFCPKTLNWSAAEPRAWATKM 180 
HFE_Rhino       ------ESHTLQVILGCEVQEDNSTRGFWKYGYDGQDHLEFCPETLDWRAAESRALTTKL 167 
HFE_Chimp       ------ESHTLQVILGCEMQEDNSTEGYWKYGYDGQDHLEFCPDTLDWRAAEPRAWPTKL 167 
                      *** ***:****::***** *:*:*************.**:* ***. * .**: 
 
HFE_HUMAN       EWERHKIRARQNRAYLERDCPAQLQQLLELGRGVLDQQVPPLVKVTHHVTSSV------E 348 
HFE_MOUSE       EWDEHKIRAKQNRDYLEKDCPEQLKRLLELGRGVLGQQVPTLVKVTRHWASTG------E 359 
HFE_RAT         EWEEHRIRARQSRDYLQRDCPQQLKQVLELQRGVLGQQVPTLVKVTRHWASTG------E 360 
HFE_Rhino       EWEVNKIRAKQNRAYLERDCPEQLQWLLELGRGVLDQQVPPLVKVTHHVASAV------E 348 
HFE_Chimp       EWERHKIRARQNRAYLERDCPAQLQQLLELGRGVLDQQVPPLVKVTHHVTSSV------E 348 
                **: ::***:*.* **::*** **: :*** ****.****.*****:* :*:       * 
 
 
 
Fig. 5.4  Conservation of alpha regions in the HFE protein in various species  
This protein multiple sequence alignment was created using the tool ClustalW2 (available 
at http://www.ebi.ac.uk/Tools/msa/clustalw2/). The alignment highlights regions of 
conservation in the HFE protein sequence amongst different species. 
Key to Fig :  
• α-1  and α-2 regions in the HFE protein  
• ---- represents amino acids and * represents conserved amino acid between species. 
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Likewise, a clustalx protein multiple sequence alignment of preprohepcidin which 
involved a variety of species showed high conservation of the leucines and 
arginines (Fig. 5.5). The leucines are a part of the signal peptide of preprohepcidin 
and the arginines are a part of the pro-region (boxed). This is the region most 
hydrophilic and possibly antigenic as shown previously in Fig. 5.2 and Fig. 5.3. 
Together, it could be concluded that there is conservation of the proposed regions 
of interaction between the HFE and pro-region of preprohepcidin (Fig. 5.4 and Fig. 
5.5). 
 
 
 
 
5.2.4 Nuclear localisation signals in preprohepcidin 
As seen in Fig. 5.5, the C-terminal region of prohepcidin encompasses repeats of 
arginines residues, typical to a nuclear localisation signal (Dingwall and Laskey, 
1986). The conservation of this region in different species suggested that it may be 
biologically significant. To ascertain this, the software programme cNLS mapper 
(Kosugi et al., 2008, Kosugi et al., 2009a) was used to assess the presence of 
nuclear localisation within the preprohepcidin sequence (Fig. 5.6).  As per the 
programme, a score of 1-2 indicates localisation of the protein in the cytoplasm, a 
score of 4-5 indicates location of the protein in both the cytoplasm and the nucleus 
Fig. 5.5  Conservation of amino acids within the pro-region of preprohepcidin  
The alignment was created by using clustalx, a windows interface for ClustalW multiple 
sequence alignments. It highlights the conservation of arginine residues within the 
preprohepcidin protein sequence in different species. * represents conserved amino acid 
between species. 
Mouse  
Rat 
Chimpanzee 
Human 
Monkey 
Cow 
Pig 
Dog 
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whereas a score of 8-10 suggests location of the protein exclusively in the nucleus. 
Since the protein Yen1 from the yeast Saccharomyces cerevisiae has been shown 
to possess a nuclear localisation signal (Kosugi et al., 2009b), this protein was 
used as a positive control, as seen below. 
 
 
 
 
   
 
 
As seen in the Fig. 5.6, the positive control achieved a high score of 9, as 
expected, whereas the test sequence of human preprohepcidin scored 5.2. 
Hepcidin-25 would be found in the cytoplasm while it is being secreted. Since this 
region was also considered by the programme while assigning the score, the score 
of 5.2 is expected. Additionally, bioinformatics revealed homologies between the 
pro-region and some members of the the Krüppel associated box (KRAB) of Zinc  
Finger Protein (ZFP) family, as shown in Fig. 5.7.  
Predicted NLSs in query sequence 
MGVSQIWEFLKPYLQDSRIPLRKFVIDFNKSQKRAPRIAIDAYGWLFECG 50  
FIQNIDISARSRSRSRSPTRSPRDSDIDSSQEYYGSRSYTTTGKAVINFI 100 
SRLKELLSLNVEFLLVFDGVMKPSFKRKFNHEQNATTCDDEKEYYSSWEQ 150 
HVKNHEVYGNCKGLLAPSDPEFISLVRKLLDLMNISYVIACGEGEAQCVW 200 
LQVSGAVDFILSNDSDTLVFGGEKILKNYSKFYDDFGPSSITSHSPSRHH 250 
DSKESFVTVIDLPKINKVAGKKFDRLSLLFFSVLLGADYNRGVKGLGKNK 300 
SLQLAQCEDPNFSMEFYDIFKDFNLEDLTSESLRKSRYRLFQKRLYLYCK 350 
DHSVELFGRNYPVLLNQGSFEGWPSTVAIMHYFHPIVQPYFDEEVLSDKY 400 
INMAGNGHYRNLNFNELKYFLQSLNLPQISSFDKWFHDSMHEMFLLREFL 450 
SIDESDNIGKGNMRITEEKIMNIDGGKFQIPCFKIRYTTFLPNIPISSQS 500 
PLKRSNSPSRSKSPTRRQMDIMEHPNSLWLPKYLIPQSHPLVIQYYETQQ 550 
LIQKEKEKKGKKSNKSRLPQKNNLDEFLRKHTSPIKSIGKVGESRKEILE 600 
PVRKRLFVDTDEDTSLEEIPAPTRLTTVDEHSDNDDDSLIFVDEITNSQS 650 
VLDSSPGKRIRDLTQDEQVDVWKDVIEISPIKKSRTTNAEKNPPESGLKS 700 
RSSITINARLQGTKMLPPNLTAPRLEREHSSVLDQLVTDAQDTVDRFVAC 750 
DSDSSSTIE                                          759 
Predicted monopartite NLS 
Pos. Sequence Score 
123 PSFKRKFNHE 9 
Predicted bipartite NLS 
Pos. Sequence Score 
53 FQRRRRRDTHFPICIFCCGCCHRSKCGMC 5.2 
Predicted NLSs in query sequence 
MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWM 50 
PMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT                 84 
A 
D C 
B 
Fig. 5.6  Nuclear localisation signal in preprohepcidin  
In order to identify the nuclear localisation signal within preprohepcidin peptide the cNLS 
Mapper (available at http//nls-mapper.iab.keio.ac.jp/), was used.  
A and B : Positive control, protein Yen1 from Saccharomyces cerevisiae and its score. 
C and D: Test sequence preprohepcidin peptide and its score. 
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1 .[ 9].AA.[4].LDPAQSNLY.[1].DVMLENYCN.[3].MG.[1].QAP.[2].DMISKL.[5].PWL 59
4 .[11].RE.[4].LDPGQRALY.[1].EVMLENHSS.[3].LA.[2].LVF.[2].ELISRL.[5].PWV 65
6 .[11].QE.[4].LQPAQRDLY.[1].CVMLENYGH.[3].LG.[1].SIS.[2].DVVSLL.[5].PWL 66
.      18 .[11] QT [5].LQPQDRAGA.[1] ASWMPMFQR [4]
 
 
 
5.2.5 Localisation studies of pro-peptide of preprohepcidin 
In order to assess whether the nuclear localisation signal in prohepcidin identified 
in silco (Fig. 5.6) performed a biological role in vitro, localisation studies were 
performed by transfecting Wt HepG2 cells with a recombinant pEGFPN1 plasmid  
containing the pre-pro region, as explained in the following sections. 
Fig. 5.7  Similarity between KRAB and pro-region of preprohepcidin 
An alignment of some human zinc-finger proteins was created using the NCBI protein 
blastp followed by conserved domain search. A section of the pro-region showed 
similarity with the KRAB of ZFP. NCBI accessions of human ZFP 37,7 and 140 are  
gi1136151, gi141685 and gi1731416, respectively. 
Human ZFP-
Human ZFP-
Human ZFP-
Pro -region 
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5.2.5.1 Screening of plasmid constructs 
Firstly, the four pEGFPN1 recombinant plasmid constructs (referred to as P1 to 
P4), each possessing a unique derivative of preprohepcidin with either a GFP or 
V5 tag, required identification of the derivative and the tag in each construct. To 
achieve this, the plasmid constructs were screened via restriction enzyme 
digestion, as shown in Fig. 5.8. 
 
                                                                           
                                                    
 
 
 
 
 
 
 
 
As seen in the Fig. 5.8, the expected size products were observed for the plasmids 
P3 and P4, but not for plasmids P1 and P2. Thus, to confirm the identity of the 
Fig. 5.8  Restriction digests of pEGFPN1 plasmid constructs 
Recombinant plasmids P1, P2, P3 and P4 containing unknown preprohepcidin derivatives 
were transformed in E.Coli XL-1 blue competent cells, extracted, purified, and subjected to 
digestion with restriction enzymes as explained in methods section 2.2.23. The digested 
products were electrophoresed on 2 % agarose gels. 
 
A: Restriction digests of plasmids P2 (lanes 1-3) and P3 (lanes 4-6)  
Lane 1= uncut plasmid; expected product size ~4956 bp 
Lane 2= plasmid cut with BamHI; expected product size ~4956 bp 
Lane 3= plasmid cut with BamHI and Hind III; expected product size~ 4704 bp and 252 bp 
Lane 4= uncut plasmid; expected product size ~4956 bp 
Lane 5= plasmid cut with BamHI; expected product size ~4956 bp 
Lane 6= plasmid cut with BamHI and Hind III; expected product size ~ 4779 bp and 177 bp 
 
B: Restriction digests of plasmids P1 (lanes 1-3) and P4 (lanes 4-6) 
Lane 1= uncut plasmid; expected product size ~4956 bp 
Lane 2= plasmid cut with BamHI; expected product size ~4956 bp 
Lane 3= plasmid cut with BamHI and Hind III; expected product size ~ 4779 bp and 177 bp 
Lane 4= uncut plasmid; expected product size ~4956 bp 
Lane 5= plasmid cut with BamHI; expected product size ~4956 bp 
Lane 6= plasmid cut with BamHI and Hind III; expected product size~ 4704 bp and 252 bp  
 1    2    3                        4    5    6     1    2    3     4   5   6      
200 
100 
300 
3000  bp 
200 
400 
1500 bp 
A B 
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constructs in all the plasmids via sequencing, vector primers (pEGFPN primers) 
were designed as shown below.  
                  5’GGTGGGAGGTCTATATAAGCAGAG >>> 3’ 
pEGFPN1           ACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTA 600 
pEGFPN2           ACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTA 600 
                  ************************************************************ 
 
                   
                                                      3’ <<< TGTGGAGGGGGACTTGGA 5’ 
pEGFPN1           -----ACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACC 1488 
pEGFPN2           -----ACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACC 2098 
                       ******************************************************* 
Each purified plasmid construct was amplified with the designed pEGFPN primers 
and the amplicons were electrophoresed on a 1 % agarose gel, as shown in Fig. 
5.9 and sent for sequencing to confirm its identity. 
 
.  
 
 
 
 
 
The characterised sequences of the recombinant plasmids were translated to 
protein sequences and the preprohepcidin derivative and the tag in each plasmid 
construct was identified as shown in Table. 5.1. Following identification, the aim 
was to perform localisation studies using all the constructs, commencing from the 
plasmid containing the pre-pro construct.   
Fig. 5.9 Amplicons of pEGFPN-
preprohepcidin constructs with 
designed vector primers 
Each recombinant plasmid was amplified 
with the designed vector primers as 
described in methods section 2.2.8. 
Following this, each product was gel 
purified and sent for sequencing as 
described in methods section 2.2.12.  
 P1    P2    P3    P4    
3000 bp 
500 bp 
100 bp 
300 bp 
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Plasmid 
construct  
Partial section of translated nucleotide sequence Conclusion  
P1 5'3' Frame 3 
S A S A T G L R S R A Q A S N S A V D G T A G P G S Met G 
K P I P N P L L G L D S T S V F P Q Q T G Q L A E L Q P Q 
D R A G A R A S W Met P Met F Q R R R R R D Stop S R S 
Stop S A I P H 
 
Pro region of 
preprohepcidin 
with V5 tag at 
N-terminus.  
 
P2 5'3' Frame 1 
X X X X R X I R Stop R Y R T Q I S S S S F E F K L Met A L 
S S Q I W A A C L L L L L L L A S L T S G S V F P Q Q T G 
Q L A E L Q P Q D R A G A R A S W Met P Met F Q R R R R R 
D T H F P I C I F C C G C C H R S K C G Met C C K T G K P 
I P N P L L G L D S T Stop S R S Stop S A I P H L Stop R F 
Y L L Stop K T S H X X X X E P  
 
Preprohepcidin 
with V5 tag at 
C-terminus 
 
P3 D  V  D  R  S  A  P  D  S  D  L  E  L  K  L  M  A  L  S  S  
Q  I  W  A  A  C  L  L  L  L  L  L  L  A  S  L  T  S  G  S  
V  F  P  Q  Q  T  G  Q  L  A  E  L  Q  P  Q  D  R  A  G  A  
R  A  S  W  M  P  M  F  Q  R  R  R  R  R D  P  P  V  A  T  
M  V  S  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D  
G  D  V  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y  
G  K  L  T  L  K  F  I  C  T  T  G  K  L  P  V  P  W  P  T  
Prepro region 
with GFP tag 
at C-terminus  
P4 5'3' Frame 2 
L  V  C  V  D  R  S  A  P  D  S  D  L  E  L  K  L  M  A  L  
S  S  Q  I  W  A  A  C  L  L  L  L  L  L  L  A  S  L  T  S  
G  S  V  F  P  Q  Q  T  G  Q  L  A  E  L  Q  P  Q  D  R  A  
G  A  R  A  S  W  M  P  M  F  Q  R  R  R  R  R  D  T  H  F  
P  I  C  I  F  C  C  G  C  C  H  R  S  K  C  G  M  C  C  K  
T  D  P  P  V  A  T  M  V  S  K  G  E  E  L  F  T  G  V  V  
P  I  L  V  E  L  D  G  D  V  N  G  H  K  F  S  V  S  G  E  
G  E  G  D  A  T  Y  G  K  L  T  L  K  F  I  C  T  T  G  K  
 
Preprohepcidin 
with GFP tag 
at C-terminus. 
 
 
 
 
 
 
 
 
 
 
 
5.2.5.2 Localisation study of hepcidin pro-peptide in Wt HepG2 cells 
Once the recombinant plasmid containing the pre-pro derivative was confirmed via 
sequencing, Wt HepG2 cells were transfected with this recombinant plasmid and 
the non-recombinant empty pEGFPN1 plasmid which acted as a control. The 
results of transfection are shown in Fig. 5.10. 
 
Table 5.1  Identification of plasmid pEGFPN1-preprohepcidin constructs 
Proteomics tool ‘Translate’ at ExPASy (http://web.expasy.org/translate/) was used to translate 
the characterised plasmid sequences to amino acid sequences and the preprohepcidin derivative 
in each construct was identified. Sequence information on preprohepcidin was obtained from 
Proteinknowledgebase UniProtKB (P81172). Tags were identified using blastn at NCBI.  
Key to table:   
• Pre region of preprohepcidin    
• Pro-hepcidin 
• V 5 tag 
• GFP Tag 
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Following this, the images were observed under a confocal microscope, as shown 
in Fig. 5.11. In the case of transfection with the non-recombinant host plasmid 
(control), the fluorescence from the GFP tag was seen all over the cell, including 
the nucleus (Fig. 5.11 B and C). However, transfection of cells with the 
recombinant plasmid containing the pre-pro construct resulted in fluorescence 
being found exclusively in the nucleus (Fig. 5.11 D, E and F). 
Fig. 5.10 Transfection of HepG2 cells with pEGFPN1 plasmids  
Wt HepG2 cells were transfected with the plasmid containing the prepro-construct, as 
described in methods section 2.2.24, to identify the location of the construct in the cells.  
A, B and C : Transfection with non-recombinant pEGFP N1 plasmid (20X) 
A : Control; untransfected cells 
B : Transfected cells under normal light 
C : Transfected cells under fluorescent light 
 
D, E and F : Transfection with prepro-pEGFP N1 construct (40X) 
D : Control; untransfected cells  
E : Transfected cells under normal light  
F : Transfected cells under fluorescent light  
 
A B 
D 
C 
F E 
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5.3 Discussion  
The 84-mer preprohepcidin in humans is cleaved to yield a 25-mer bioactive 
hepcidin and a 35-mer pro-region (Park et al., 2001) which has an unknown 
function. Based on the similarities in structures between the HFE protein and MHC 
class I molecules, it was hypothesised that HFE may be involved in peptide binding 
and presentation like the MHC class I molecule and that this peptide could be a 
part of the pro-region. Hence to explore this hypothesis, bioinformatics was used to 
investigate the putative interaction between the pro-region of preprohepcidin and 
 
GFP GFP GFP 
Pre-Pro-GFP Pre-Pro-GFP Pre-Pro-GFP 
Fig. 5.11 Localisation of prepro-region in HepG2 cells  
Wt HepG2 cells were transfected with the plasmid containing the ‘prepro’ construct, as 
described in methods section 2.2.24, to identify the location of the construct in the cells.  
 
A, B, C : Transfection with non-recombinant pEGFP N1 plasmid 
A: Location of nucleus in the cells. 
B: Localisation of GFP in the cells.  
C: Superimposition of the images A and B. 
 
D, E, F: Transfection with prepro-pEGFP N1 construct 
D: Location of nucleus in the cells 
E: Location of GFP tag within the cell.  
F: Superimposition of images D and E.  
A B C 
D E F 
 161 
 
the HFE. The study showed that the C-terminal part of the prohepcidin sequence 
was the most hydrophilic and hence would be the most antigenic region (Fig. 5.2). 
Since the HFE is regarded as a pseudo MHC (HLA) (Feder et al., 1996), the 
binding affinity between nonamers of preprohepcidin and different serotypes of 
HLAs was investigated (Fig. 5.3). Data suggested that the C-terminal region of the 
pro-region showed the highest possibility of interaction with the HLA. Additionally, 
this region matched the most hydrophilic region in preprohepcidin as seen in Fig. 
5.2. Together this suggests that the C–terminus of the pro-region had the most 
potential for binding to a HLA and hence the HFE protein.  
 
Conservation of α-1 and α-2 regions of HFE in different species (Fig. 5.4) suggests 
that these regions might be functionally significant. Although it has been 
established that the HFE protein, through its α -1 and α - 2 regions, interacts with 
TfR1 and regulates iron uptake by cells (Fleming, 2009), it should not be excluded 
that that these α-regions may also be involved in peptide binding, particularly in the 
scenario when the HFE has been proposed to exhibit multiple roles. The bound 
peptide could be a section of the pro-region which by binding to the HFE in the 
endoplasmic reticulum (ER) would allow its maturation and may activate the HFE 
to traverse across the ER to be expressed on the cell surface where it would fulfil 
its role of limiting iron import inside the cell. Another role of the section of the pro-
peptide could be where its presentation on the cell surface may be a part of a 
signal to regulate hepcidin levels via a feedback mechanism. The C-terminal part 
of the pro-region, RRRRRDTHF, which was found to be the most hydrophilic and 
antigenic (figures 5.2 and 5.3), also contains a motif typical of a nuclear localisation 
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signal (figures 5.5 and 5.6). This motif indicates functional significance of the pro-
region as found in many proteins with arginine-rich domains that function as a 
nuclear localisation signal, for example as found in the HIV type 1, Tat and Rev 
proteins (Truant and Cullen, 1999). Further bioinformatics analysis indicated that 
the pro-region bore a similarity to the KRAB domain of some of the members of the 
Zinc-finger protein (ZFP) family (Fig. 5.7). The KRAB is a domain of around 75 
amino acids located at the N-terminal part of about one third of eukaryotic ZFP and 
some of the functions of the KRAB-containing protein family include transcriptional 
repression of RNA polymerase I, II, and III promoters, binding and splicing of RNA 
(Hirasawa and Feil, 2008, Pengue and Lania, 1996). Since the KRAB-zinc fingers 
constitute the largest class of transcription factors within the human genome (Mark 
et al., 1999), here it was hypothesised that the pro-region or part of the pro-region 
with the amino acids RRRRRDTHF may localise into the nucleus. 
 
Localisation studies of prohepcidin have been conducted by other research groups. 
Pigeon et.al. (2001) used a GFP-construct in which the GFP tag was inserted at 
the N-terminus of the prohepcidin sequence. When the recombinant peptide was 
expressed in HepG2 cells, it was found to be located in the nucleus. This showed 
the presence of GFP-tagged prohepcidin in the nucleus. However, this construct 
did not include the ‘pre’ region and therefore probably may not have been 
expressed through the ER but directly in the cytoplasm. Although the primary 
sequence of prohepcidin does not suggest posttranslational modifications, the 
presence of an ER targeting sequence in the first 24 amino acids in the 
preprohepcidin suggests that it is important for the recombinant peptide to traverse 
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across the ER for the original maturation process. Since the pro-region is proposed 
to be cleaved by a furin-like convertase to release the mature peptide it could be 
that in the study by Pigeon et.al. (2001) the GFP-pro region may have entered the 
nucleus. However, GFP is a much larger protein (238 mer, 26.9 kD)(Tsien, 1998) 
than the small pro-region (35 mer) and whether the size and placement of the GFP 
tag during the creation of the chimera influenced the localisation process, needs to 
be fully understood.  
 
Another study which used antibodies raised against human prohepcidin showed 
that in the HepG2 cells prohepcidin was localised in intracellular vesicular 
structures (Kulaksiz et al., 2004). Also, when human preprohepcidin was 
transfected in human embryonic kidney cells, the C-terminal part (i.e. tagged 
hepcidin-25) or prohepcidin was localised to the golgi complex (Wallace et al., 
2006). Detection of hepcidin or pro-hepcidin in vesicular structures or the golgi 
complex is not surprising as these may have been captured when prohepcidin was 
about to mature into hepcidin-25, ready to be cleaved by furin which is found to be 
localised in the transgolgi network (Nakayama, 1997) or when hepcidin-25 was 
about to exit the cell.  
 
Hence, to further investigate the potential role of the pro-region as a NLS, 
recombinant plasmid pEGFPN1 with the pre-pro-GFP was transfected into Wt 
HepG2 cells. In this construct the GPF tag was placed after the pre-pro region to 
allow normal process through the ER and to alleviate any interference in 
localisation from the huge GFP tag, unlike the previous studies. Here, localisation 
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studies showed that the construct entered the nucleus (Fig. 5.11 E and F). Since 
the pre-region of preprohepcidin is cleaved by the signal peptidase (Nemeth and 
Ganz, 2006), it is probably only the pro-GFP protein that is localised in the nucleus. 
The role of the pro-peptide in the nucleus remains to be identified. Its similarity with 
the KRAB motif suggests that it may act as a transcription factor to regulate gene 
expression of hepcidin or other iron-regulated genes. Further localisation studies 
using all the other characterised preprohepcidin constructs will be necessary to 
better understand the cellular trafficking of hepcidin and any role of the pro-region.  
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Chapter 6 
Overall summary and future work 
6.1 Overall summary 
The aim of this project was to understand how iron regulates hepcidin gene 
expression. To achieve this, in the first instance CHO TRVb1 cells were chosen for 
iron overdose studies. It was hypothesised that due to the over-expression of 
human TfR1, these cells would be able to uptake excess amounts of iron via 
holotransferrin and the resultant effect on gene expression of hepcidin and other 
iron-related genes could be investigated. Since the sequences of iron-related 
genes of interest in the CHO cells were not known, their characterisation was 
carried out to enable gene expression studies through real time PCR. 
Subsequently, in this study (chapter 3), CHO gene sequences of Hfe, ferroportin 
and Irp2 were partially characterised.  
 
However, the gene sequence of hepcidin in these cells could not be characterised 
which prevented the evaluation of hepcidin mRNA expression. Hence, studies 
focusing on hepcidin peptide secretion were carried out. For the first time it was 
shown that the CHO TRVb1 cells secreted significantly increased hepcidin peptide 
levels after 30 min, 2, 4, 24 and 48 hours following holotransferrin overdose 
(figures 3.22 and 3.26), as observed in human and animal models (Lin et al., 2007, 
Nemeth et al., 2003, Pigeon et al., 2001). Despite over-expressing TfR1 on the cell 
surface, the CHO TRVb1 cells did not uptake increased amounts of iron (Fig. 3.25) 
implying that over-expressed TfR1 along with holotransferrin overdose may not 
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necessitate intracellular iron overload, primarily because the TfR1 mRNA in these 
cell was IRE-regulated which limited the amount of iron intake via TfR1. Since the 
increase in hepcidin peptide levels by the CHO TRVb1 cells was achieved without 
intracellular iron overload, it was important to understand the effect of intracellular 
iron overload on hepcidin mRNA and peptide expression. Hence, rec-TfR1 HepG2 
cells were created such that they expressed an IRE-independent TfR1 so that the 
TfR1 mRNA would be insensitive to increase in intracellular iron content and this 
would maximise iron uptake (chapter 4). Consequently, the cells showed higher 
basal levels of iron than Wt HepG2 cells (figures 4.4C and 4.11F) and significantly 
increased iron uptake with increased holotransferrin concentrations at  2, 4 and 24 
hours after treatment (figures 4.8C and 4.14F). 
 
Holotransferrin dosage of 1 g/L and 5 g/L to the control Wt HepG2 cells for 30 min, 
2, 4, 6 and 24 h resulted in a physiological increase in hepcidin mRNA levels 
(figures 4.7C and 4.15). Despite increased intracellular iron levels, the rec-TfR1 
HepG2 cells did not demonstrate an expected increase in hepcidin mRNA levels, 
although after 2 h of 5 g/L holotransferrin treatment, a 0.5-fold increase was 
observed (p<0.02)(Fig. 4.17). This suggested that hepcidin mRNA expression was 
not directly proportional to intracellular iron levels. Interestingly, it was also 
observed that ferroportin mRNA levels in the rec-TfR1HepG2 cells were 
considerably higher compared to the Wt HepG2 cells and also significantly 
increased upon 5 g/L holotransferrin treatment indicating that the rec-TfR1 HepG2 
cells were excreting intracellular iron (figures 4.5B, 4.12D, 4.17). 
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Additionally, in this study, it was shown for the first time that HepG2 cells secreted 
significantly increased levels of hepcidin peptide upon holotransferrin overdose 
(Fig. 4.19 and 4.20) as observed in humans and animal models (Lin et al., 2007, 
Nemeth et al., 2003, Pigeon et al., 2001). Similarity in the levels of hepcidin peptide 
secretion by both the Wt and rec-TfR1 HepG2 cells, despite having different 
intracellular iron contents, suggested that both intracellular and extracellular iron 
concentrations affected hepcidin synthesis and secretion.  
 
Gene expression studies demonstrated the impact of HFE on hepcidin. The HFE 
and hepcidin gene expressions mirrored each other (figures 4.12C and 4.18C) 
which suggested that in the human body HFE may participate in regulating 
circulating iron levels via hepcidin. HFE is crucial for hepcidin expression, as is 
evident by comparing hepatocytes from haemochromatotic patients where the 
absence of HFE on the cell-surface is linked to reduced hepcidin production (Feder 
et al., 1996) and rec-TfR1 HepG2 cells where hepcidin is secreted with the help of 
functional HFE on the cell-surface. This study also suggested a probable role of 
HFE in sensing intracellular iron levels, either independently (Carlson et al., 2005) 
or via TfR1, and also in sensing extracellular iron levels (Fig. 4.25). Thus it 
appeared that HFE played multiple roles depending on the extracellular and 
intracellular iron environment. 
 
Gene expression studies showed evidence of opposing functionalities of TfR1 and 
ferroportin transcripts in regulating intracellular iron levels. For example, in the Wt 
HepG2 cells, basal intracellular iron levels along with increased extracellular iron 
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levels reduced TfR1 mRNA expression to prevent any further iron uptake (figures 
4.7A and 4.15). On the other hand, in the rec-TfR1 HepG2 cells, high basal 
intracellular iron content along with increased extracellular iron levels led to 
increased ferroportin mRNA expression to excrete the excess iron (Fig. 4.17). The 
process of down-regulation of the TfR1 transcript and up-regulation of the 
ferroportin transcript had the same purpose which was to maintain intracellular iron 
homeostasis.  
 
Simultaneously, this study attempted to understand the significance of the pro-
region of preprohepcidin. As a result of the in silco studies demonstrated in 
chapter 5, a potential binding between the HFE and a section of the pro-region of 
preprohepcidin has been proposed. The first proposed role of the pro-region is to 
aid in the maturation process of HFE to be expressed on the cell surface. 
Localisation of the pro-region within the cell was investigated which revealed that 
transfection of HepG2 cells with the pre-pro-GFP construct resulted in localisation 
of the pro-GFP in the nucleus (Fig. 5.11). This, along with the similarity of the pro-
region with the KRAB domain of ZFP family (Fig. 5.7) together propose a second 
role of the pro-region which is to act as a transcription factor in regulating gene 
expression.  
 
6.2 Future work 
Although hepcidin is regarded as a key iron homeostatic regulator, its expression is 
linked with the expression of other iron-related proteins. Hence, to obtain a 
complete picture of iron regulation it would be more beneficial to study hepcidin 
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expression along with and in relation to other iron-related proteins such as HFE, 
TfR2 and ferritin. Such a study is supported by the fact that liver cells express HFE 
in higher amounts than other cells, hepcidin is produced predominantly by the liver 
and TfR2 is present only on hepatocytes (Zhang et al., 2004, Park et al., 2001, 
Pigeon et al., 2001, Schmidt et al., 2008, Rapisarda et al., 2010). The three 
proteins influence each other and hence the interrelationship between the 
expressions of their genes would help in the overall understanding of iron 
regulation. 
 
The rec-TfR1 HepG2 cells possess an IRE-independent TfR1 and were able to 
demonstrate intracellular iron overload (figures 4.8C and 4.14F). However, 
increased ferroportin mRNA expression in the rec-TfR1 HepG2 cells implies that 
the cells may have only partially retained the iron content. Hence the question 
whether high intracellular iron levels influence hepcidin mRNA and protein 
expression and if so to what extent, still remains to be fully answered. This involves 
the influence of other genes like ferroportin and HFE. The loss of intracellular iron 
occurring in the rec-TfR1 HepG2 cells could be prevented by deletion of the 5’ 
IREs in the ferroportin gene. This will ensure that both the entry and the exit points 
of iron via TfR1 and ferroportin, respectively, are modified to maximise iron uptake 
and then retain the attained high intracellular iron. The effect on hepcidin 
expression could then be investigated. In addition, since HFE has been shown to 
limit intracellular iron uptake (Chua et al., 2008), iron supplementation experiments 
could be performed on HFE-deficient HepG2 cells and HFE- over-expressing cells 
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and the effects could be compared to Wt HepG2 and rec-TfR1 HepG2 cells used in 
this study.  
 
Also, the potential binding between the HFE and preprohepcidin derivative 
suggested by in silico studies performed in chapter 5 could be fully elucidated by in 
vitro peptide binding studies. Synthetic nonamers of HFE and the pro-region could 
be synthesised and their binding could be checked by probing the HFE nonamers 
to the pro-sections and vice-versa. This will not only help to understand the 
relationship between HFE and hepcidin but also aid in elucidating the proposed 
multiple roles of HFE, which have not yet been fully understood.  
 
Furin cleavage of prohepcidin into bioactive hepcidin is affected by the amino acids 
positioned C-terminal to the cleavage site (Lee, 2008). In the pre-pro-GFP 
construct used here, the furin cleavage site (RRRRR) as well as the first amino 
acid after the cleavage site i.e. aspartic acid (D) are preserved. Hence, it would be 
important to know if the substitution of hepcidin with GFP tag in the construct has 
affected the furin-cleavage process. This could be shown by performing an SDS-
PAGE with the extracted plasmids from transfected cells and comparing the sizes 
of the furin-cleaved and uncleaved products. Also, further studies should be 
performed with the other preprohepcidin GFP-construct characterised in this study. 
 
In the case of preprohepcidin constructs with GFP, a large GFP tag is attached to a 
small peptide whose movement within the cell is required to be traced. In order to 
ease the process, various combinations of preprohepcidin constructs could be 
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created with V5 tags at the C and N termini, two of which are already characterised 
in this study. These could be probed with V5 antibodies which will provide finer 
information than studies with the larger GFP-tagged preprohepcidin constructs. 
The tag will identify the location of the construct whereas the coherent view of all 
the constructs will show the pathway of secretion of bioactive hepcidin. Thus, such 
localisation studies will help to better understand the cell trafficking of hepcidin and 
may provide a new insight into the secretion process. It has been proposed by 
Farnaud et al. (2008) that iron may play a role in processing of prohepcidin. In 
order to verify this proposition, a combination of iron supplementation and 
localisation studies in HepG2 cells should be carried out. This may provide a better 
insight into the bio-processing of hepcidin as well as the destination of the pro-
region within the cell.    
 
It is clear that hepcidin regulation and secretion to regulate circulating iron levels is 
a complex mechanism, involving various genes/proteins and their responses under 
different extracellular and intracellular environments. The responses of cells are 
also governed by the concentration and exposure-time of iron. Since gene 
expressions are affected by the extracellular environment and vice-versa, the 
challenge is to elucidate what acts as the first trigger.  
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